data_6mw6_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6mw6 _Structure_validation_residue.Date_analyzed 2019-03-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 119.529 2.572 . . . . 0.0 119.529 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.69 -140.6 2.93 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.891 2.186 . . . . 0.0 114.898 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.4 p -100.09 157.95 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.089 1.355 . . . . 0.0 113.038 176.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 141.78 -156.9 26.12 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 120.055 -1.653 . . . . 0.0 115.075 164.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -77.11 -76.53 0.17 Allowed 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.99 2.516 . . . . 0.0 113.347 -174.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.8 pt -80.02 147.47 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-O 122.609 1.195 . . . . 0.0 112.906 -174.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -61.96 138.8 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 C-N-CA 124.924 1.29 . . . . 0.0 113.026 -173.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -143.76 7.15 1.44 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.542 2.337 . . . . 0.0 113.423 -172.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -68.65 -26.74 65.48 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 118.75 -2.469 . . . . 0.0 113.959 -171.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -82.31 -8.15 59.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 117.546 2.424 . . . . 0.0 117.546 173.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.2 pt -133.0 82.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 127.192 2.197 . . . . 0.0 111.085 175.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 125.45 37.47 0.52 Allowed Glycine 0 CA--C 1.523 0.543 0 C-N-CA 124.773 1.178 . . . . 0.0 113.153 -170.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.2 -56.81 5.08 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 127.659 2.552 . . . . 0.0 113.656 163.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.9 -11.16 0.05 OUTLIER Glycine 0 C--N 1.335 0.522 0 C-N-CA 125.23 1.395 . . . . 0.0 115.53 -177.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.2 t -49.58 -27.15 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 C-N-CA 126.999 2.12 . . . . 0.0 115.779 -170.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.16 -89.34 0.17 Allowed Glycine 0 C--N 1.335 0.486 0 CA-C-N 122.028 2.194 . . . . 0.0 115.773 160.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -129.83 -176.89 4.06 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 127.645 2.378 . . . . 0.0 113.029 -166.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -155.52 -10.33 0.11 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 116.657 2.095 . . . . 0.0 116.657 169.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.122 -1.932 . . . . 0.0 116.679 -176.989 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.506 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.11 -111.14 0.32 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-N 121.376 2.588 . . . . 0.0 115.925 176.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.4 p -138.21 145.06 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 128.64 2.776 . . . . 0.0 111.218 -159.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.56 -173.95 33.65 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 127.483 2.468 . . . . 0.0 114.709 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.32 -53.84 5.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 172.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.2 pt -85.64 149.37 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-O 122.254 1.026 . . . . 0.0 113.412 178.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.6 tp -68.79 149.02 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 125.598 1.559 . . . . 0.0 114.26 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -118.91 -14.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 126.702 2.001 . . . . 0.0 111.683 175.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -35.45 -57.98 0.6 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.926 2.09 . . . . 0.0 115.299 177.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -47.18 -37.87 10.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 116.902 2.186 . . . . 0.0 116.902 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 34.3 pt -109.74 -10.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 127.613 2.365 . . . . 0.0 115.73 -178.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -144.59 39.09 1.24 Allowed Glycine 0 C--N 1.336 0.535 0 O-C-N 119.579 -1.951 . . . . 0.0 114.296 -165.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.23 -80.29 1.64 Allowed Glycine 0 CA--C 1.522 0.512 0 C-N-CA 126.007 1.765 . . . . 0.0 112.692 163.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.7 2.64 0.04 OUTLIER Glycine 0 CA--C 1.522 0.509 0 N-CA-C 116.596 1.398 . . . . 0.0 116.596 -165.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.3 t -72.31 -42.29 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 CA-C-N 118.154 0.977 . . . . 0.0 109.949 -169.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -100.2 0.2 Allowed Glycine 0 N--CA 1.448 -0.518 0 CA-C-O 121.757 0.643 . . . . 0.0 113.2 175.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -119.34 178.08 4.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 128.451 2.7 . . . . 0.0 112.675 -167.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -149.39 -32.9 0.21 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 117.599 2.444 . . . . 0.0 117.599 170.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.144 0 CA-C-O 116.917 -2.046 . . . . 0.0 113.078 -175.994 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.524 0 N-CA-C 116.8 1.48 . . . . 0.0 116.8 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.44 -107.1 0.2 Allowed Glycine 0 C--N 1.335 0.513 0 CA-C-N 119.847 1.824 . . . . 0.0 114.726 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.8 p -128.66 153.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 126.86 2.064 . . . . 0.0 114.259 -152.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 109.21 -142.16 16.15 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 115.367 0.907 . . . . 0.0 115.367 162.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -77.0 -32.67 57.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 116.777 2.14 . . . . 0.0 116.777 -153.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.8 pt -139.75 150.39 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-O 121.903 0.858 . . . . 0.0 109.959 -175.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.1 tp -58.95 150.18 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.794 2.038 . . . . 0.0 113.369 -171.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -133.77 -27.23 1.5 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 126.586 1.955 . . . . 0.0 110.709 175.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -51.46 -40.44 59.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 121.389 1.904 . . . . 0.0 115.516 -166.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 12.6 p90 -55.54 -14.08 1.88 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.715 2.006 . . . . 0.0 115.372 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.1 pt -118.77 -38.6 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 C-N-CA 125.968 1.707 . . . . 0.0 112.224 162.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.88 67.02 0.78 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 127.992 2.71 . . . . 0.0 112.276 -171.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 47.9 -93.15 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 129.21 3.29 . . . . 0.0 114.239 178.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -143.8 3.09 1.51 Allowed Glycine 0 C--N 1.335 0.52 0 C-N-CA 125.41 1.481 . . . . 0.0 116.544 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -63.34 -37.66 80.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 119.402 1.601 . . . . 0.0 113.408 -160.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.89 -99.86 0.22 Allowed Glycine 0 C--N 1.335 0.516 0 C-N-CA 125.912 1.72 . . . . 0.0 112.455 171.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -116.17 -174.08 2.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.135 2.174 . . . . 0.0 114.288 -171.219 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -153.89 -20.91 0.14 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 115.427 1.64 . . . . 0.0 115.427 168.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 127.019 2.247 . . . . 0.0 116.852 -179.051 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.482 0 N-CA-C 120.819 3.087 . . . . 0.0 120.819 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.05 -117.29 0.42 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-N 120.9 2.35 . . . . 0.0 115.251 -174.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -133.0 159.09 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 127.304 2.241 . . . . 0.0 109.894 -170.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.31 -162.88 29.69 Favored Glycine 0 CA--C 1.523 0.546 0 O-C-N 119.682 -1.886 . . . . 0.0 110.293 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 mttp -86.32 -70.79 0.58 Allowed 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 125.023 1.329 . . . . 0.0 113.469 -176.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.448 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.9 pt -73.46 157.23 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 122.545 1.164 . . . . 0.0 112.311 171.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.9 tp -71.62 142.64 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 127.836 2.454 . . . . 0.0 115.027 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -105.29 -23.42 12.87 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 129.323 3.049 . . . . 0.0 110.459 173.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 4.6 t80 -43.11 -49.08 6.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.642 2.777 . . . . 0.0 115.424 -168.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -63.71 -11.9 30.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.083 1.753 . . . . 0.0 114.442 -175.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.5 pt -127.38 16.28 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 127.702 2.401 . . . . 0.0 113.078 172.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.09 73.1 0.23 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.439 1.018 . . . . 0.0 113.151 -168.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 25.79 -84.92 0.0 OUTLIER Glycine 0 N--CA 1.448 -0.502 1 C-N-CA 132.13 4.681 . . . . 0.0 114.728 -176.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -160.95 76.06 0.18 Allowed Glycine 0 C--N 1.336 0.546 0 C-N-CA 126.2 1.857 . . . . 0.0 113.032 161.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.21 -55.7 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 CA-C-O 122.173 0.987 . . . . 0.0 111.404 177.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.11 -110.65 0.45 Allowed Glycine 0 C--N 1.336 0.539 0 O-C-N 119.433 -2.042 . . . . 0.0 114.393 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -123.03 172.42 8.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.875 2.07 . . . . 0.0 115.407 -162.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -152.5 -7.24 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.233 1.568 . . . . 0.0 115.233 173.732 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.448 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 115.819 -2.656 . . . . 0.0 115.929 -171.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.473 0 N-CA-C 117.597 1.799 . . . . 0.0 117.597 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.33 -144.32 4.03 Favored Glycine 0 CA--C 1.522 0.493 0 CA-C-N 120.118 1.959 . . . . 0.0 115.412 -174.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 53.5 t -99.34 142.31 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 127.92 2.488 . . . . 0.0 108.022 175.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 167.11 -173.16 42.33 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 125.976 1.751 . . . . 0.0 114.45 -171.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -85.46 -44.96 12.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 115.939 1.829 . . . . 0.0 115.939 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 36.9 pt -103.84 133.13 48.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 126.468 1.907 . . . . 0.0 111.007 -166.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.9 tp -63.62 117.63 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 C-N-CA 127.307 2.243 . . . . 0.0 115.256 -164.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -95.19 -21.62 18.36 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 127.042 2.137 . . . . 0.0 112.494 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -49.46 -47.47 48.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.098 1.759 . . . . 0.0 110.355 -173.044 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -58.75 -17.88 26.92 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.018 2.127 . . . . 0.0 115.79 -175.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.7 pt -132.16 -9.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 125.714 1.605 . . . . 0.0 113.948 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -124.34 40.93 1.82 Allowed Glycine 0 CA--C 1.522 0.497 0 C-N-CA 129.286 3.327 . . . . 0.0 112.141 -170.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.98 -81.22 0.05 OUTLIER Glycine 0 C--N 1.335 0.516 0 C-N-CA 128.646 3.022 . . . . 0.0 111.658 -177.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -158.75 23.41 0.33 Allowed Glycine 0 C--N 1.335 0.49 0 C-N-CA 127.11 2.291 . . . . 0.0 115.79 174.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.23 -63.07 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 119.348 1.574 . . . . 0.0 112.901 -169.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.34 -105.58 0.21 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 120.236 1.38 . . . . 0.0 113.907 -176.133 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.7 mpt_? -146.89 154.58 41.46 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.967 1.707 . . . . 0.0 114.99 -171.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -127.4 7.6 6.43 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 120.735 3.606 . . . . 0.0 120.735 -162.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 118.733 -1.037 . . . . 0.0 115.182 -178.552 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.472 0 N-CA-C 116.45 1.34 . . . . 0.0 116.45 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.47 -100.11 0.14 Allowed Glycine 0 CA--C 1.522 0.527 0 C-N-CA 126.629 2.062 . . . . 0.0 108.61 176.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.2 t -114.35 160.94 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 126.685 1.994 . . . . 0.0 109.164 177.161 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.97 -177.63 33.76 Favored Glycine 0 C--N 1.335 0.503 0 O-C-N 120.956 -1.09 . . . . 0.0 114.315 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.2 mttp -67.43 -53.91 24.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.201 2.2 . . . . 0.0 112.52 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.438 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.3 pt -114.38 155.13 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 CA-C-O 122.685 1.231 . . . . 0.0 111.761 -168.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -69.38 139.56 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 113.227 -1.806 . . . . 0.0 114.746 -160.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -117.55 -20.29 9.07 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 127.024 2.13 . . . . 0.0 111.736 171.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -45.62 -33.08 2.66 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 116.2 1.926 . . . . 0.0 116.2 173.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -67.23 -14.01 62.51 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 127.826 2.45 . . . . 0.0 115.532 175.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 36.2 pt -129.16 -6.9 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 127.459 2.304 . . . . 0.0 114.36 176.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -152.48 92.5 0.14 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.738 1.637 . . . . 0.0 113.55 -175.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 29.03 -93.56 0.01 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 130.012 3.672 . . . . 0.0 115.02 159.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -124.49 17.73 7.35 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 126.691 2.091 . . . . 0.0 113.922 175.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.1 t -90.32 40.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.527 2.331 . . . . 0.0 111.92 -170.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 43.48 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 129.617 3.484 . . . . 0.0 118.286 167.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -138.54 170.42 16.03 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.281 1.833 . . . . 0.0 113.81 -166.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -146.18 -2.86 0.68 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 174.349 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.438 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.25 1.105 0 N-CA-C 117.543 1.777 . . . . 0.0 117.543 -175.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.455 0 CA-C-O 121.221 0.345 . . . . 0.0 112.69 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 165.39 -48.04 0.28 Allowed Glycine 0 CA--C 1.522 0.515 0 C-N-CA 128.359 2.885 . . . . 0.0 114.486 168.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -119.25 137.61 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 126.779 2.032 . . . . 0.0 111.588 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.19 -171.21 37.17 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 116.489 1.356 . . . . 0.0 116.489 -179.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 40.6 mttp -76.61 -50.46 13.76 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 129.458 3.103 . . . . 0.0 114.095 177.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.1 pt -121.29 151.96 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 O-C-N 124.251 0.97 . . . . 0.0 111.782 -172.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.492 HG13 ' H ' ' A' ' 9' ' ' TYR . 7.7 tp -68.91 139.02 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 127.762 2.425 . . . . 0.0 115.003 -165.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -111.11 -3.04 15.61 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.57 2.348 . . . . 0.0 112.318 177.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.492 ' H ' HG13 ' A' ' 7' ' ' ILE . 71.1 t80 -47.21 -48.45 24.02 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 128.625 2.77 . . . . 0.0 115.437 -170.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.57 -9.11 16.93 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.8 pt -125.57 0.96 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 122.413 2.369 . . . . 0.0 113.655 172.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.66 5.52 10.69 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 126.98 2.229 . . . . 0.0 116.381 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.77 -70.55 0.93 Allowed Glycine 0 C--N 1.335 0.49 0 O-C-N 120.3 -1.706 . . . . 0.0 115.296 -171.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -163.46 13.95 0.1 Allowed Glycine 0 C--N 1.335 0.496 0 CA-C-O 117.878 -1.512 . . . . 0.0 115.582 -163.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.1 t -81.85 -75.09 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 121.254 2.527 . . . . 0.0 110.729 -177.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.44 -122.63 0.78 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 118.351 2.1 . . . . 0.0 118.351 178.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 68.7 mtt180 -107.85 176.84 5.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 126.852 2.061 . . . . 0.0 111.731 -168.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 p90 -151.66 -19.51 0.19 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 117.92 2.563 . . . . 0.0 117.92 174.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 117.682 -1.621 . . . . 0.0 113.994 -175.039 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 CA-C-O 116.534 -2.259 . . . . 0.0 116.439 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.3 -161.09 11.63 Favored Glycine 0 C--N 1.336 0.543 0 CA-C-N 120.694 2.247 . . . . 0.0 111.001 -177.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -133.08 153.96 38.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.208 1.803 . . . . 0.0 109.431 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.13 -141.44 8.25 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.966 -2.053 . . . . 0.0 107.966 -161.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mtmp? -126.27 -54.45 1.47 Allowed 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 116.225 -1.845 . . . . 0.0 112.394 -166.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 32.8 pt -79.27 136.11 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 CA-C-N 120.3 1.409 . . . . 0.0 109.53 174.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.508 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.8 tp -70.9 139.23 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 114.279 1.214 . . . . 0.0 114.279 -170.129 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -90.88 -4.7 56.35 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.405 1.882 . . . . 0.0 113.231 174.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.508 ' H ' HG13 ' A' ' 7' ' ' ILE . 72.8 t80 -46.64 -58.15 4.11 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 126.166 1.786 . . . . 0.0 113.689 -174.587 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.2 -13.7 5.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 119.345 -2.097 . . . . 0.0 115.59 176.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 29.7 pt -128.53 6.36 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 128.539 2.735 . . . . 0.0 115.254 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.77 -9.06 0.03 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 64.92 -18.66 0.12 Allowed Glycine 0 C--N 1.335 0.503 0 C-N-CA 128.246 2.831 . . . . 0.0 119.881 161.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.65 34.03 0.45 Allowed Glycine 0 C--N 1.335 0.482 0 CA-C-N 121.227 2.513 . . . . 0.0 116.514 -166.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 79.8 t -135.22 -76.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.871 1.836 . . . . 0.0 111.799 177.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -176.93 -115.69 0.44 Allowed Glycine 0 N--CA 1.448 -0.527 0 O-C-N 120.573 -1.329 . . . . 0.0 115.598 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 8.9 mpt_? -112.79 178.63 4.22 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.801 2.04 . . . . 0.0 112.5 -172.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -149.06 -3.82 0.43 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 116.889 2.181 . . . . 0.0 116.889 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 O-C-N 119.132 -2.23 . . . . 0.0 113.354 -176.95 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.466 0 N-CA-C 119.302 2.481 . . . . 0.0 119.302 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.15 -105.37 0.18 Allowed Glycine 0 C--N 1.335 0.519 0 O-C-N 119.852 -1.969 . . . . 0.0 112.196 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -150.8 170.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-O 121.132 0.491 . . . . 0.0 110.238 -175.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.02 -119.68 1.27 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 124.202 0.906 . . . . 0.0 112.64 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.9 mttp -130.35 -55.94 1.09 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 128.899 2.88 . . . . 0.0 110.566 -169.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.6 pt -90.35 149.91 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.054 1.342 . . . . 0.0 111.238 -175.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.2 tp -86.29 149.21 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.698 1.999 . . . . 0.0 112.889 -160.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -128.33 -31.62 2.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 126.784 2.034 . . . . 0.0 116.11 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -54.32 -24.88 20.99 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 -165.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -69.73 -22.7 63.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.502 2.321 . . . . 0.0 113.475 176.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 24.1 pt -110.06 20.78 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.418 2.287 . . . . 0.0 111.635 169.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -138.52 -69.52 0.05 OUTLIER Glycine 0 CA--C 1.523 0.535 0 O-C-N 120.651 -1.281 . . . . 0.0 114.313 -170.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 150.74 -82.02 0.18 Allowed Glycine 0 C--N 1.335 0.507 0 C-N-CA 129.511 3.434 . . . . 0.0 110.143 -167.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.63 2.69 0.09 OUTLIER Glycine 0 C--N 1.335 0.507 0 N-CA-C 118.693 2.237 . . . . 0.0 118.693 -166.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 76.2 t -67.95 -29.62 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-N 120.644 2.222 . . . . 0.0 112.966 -179.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.47 -96.89 0.71 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 126.471 1.986 . . . . 0.0 113.327 161.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -95.87 178.92 5.28 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.302 2.641 . . . . 0.0 113.675 -178.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.4 p90 -159.46 -8.57 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 121.002 1.728 . . . . 0.0 114.981 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 117.08 -1.955 . . . . 0.0 111.707 -171.14 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.468 0 CA-C-O 122.554 1.085 . . . . 0.0 112.171 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.19 -70.16 0.03 OUTLIER Glycine 0 CA--C 1.522 0.525 0 C-N-CA 126.001 1.762 . . . . 0.0 113.041 172.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.9 t -137.49 154.44 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.293 1.837 . . . . 0.0 108.035 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.87 -168.53 33.42 Favored Glycine 0 C--N 1.335 0.514 0 O-C-N 121.102 -0.999 . . . . 0.0 111.697 -166.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.2 mttp -98.1 -53.84 3.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 115.553 -2.165 . . . . 0.0 112.95 -172.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.44 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 31.2 pt -84.5 151.38 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.939 1.245 . . . . 0.0 111.695 169.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.89 147.77 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 126.849 2.059 . . . . 0.0 114.119 -178.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -113.9 -20.38 11.09 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.534 2.734 . . . . 0.0 112.272 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 49.3 t80 -10.71 -73.33 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 129.916 3.286 . . . . 0.0 115.248 169.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -54.72 -18.51 4.75 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 131.204 3.802 . . . . 0.0 115.649 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.6 pt -121.01 15.21 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 C-N-CA 127.614 2.365 . . . . 0.0 114.598 175.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -140.06 -2.77 1.56 Allowed Glycine 0 C--N 1.335 0.505 0 N-CA-C 116.08 1.192 . . . . 0.0 116.08 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.64 -73.5 0.62 Allowed Glycine 0 CA--C 1.523 0.55 0 CA-C-N 118.618 1.209 . . . . 0.0 110.16 -170.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -145.29 85.01 0.18 Allowed Glycine 0 N--CA 1.449 -0.493 0 CA-C-O 117.807 -1.552 . . . . 0.0 113.341 177.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.6 t -132.25 -29.45 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 CA-C-N 119.476 1.638 . . . . 0.0 114.738 -171.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.86 -126.88 7.42 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 120.459 1.482 . . . . 0.0 113.919 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -124.57 171.12 10.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.726 1.21 . . . . 0.0 112.134 -168.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -154.71 5.01 0.24 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.44 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.162 0 CA-C-O 116.964 -2.02 . . . . 0.0 112.821 175.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.521 0 N-CA-C 114.694 0.638 . . . . 0.0 114.694 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.62 -129.94 1.32 Allowed Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 173.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 82.7 t -60.88 144.08 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 125.64 1.576 . . . . 0.0 108.657 160.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 168.37 -170.29 42.04 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 114.772 0.669 . . . . 0.0 114.772 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -101.23 -71.91 0.7 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 128.874 2.87 . . . . 0.0 114.758 -175.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.1 pt -84.55 147.04 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 C-N-CA 125.325 1.45 . . . . 0.0 111.721 177.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 tp -73.57 150.42 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 124.331 1.052 . . . . 0.0 113.542 -160.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -111.08 -2.17 15.97 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.096 1.759 . . . . 0.0 112.233 -176.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.0 t80 -52.61 -53.46 46.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -167.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -76.66 -5.14 46.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -177.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.9 pt -124.68 -15.55 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 126.635 1.974 . . . . 0.0 114.946 -176.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -123.52 19.08 7.61 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 126.503 2.001 . . . . 0.0 117.164 176.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.12 -54.51 3.89 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-N 118.76 1.28 . . . . 0.0 115.151 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.23 74.51 0.04 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.514 2.959 . . . . 0.0 113.074 -177.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 77.5 t -122.21 -51.29 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 118.777 1.289 . . . . 0.0 111.656 -171.23 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 156.15 -98.85 0.18 Allowed Glycine 0 C--N 1.336 0.551 0 CA-C-N 118.821 0.737 . . . . 0.0 112.387 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.5 mpt_? -127.56 171.81 11.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 127.054 2.141 . . . . 0.0 112.144 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -143.87 -12.82 0.65 Allowed 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 120.096 -1.628 . . . . 0.0 115.089 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 126.298 1.904 . . . . 0.0 115.352 173.824 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.547 0 N-CA-C 112.923 -0.071 . . . . 0.0 112.923 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.37 -48.46 0.04 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.66 149.36 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.694 1.197 . . . . 0.0 112.158 -170.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.07 -157.31 27.34 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 120.01 -1.682 . . . . 0.0 115.559 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -85.96 -38.85 17.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.362 3.065 . . . . 0.0 114.956 -169.362 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.4 pt -134.59 155.33 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 125.955 1.702 . . . . 0.0 111.173 -174.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.403 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.7 tp -78.51 133.93 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.755 2.022 . . . . 0.0 114.48 -165.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -86.27 -8.96 57.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 118.41 -2.681 . . . . 0.0 114.836 171.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.403 ' H ' HG13 ' A' ' 7' ' ' ILE . 59.6 t80 -38.87 -64.41 0.45 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.58 2.352 . . . . 0.0 113.81 -169.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -69.21 -9.39 52.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 115.924 1.824 . . . . 0.0 115.924 -176.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 25.2 pt -114.77 -18.45 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 125.965 1.706 . . . . 0.0 113.321 178.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -145.28 41.32 1.06 Allowed Glycine 0 C--N 1.335 0.509 0 C-N-CA 127.873 2.654 . . . . 0.0 115.117 -173.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.77 -45.87 2.78 Favored Glycine 0 CA--C 1.522 0.519 0 C-N-CA 128.036 2.731 . . . . 0.0 115.642 161.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.52 21.89 0.09 OUTLIER Glycine 0 CA--C 1.523 0.532 0 N-CA-C 117.111 1.604 . . . . 0.0 117.111 173.007 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -59.31 -33.2 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 124.997 1.319 . . . . 0.0 113.937 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.52 -148.38 20.11 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 119.704 -1.873 . . . . 0.0 113.49 -176.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -80.92 179.54 7.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 178.267 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -160.47 -13.44 0.05 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 176.217 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.983 -1.454 . . . . 0.0 114.369 -178.759 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 N-CA-C 118.687 2.235 . . . . 0.0 118.687 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -160.88 -160.05 10.41 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 120.75 2.275 . . . . 0.0 117.946 -174.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 89.5 t -91.63 150.73 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 124.811 1.244 . . . . 0.0 108.617 173.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.91 -169.28 35.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 116.154 1.222 . . . . 0.0 116.154 -173.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -71.75 -71.07 0.29 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.08 2.952 . . . . 0.0 112.812 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.3 pt -99.76 139.09 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 124.786 1.234 . . . . 0.0 112.628 -164.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.3 tp -67.34 145.85 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 126.17 1.788 . . . . 0.0 112.563 -169.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -109.47 -29.8 8.24 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 127.558 2.343 . . . . 0.0 112.336 -171.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -63.07 -21.03 65.9 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.488 -2.007 . . . . 0.0 115.703 -163.709 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -52.49 -25.77 11.14 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 126.529 1.932 . . . . 0.0 113.662 170.139 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 17.7 pt -121.52 -18.74 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.67 2.388 . . . . 0.0 111.839 169.466 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.8 -124.18 3.2 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 127.521 2.486 . . . . 0.0 111.841 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -177.66 -9.41 0.02 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 120.402 2.921 . . . . 0.0 120.402 -177.466 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 152.88 57.19 0.01 OUTLIER Glycine 0 CA--C 1.523 0.544 0 CA-C-N 120.478 2.139 . . . . 0.0 116.087 172.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.8 t -128.74 -44.42 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 126.198 1.799 . . . . 0.0 110.461 178.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.22 -94.04 0.15 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.154 1.835 . . . . 0.0 115.316 175.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -132.56 169.03 17.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.205 1.802 . . . . 0.0 113.545 -159.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -148.14 12.85 0.97 Allowed 'General case' 0 N--CA 1.449 -0.513 0 CA-C-O 117.864 -1.065 . . . . 0.0 113.699 -174.025 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-N 120.953 1.706 . . . . 0.0 112.305 -177.586 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 CA-C-O 117.974 -1.459 . . . . 0.0 114.381 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.16 -109.92 0.31 Allowed Glycine 0 C--N 1.336 0.549 0 C-N-CA 125.03 1.3 . . . . 0.0 110.668 -172.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.2 p -72.16 159.29 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 122.137 0.97 . . . . 0.0 112.748 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.75 -152.65 24.72 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 127.112 2.291 . . . . 0.0 115.599 170.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -129.0 -46.91 1.23 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 127.511 2.324 . . . . 0.0 110.754 172.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.0 pt -73.35 133.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 125.108 1.363 . . . . 0.0 112.618 171.258 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.7 tp -63.76 157.52 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.263 1.825 . . . . 0.0 113.113 -170.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -136.15 -24.48 1.26 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 127.17 2.188 . . . . 0.0 113.083 171.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -48.19 -29.33 3.63 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 115.99 1.848 . . . . 0.0 115.99 -164.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -60.51 -28.96 68.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 116.942 2.201 . . . . 0.0 116.942 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 27.3 pt -96.27 -33.86 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 127.577 2.351 . . . . 0.0 111.384 160.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -95.61 53.04 1.75 Allowed Glycine 0 C--N 1.335 0.522 0 CA-C-O 118.309 -1.273 . . . . 0.0 114.643 -170.185 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 51.49 -94.43 0.01 OUTLIER Glycine 0 C--N 1.335 0.502 0 C-N-CA 126.578 2.037 . . . . 0.0 116.253 173.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -131.11 9.05 5.69 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.751 2.12 . . . . 0.0 115.562 171.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -72.0 -56.67 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 128.043 2.537 . . . . 0.0 113.725 -157.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 154.88 -125.37 1.68 Allowed Glycine 0 CA--C 1.523 0.547 0 CA-C-N 120.974 1.715 . . . . 0.0 115.649 -172.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -112.29 -178.58 3.45 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 128.179 2.591 . . . . 0.0 111.41 -161.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -143.1 -1.51 1.07 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 119.075 2.991 . . . . 0.0 119.075 163.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 O-C-N 119.623 -1.923 . . . . 0.0 113.931 -178.496 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.539 0 CA-C-O 116.81 -2.106 . . . . 0.0 118.161 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.88 -100.07 0.14 Allowed Glycine 0 C--N 1.336 0.533 0 CA-C-N 119.649 1.724 . . . . 0.0 115.334 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.3 p -156.01 176.56 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-N 121.064 2.432 . . . . 0.0 110.052 -172.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 111.29 -97.9 0.99 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-O 119.72 -0.489 . . . . 0.0 114.126 153.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.6 mttp -107.71 -103.31 0.35 Allowed 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 125.459 1.504 . . . . 0.0 111.007 -163.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.8 pt -63.09 154.35 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 115.716 1.747 . . . . 0.0 115.716 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.8 tp -73.74 156.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.946 1.699 . . . . 0.0 111.838 -174.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -142.56 -22.36 0.66 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.99 2.219 . . . . 0.0 116.99 -178.307 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 25.0 p90 -56.16 -34.85 66.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 119.832 1.197 . . . . 0.0 113.319 -161.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.72 -20.02 45.18 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 119.522 1.055 . . . . 0.0 113.698 177.118 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.3 pt -122.91 20.96 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.601 1.96 . . . . 0.0 111.704 169.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.03 60.29 0.33 Allowed Glycine 0 C--N 1.335 0.513 0 C-N-CA 127.793 2.616 . . . . 0.0 112.341 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.25 -96.59 0.01 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.331 2.872 . . . . 0.0 114.983 174.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.2 14.43 4.57 Favored Glycine 0 CA--C 1.522 0.513 0 C-N-CA 129.347 3.356 . . . . 0.0 115.462 176.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -60.16 -50.99 78.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.619 1.71 . . . . 0.0 110.69 -176.432 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 133.53 -88.15 0.26 Allowed Glycine 0 CA--C 1.523 0.542 0 O-C-N 124.77 1.294 . . . . 0.0 115.915 174.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -114.41 -172.87 2.19 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 128.527 2.731 . . . . 0.0 111.35 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -159.4 -12.97 0.06 Allowed 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 116.57 2.063 . . . . 0.0 116.57 169.105 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 117.23 -1.872 . . . . 0.0 116.185 -168.145 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.56 -85.64 0.06 OUTLIER Glycine 0 CA--C 1.522 0.528 0 C-N-CA 126.821 2.153 . . . . 0.0 108.974 170.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.44 158.48 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 126.211 1.805 . . . . 0.0 112.087 176.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.05 -173.99 33.3 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 119.414 -2.054 . . . . 0.0 113.969 -178.102 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -68.51 -27.8 66.44 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 128.48 2.712 . . . . 0.0 116.757 -174.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.9 pt -140.56 163.72 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 124.808 1.243 . . . . 0.0 112.341 -171.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.69 141.36 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.247 2.219 . . . . 0.0 114.218 -166.175 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -126.17 -22.41 4.08 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 127.618 2.367 . . . . 0.0 113.482 174.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -53.16 -32.41 47.55 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 118.227 2.677 . . . . 0.0 118.227 -169.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -66.37 -15.61 63.42 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 116.29 1.959 . . . . 0.0 116.29 177.028 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 20.6 pt -117.76 11.74 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 128.968 2.907 . . . . 0.0 110.723 169.304 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -155.51 55.61 0.41 Allowed Glycine 0 CA--C 1.522 0.506 0 C-N-CA 126.203 1.858 . . . . 0.0 111.317 -161.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 28.62 -88.66 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 1 C-N-CA 131.973 4.606 . . . . 0.0 115.102 179.297 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.38 33.62 2.55 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 126.354 1.93 . . . . 0.0 114.351 172.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 81.9 t -73.16 -79.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 127.162 2.185 . . . . 0.0 110.306 -178.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -93.12 0.14 Allowed Glycine 0 CA--C 1.522 0.513 0 O-C-N 121.79 -0.569 . . . . 0.0 113.841 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.4 mtt85 -126.33 177.43 6.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 127.661 2.384 . . . . 0.0 113.367 -169.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -154.89 -25.05 0.12 Allowed 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 118.183 2.66 . . . . 0.0 118.183 178.564 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.155 0 C-N-CA 129.336 3.351 . . . . 0.0 115.843 -179.323 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.496 ' H ' ' CG1' ' A' ' 15' ' ' VAL . . . 104.86 -107.53 2.91 Favored Glycine 0 C--N 1.335 0.475 0 O-C-N 120.871 -1.37 . . . . 0.0 112.722 -175.263 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.46 163.68 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 C-N-CA 125.538 1.535 . . . . 0.0 108.935 165.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 149.45 -171.9 29.53 Favored Glycine 0 C--N 1.335 0.515 0 O-C-N 120.704 -1.247 . . . . 0.0 113.568 177.271 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 mptp? -66.45 -83.69 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 125.341 1.456 . . . . 0.0 112.277 -177.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 pt -64.49 149.93 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-O 121.397 0.618 . . . . 0.0 112.154 -175.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.6 tp -61.93 154.04 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.234 1.814 . . . . 0.0 114.97 -179.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -133.8 -26.48 1.56 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.228 2.611 . . . . 0.0 114.941 174.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -55.05 -24.2 23.72 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 118.219 2.674 . . . . 0.0 118.219 -173.323 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -65.81 -16.23 63.62 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.983 1.313 . . . . 0.0 114.474 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.5 pt -123.16 -19.97 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 127.593 2.357 . . . . 0.0 112.591 172.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.36 41.13 2.26 Favored Glycine 0 CA--C 1.522 0.523 0 C-N-CA 128.284 2.85 . . . . 0.0 112.071 179.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.94 -95.61 0.04 OUTLIER Glycine 0 C--N 1.335 0.503 0 C-N-CA 126.485 1.993 . . . . 0.0 116.106 171.006 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -123.77 2.99 9.33 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 126.584 2.04 . . . . 0.0 112.637 -176.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.496 ' CG1' ' H ' ' A' ' 2' ' ' GLY . 50.7 t -53.73 -66.59 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.712 1.605 . . . . 0.0 113.867 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.83 -110.44 0.58 Allowed Glycine 0 C--N 1.335 0.525 0 CA-C-O 118.39 -1.228 . . . . 0.0 114.565 -175.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 60.8 mtm-85 -129.03 167.44 17.49 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 128.595 2.758 . . . . 0.0 110.225 -165.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -151.61 -12.49 0.2 Allowed 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 -178.347 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.127 0 O-C-N 125.522 1.764 . . . . 0.0 116.74 -175.962 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.483 0 CA-C-O 121.981 0.767 . . . . 0.0 112.826 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.58 -95.36 1.34 Allowed Glycine 0 C--N 1.335 0.517 0 C-N-CA 126.447 1.975 . . . . 0.0 112.433 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.86 157.83 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 124.703 1.201 . . . . 0.0 110.206 173.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 160.49 -167.05 35.58 Favored Glycine 0 CA--C 1.523 0.539 0 O-C-N 120.836 -1.165 . . . . 0.0 115.381 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -92.81 -64.84 1.05 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.897 1.679 . . . . 0.0 112.585 176.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 10.7 pt -78.0 145.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 O-C-N 121.489 -0.757 . . . . 0.0 112.083 -179.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.7 tp -65.04 149.25 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 C-N-CA 124.488 1.115 . . . . 0.0 112.271 -169.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -122.4 -20.43 6.1 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 128.535 2.734 . . . . 0.0 112.763 172.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -40.39 -44.95 2.08 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.434 1.894 . . . . 0.0 114.582 175.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -50.38 -21.74 1.56 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.195 1.924 . . . . 0.0 116.195 174.243 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 pt -131.07 -1.98 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 126.326 1.85 . . . . 0.0 114.734 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -137.0 67.93 0.53 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.945 2.212 . . . . 0.0 112.481 -167.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 30.95 -100.34 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 C-N-CA 129.037 3.208 . . . . 0.0 115.491 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -127.0 13.46 6.72 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 116.063 1.185 . . . . 0.0 116.063 172.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.1 t -61.26 -37.82 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -171.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.77 -93.03 0.37 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 124.997 1.284 . . . . 0.0 112.616 166.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -120.75 175.45 6.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.563 1.945 . . . . 0.0 113.75 -172.793 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.54 -29.8 0.51 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 172.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.122 0 CA-C-N 120.55 1.523 . . . . 0.0 115.782 -172.029 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.488 0 N-CA-C 118.994 2.358 . . . . 0.0 118.994 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.35 -101.84 0.22 Allowed Glycine 0 CA--C 1.522 0.525 0 C-N-CA 128.777 3.084 . . . . 0.0 114.362 165.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 p -73.47 156.25 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 124.272 1.029 . . . . 0.0 112.234 168.096 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 133.81 -175.44 20.29 Favored Glycine 0 CA--C 1.522 0.515 0 O-C-N 118.803 -2.436 . . . . 0.0 112.534 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.2 mttp -84.89 -79.43 0.22 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.449 2.3 . . . . 0.0 111.51 -173.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt -72.75 154.38 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-O 121.981 0.896 . . . . 0.0 111.91 -169.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -63.33 141.57 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 126.8 2.04 . . . . 0.0 112.649 -175.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -125.37 -25.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 127.359 2.263 . . . . 0.0 113.561 174.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -42.33 -40.29 2.43 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 127.791 2.436 . . . . 0.0 116.463 -172.207 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -53.93 -31.11 49.26 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 117.016 2.228 . . . . 0.0 117.016 174.373 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 18.1 pt -112.04 -19.59 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.419 1.488 . . . . 0.0 113.729 172.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -73.14 -34.06 58.67 Favored Glycine 0 C--N 1.335 0.497 0 CA-C-O 118.537 -1.146 . . . . 0.0 112.723 177.119 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.06 -100.21 2.53 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 118.755 1.278 . . . . 0.0 110.666 -169.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -109.54 29.63 9.3 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 128.123 2.773 . . . . 0.0 113.785 -176.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.3 t -107.48 -26.94 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 -157.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.25 -102.52 2.66 Favored Glycine 0 C--N 1.335 0.498 0 O-C-N 121.164 -0.96 . . . . 0.0 113.502 174.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -128.45 -174.51 3.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 124.945 1.298 . . . . 0.0 110.015 -160.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -164.44 -8.72 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 120.349 3.463 . . . . 0.0 120.349 173.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.093 0 C-N-CA 125.406 1.479 . . . . 0.0 115.114 -175.718 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.539 0 CA-C-O 121.728 0.626 . . . . 0.0 111.541 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 116.28 -151.37 18.35 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.947 1.261 . . . . 0.0 114.163 -174.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 90.5 t -70.31 147.34 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.375 1.87 . . . . 0.0 109.934 171.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.23 -173.65 34.11 Favored Glycine 0 CA--C 1.522 0.52 0 O-C-N 120.535 -1.353 . . . . 0.0 111.123 177.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 mttp -88.84 -77.57 0.37 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.506 2.322 . . . . 0.0 112.18 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.0 pt -76.32 141.04 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.524 1.929 . . . . 0.0 110.89 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.422 HG13 ' H ' ' A' ' 9' ' ' TYR . 4.8 tp -61.56 147.34 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.704 1.601 . . . . 0.0 113.197 -173.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -117.66 -3.04 11.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.933 2.493 . . . . 0.0 110.821 176.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.422 ' H ' HG13 ' A' ' 7' ' ' ILE . 60.8 t80 -38.1 -53.78 1.38 Allowed 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 128.197 2.599 . . . . 0.0 114.053 -176.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 25.5 p90 -73.35 -12.04 60.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 127.639 2.376 . . . . 0.0 114.485 -175.319 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.2 pt -133.74 -21.02 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 122.314 2.324 . . . . 0.0 116.346 -171.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -115.05 47.69 1.01 Allowed Glycine 0 C--N 1.335 0.498 0 CA-C-N 119.356 0.98 . . . . 0.0 114.359 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.65 -78.4 1.02 Allowed Glycine 0 CA--C 1.523 0.576 0 C-N-CA 124.017 0.818 . . . . 0.0 112.894 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 163.98 71.09 0.02 OUTLIER Glycine 0 CA--C 1.523 0.564 0 C-N-CA 126.071 1.796 . . . . 0.0 113.271 -175.012 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -120.78 -53.77 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 120.913 -1.345 . . . . 0.0 111.412 173.464 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.54 -95.75 0.11 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 121.517 1.962 . . . . 0.0 113.608 177.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -121.17 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.37 3.068 . . . . 0.0 114.281 -171.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -153.73 -30.83 0.12 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 116.984 2.216 . . . . 0.0 116.984 172.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.064 -1.965 . . . . 0.0 115.713 -171.008 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 119.529 2.572 . . . . 0.0 119.529 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.69 -140.6 2.93 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.891 2.186 . . . . 0.0 114.898 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.4 p -100.09 157.95 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.089 1.355 . . . . 0.0 113.038 176.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 141.78 -156.9 26.12 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 120.055 -1.653 . . . . 0.0 115.075 164.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -77.11 -76.53 0.17 Allowed 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.99 2.516 . . . . 0.0 113.347 -174.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.8 pt -80.02 147.47 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-O 122.609 1.195 . . . . 0.0 112.906 -174.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -61.96 138.8 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 C-N-CA 124.924 1.29 . . . . 0.0 113.026 -173.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -143.76 7.15 1.44 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.542 2.337 . . . . 0.0 113.423 -172.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -68.65 -26.74 65.48 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 118.75 -2.469 . . . . 0.0 113.959 -171.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -82.31 -8.15 59.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 117.546 2.424 . . . . 0.0 117.546 173.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.2 pt -133.0 82.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 127.192 2.197 . . . . 0.0 111.085 175.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 125.45 37.47 0.52 Allowed Glycine 0 CA--C 1.523 0.543 0 C-N-CA 124.773 1.178 . . . . 0.0 113.153 -170.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.2 -56.81 5.08 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 127.659 2.552 . . . . 0.0 113.656 163.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.9 -11.16 0.05 OUTLIER Glycine 0 C--N 1.335 0.522 0 C-N-CA 125.23 1.395 . . . . 0.0 115.53 -177.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.2 t -49.58 -27.15 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 C-N-CA 126.999 2.12 . . . . 0.0 115.779 -170.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.16 -89.34 0.17 Allowed Glycine 0 C--N 1.335 0.486 0 CA-C-N 122.028 2.194 . . . . 0.0 115.773 160.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -129.83 -176.89 4.06 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 127.645 2.378 . . . . 0.0 113.029 -166.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -155.52 -10.33 0.11 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 116.657 2.095 . . . . 0.0 116.657 169.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.122 -1.932 . . . . 0.0 116.679 -176.989 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.506 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.11 -111.14 0.32 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-N 121.376 2.588 . . . . 0.0 115.925 176.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.4 p -138.21 145.06 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 128.64 2.776 . . . . 0.0 111.218 -159.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.56 -173.95 33.65 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 127.483 2.468 . . . . 0.0 114.709 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.32 -53.84 5.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 172.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.2 pt -85.64 149.37 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-O 122.254 1.026 . . . . 0.0 113.412 178.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.6 tp -68.79 149.02 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 125.598 1.559 . . . . 0.0 114.26 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -118.91 -14.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 126.702 2.001 . . . . 0.0 111.683 175.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -35.45 -57.98 0.6 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.926 2.09 . . . . 0.0 115.299 177.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -47.18 -37.87 10.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 116.902 2.186 . . . . 0.0 116.902 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 34.3 pt -109.74 -10.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 127.613 2.365 . . . . 0.0 115.73 -178.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -144.59 39.09 1.24 Allowed Glycine 0 C--N 1.336 0.535 0 O-C-N 119.579 -1.951 . . . . 0.0 114.296 -165.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.23 -80.29 1.64 Allowed Glycine 0 CA--C 1.522 0.512 0 C-N-CA 126.007 1.765 . . . . 0.0 112.692 163.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.7 2.64 0.04 OUTLIER Glycine 0 CA--C 1.522 0.509 0 N-CA-C 116.596 1.398 . . . . 0.0 116.596 -165.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.3 t -72.31 -42.29 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 CA-C-N 118.154 0.977 . . . . 0.0 109.949 -169.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -100.2 0.2 Allowed Glycine 0 N--CA 1.448 -0.518 0 CA-C-O 121.757 0.643 . . . . 0.0 113.2 175.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -119.34 178.08 4.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 128.451 2.7 . . . . 0.0 112.675 -167.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -149.39 -32.9 0.21 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 117.599 2.444 . . . . 0.0 117.599 170.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.144 0 CA-C-O 116.917 -2.046 . . . . 0.0 113.078 -175.994 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.524 0 N-CA-C 116.8 1.48 . . . . 0.0 116.8 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.44 -107.1 0.2 Allowed Glycine 0 C--N 1.335 0.513 0 CA-C-N 119.847 1.824 . . . . 0.0 114.726 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.8 p -128.66 153.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 126.86 2.064 . . . . 0.0 114.259 -152.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 109.21 -142.16 16.15 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 115.367 0.907 . . . . 0.0 115.367 162.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -77.0 -32.67 57.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 116.777 2.14 . . . . 0.0 116.777 -153.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.8 pt -139.75 150.39 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-O 121.903 0.858 . . . . 0.0 109.959 -175.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.1 tp -58.95 150.18 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.794 2.038 . . . . 0.0 113.369 -171.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -133.77 -27.23 1.5 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 126.586 1.955 . . . . 0.0 110.709 175.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -51.46 -40.44 59.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 121.389 1.904 . . . . 0.0 115.516 -166.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 12.6 p90 -55.54 -14.08 1.88 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.715 2.006 . . . . 0.0 115.372 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.1 pt -118.77 -38.6 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 C-N-CA 125.968 1.707 . . . . 0.0 112.224 162.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.88 67.02 0.78 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 127.992 2.71 . . . . 0.0 112.276 -171.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 47.9 -93.15 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 129.21 3.29 . . . . 0.0 114.239 178.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -143.8 3.09 1.51 Allowed Glycine 0 C--N 1.335 0.52 0 C-N-CA 125.41 1.481 . . . . 0.0 116.544 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -63.34 -37.66 80.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 119.402 1.601 . . . . 0.0 113.408 -160.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.89 -99.86 0.22 Allowed Glycine 0 C--N 1.335 0.516 0 C-N-CA 125.912 1.72 . . . . 0.0 112.455 171.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -116.17 -174.08 2.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.135 2.174 . . . . 0.0 114.288 -171.219 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -153.89 -20.91 0.14 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 115.427 1.64 . . . . 0.0 115.427 168.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 127.019 2.247 . . . . 0.0 116.852 -179.051 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.482 0 N-CA-C 120.819 3.087 . . . . 0.0 120.819 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.05 -117.29 0.42 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-N 120.9 2.35 . . . . 0.0 115.251 -174.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -133.0 159.09 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 127.304 2.241 . . . . 0.0 109.894 -170.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.31 -162.88 29.69 Favored Glycine 0 CA--C 1.523 0.546 0 O-C-N 119.682 -1.886 . . . . 0.0 110.293 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 mttp -86.32 -70.79 0.58 Allowed 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 125.023 1.329 . . . . 0.0 113.469 -176.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.448 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.9 pt -73.46 157.23 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 122.545 1.164 . . . . 0.0 112.311 171.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.9 tp -71.62 142.64 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 127.836 2.454 . . . . 0.0 115.027 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -105.29 -23.42 12.87 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 129.323 3.049 . . . . 0.0 110.459 173.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 4.6 t80 -43.11 -49.08 6.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.642 2.777 . . . . 0.0 115.424 -168.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -63.71 -11.9 30.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.083 1.753 . . . . 0.0 114.442 -175.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.5 pt -127.38 16.28 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 127.702 2.401 . . . . 0.0 113.078 172.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.09 73.1 0.23 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.439 1.018 . . . . 0.0 113.151 -168.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 25.79 -84.92 0.0 OUTLIER Glycine 0 N--CA 1.448 -0.502 1 C-N-CA 132.13 4.681 . . . . 0.0 114.728 -176.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -160.95 76.06 0.18 Allowed Glycine 0 C--N 1.336 0.546 0 C-N-CA 126.2 1.857 . . . . 0.0 113.032 161.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.21 -55.7 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 CA-C-O 122.173 0.987 . . . . 0.0 111.404 177.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.11 -110.65 0.45 Allowed Glycine 0 C--N 1.336 0.539 0 O-C-N 119.433 -2.042 . . . . 0.0 114.393 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -123.03 172.42 8.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.875 2.07 . . . . 0.0 115.407 -162.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -152.5 -7.24 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.233 1.568 . . . . 0.0 115.233 173.732 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.448 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 115.819 -2.656 . . . . 0.0 115.929 -171.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.473 0 N-CA-C 117.597 1.799 . . . . 0.0 117.597 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.33 -144.32 4.03 Favored Glycine 0 CA--C 1.522 0.493 0 CA-C-N 120.118 1.959 . . . . 0.0 115.412 -174.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 53.5 t -99.34 142.31 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 127.92 2.488 . . . . 0.0 108.022 175.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 167.11 -173.16 42.33 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 125.976 1.751 . . . . 0.0 114.45 -171.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -85.46 -44.96 12.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 115.939 1.829 . . . . 0.0 115.939 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 36.9 pt -103.84 133.13 48.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 126.468 1.907 . . . . 0.0 111.007 -166.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.9 tp -63.62 117.63 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 C-N-CA 127.307 2.243 . . . . 0.0 115.256 -164.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -95.19 -21.62 18.36 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 127.042 2.137 . . . . 0.0 112.494 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -49.46 -47.47 48.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.098 1.759 . . . . 0.0 110.355 -173.044 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -58.75 -17.88 26.92 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.018 2.127 . . . . 0.0 115.79 -175.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.7 pt -132.16 -9.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 125.714 1.605 . . . . 0.0 113.948 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -124.34 40.93 1.82 Allowed Glycine 0 CA--C 1.522 0.497 0 C-N-CA 129.286 3.327 . . . . 0.0 112.141 -170.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.98 -81.22 0.05 OUTLIER Glycine 0 C--N 1.335 0.516 0 C-N-CA 128.646 3.022 . . . . 0.0 111.658 -177.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -158.75 23.41 0.33 Allowed Glycine 0 C--N 1.335 0.49 0 C-N-CA 127.11 2.291 . . . . 0.0 115.79 174.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.23 -63.07 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 119.348 1.574 . . . . 0.0 112.901 -169.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.34 -105.58 0.21 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 120.236 1.38 . . . . 0.0 113.907 -176.133 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.7 mpt_? -146.89 154.58 41.46 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.967 1.707 . . . . 0.0 114.99 -171.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -127.4 7.6 6.43 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 120.735 3.606 . . . . 0.0 120.735 -162.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 118.733 -1.037 . . . . 0.0 115.182 -178.552 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.472 0 N-CA-C 116.45 1.34 . . . . 0.0 116.45 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.47 -100.11 0.14 Allowed Glycine 0 CA--C 1.522 0.527 0 C-N-CA 126.629 2.062 . . . . 0.0 108.61 176.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.2 t -114.35 160.94 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 126.685 1.994 . . . . 0.0 109.164 177.161 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.97 -177.63 33.76 Favored Glycine 0 C--N 1.335 0.503 0 O-C-N 120.956 -1.09 . . . . 0.0 114.315 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.2 mttp -67.43 -53.91 24.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.201 2.2 . . . . 0.0 112.52 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.438 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.3 pt -114.38 155.13 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 CA-C-O 122.685 1.231 . . . . 0.0 111.761 -168.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -69.38 139.56 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 113.227 -1.806 . . . . 0.0 114.746 -160.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -117.55 -20.29 9.07 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 127.024 2.13 . . . . 0.0 111.736 171.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -45.62 -33.08 2.66 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 116.2 1.926 . . . . 0.0 116.2 173.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -67.23 -14.01 62.51 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 127.826 2.45 . . . . 0.0 115.532 175.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 36.2 pt -129.16 -6.9 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 127.459 2.304 . . . . 0.0 114.36 176.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -152.48 92.5 0.14 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.738 1.637 . . . . 0.0 113.55 -175.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 29.03 -93.56 0.01 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 130.012 3.672 . . . . 0.0 115.02 159.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -124.49 17.73 7.35 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 126.691 2.091 . . . . 0.0 113.922 175.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.1 t -90.32 40.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.527 2.331 . . . . 0.0 111.92 -170.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 43.48 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 129.617 3.484 . . . . 0.0 118.286 167.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -138.54 170.42 16.03 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.281 1.833 . . . . 0.0 113.81 -166.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -146.18 -2.86 0.68 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 174.349 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.438 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.25 1.105 0 N-CA-C 117.543 1.777 . . . . 0.0 117.543 -175.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.455 0 CA-C-O 121.221 0.345 . . . . 0.0 112.69 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 165.39 -48.04 0.28 Allowed Glycine 0 CA--C 1.522 0.515 0 C-N-CA 128.359 2.885 . . . . 0.0 114.486 168.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -119.25 137.61 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 126.779 2.032 . . . . 0.0 111.588 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.19 -171.21 37.17 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 116.489 1.356 . . . . 0.0 116.489 -179.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 40.6 mttp -76.61 -50.46 13.76 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 129.458 3.103 . . . . 0.0 114.095 177.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.1 pt -121.29 151.96 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 O-C-N 124.251 0.97 . . . . 0.0 111.782 -172.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.492 HG13 ' H ' ' A' ' 9' ' ' TYR . 7.7 tp -68.91 139.02 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 127.762 2.425 . . . . 0.0 115.003 -165.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -111.11 -3.04 15.61 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.57 2.348 . . . . 0.0 112.318 177.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.492 ' H ' HG13 ' A' ' 7' ' ' ILE . 71.1 t80 -47.21 -48.45 24.02 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 128.625 2.77 . . . . 0.0 115.437 -170.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.57 -9.11 16.93 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.8 pt -125.57 0.96 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 122.413 2.369 . . . . 0.0 113.655 172.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.66 5.52 10.69 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 126.98 2.229 . . . . 0.0 116.381 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.77 -70.55 0.93 Allowed Glycine 0 C--N 1.335 0.49 0 O-C-N 120.3 -1.706 . . . . 0.0 115.296 -171.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -163.46 13.95 0.1 Allowed Glycine 0 C--N 1.335 0.496 0 CA-C-O 117.878 -1.512 . . . . 0.0 115.582 -163.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.1 t -81.85 -75.09 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 121.254 2.527 . . . . 0.0 110.729 -177.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.44 -122.63 0.78 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 118.351 2.1 . . . . 0.0 118.351 178.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 68.7 mtt180 -107.85 176.84 5.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 126.852 2.061 . . . . 0.0 111.731 -168.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 p90 -151.66 -19.51 0.19 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 117.92 2.563 . . . . 0.0 117.92 174.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 117.682 -1.621 . . . . 0.0 113.994 -175.039 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 CA-C-O 116.534 -2.259 . . . . 0.0 116.439 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.3 -161.09 11.63 Favored Glycine 0 C--N 1.336 0.543 0 CA-C-N 120.694 2.247 . . . . 0.0 111.001 -177.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -133.08 153.96 38.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.208 1.803 . . . . 0.0 109.431 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.13 -141.44 8.25 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.966 -2.053 . . . . 0.0 107.966 -161.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mtmp? -126.27 -54.45 1.47 Allowed 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 116.225 -1.845 . . . . 0.0 112.394 -166.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 32.8 pt -79.27 136.11 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 CA-C-N 120.3 1.409 . . . . 0.0 109.53 174.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.508 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.8 tp -70.9 139.23 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 114.279 1.214 . . . . 0.0 114.279 -170.129 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -90.88 -4.7 56.35 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.405 1.882 . . . . 0.0 113.231 174.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.508 ' H ' HG13 ' A' ' 7' ' ' ILE . 72.8 t80 -46.64 -58.15 4.11 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 126.166 1.786 . . . . 0.0 113.689 -174.587 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.2 -13.7 5.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 119.345 -2.097 . . . . 0.0 115.59 176.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 29.7 pt -128.53 6.36 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 128.539 2.735 . . . . 0.0 115.254 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.77 -9.06 0.03 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 64.92 -18.66 0.12 Allowed Glycine 0 C--N 1.335 0.503 0 C-N-CA 128.246 2.831 . . . . 0.0 119.881 161.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.65 34.03 0.45 Allowed Glycine 0 C--N 1.335 0.482 0 CA-C-N 121.227 2.513 . . . . 0.0 116.514 -166.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 79.8 t -135.22 -76.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.871 1.836 . . . . 0.0 111.799 177.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -176.93 -115.69 0.44 Allowed Glycine 0 N--CA 1.448 -0.527 0 O-C-N 120.573 -1.329 . . . . 0.0 115.598 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 8.9 mpt_? -112.79 178.63 4.22 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.801 2.04 . . . . 0.0 112.5 -172.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -149.06 -3.82 0.43 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 116.889 2.181 . . . . 0.0 116.889 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 O-C-N 119.132 -2.23 . . . . 0.0 113.354 -176.95 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.466 0 N-CA-C 119.302 2.481 . . . . 0.0 119.302 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.15 -105.37 0.18 Allowed Glycine 0 C--N 1.335 0.519 0 O-C-N 119.852 -1.969 . . . . 0.0 112.196 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -150.8 170.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-O 121.132 0.491 . . . . 0.0 110.238 -175.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.02 -119.68 1.27 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 124.202 0.906 . . . . 0.0 112.64 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.9 mttp -130.35 -55.94 1.09 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 128.899 2.88 . . . . 0.0 110.566 -169.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.6 pt -90.35 149.91 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.054 1.342 . . . . 0.0 111.238 -175.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.2 tp -86.29 149.21 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.698 1.999 . . . . 0.0 112.889 -160.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -128.33 -31.62 2.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 126.784 2.034 . . . . 0.0 116.11 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -54.32 -24.88 20.99 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 -165.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -69.73 -22.7 63.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.502 2.321 . . . . 0.0 113.475 176.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 24.1 pt -110.06 20.78 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.418 2.287 . . . . 0.0 111.635 169.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -138.52 -69.52 0.05 OUTLIER Glycine 0 CA--C 1.523 0.535 0 O-C-N 120.651 -1.281 . . . . 0.0 114.313 -170.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 150.74 -82.02 0.18 Allowed Glycine 0 C--N 1.335 0.507 0 C-N-CA 129.511 3.434 . . . . 0.0 110.143 -167.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.63 2.69 0.09 OUTLIER Glycine 0 C--N 1.335 0.507 0 N-CA-C 118.693 2.237 . . . . 0.0 118.693 -166.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 76.2 t -67.95 -29.62 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-N 120.644 2.222 . . . . 0.0 112.966 -179.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.47 -96.89 0.71 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 126.471 1.986 . . . . 0.0 113.327 161.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -95.87 178.92 5.28 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.302 2.641 . . . . 0.0 113.675 -178.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.4 p90 -159.46 -8.57 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 121.002 1.728 . . . . 0.0 114.981 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 117.08 -1.955 . . . . 0.0 111.707 -171.14 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.468 0 CA-C-O 122.554 1.085 . . . . 0.0 112.171 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.19 -70.16 0.03 OUTLIER Glycine 0 CA--C 1.522 0.525 0 C-N-CA 126.001 1.762 . . . . 0.0 113.041 172.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.9 t -137.49 154.44 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.293 1.837 . . . . 0.0 108.035 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.87 -168.53 33.42 Favored Glycine 0 C--N 1.335 0.514 0 O-C-N 121.102 -0.999 . . . . 0.0 111.697 -166.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.2 mttp -98.1 -53.84 3.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 115.553 -2.165 . . . . 0.0 112.95 -172.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.44 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 31.2 pt -84.5 151.38 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.939 1.245 . . . . 0.0 111.695 169.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.89 147.77 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 126.849 2.059 . . . . 0.0 114.119 -178.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -113.9 -20.38 11.09 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.534 2.734 . . . . 0.0 112.272 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 49.3 t80 -10.71 -73.33 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 129.916 3.286 . . . . 0.0 115.248 169.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -54.72 -18.51 4.75 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 131.204 3.802 . . . . 0.0 115.649 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.6 pt -121.01 15.21 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 C-N-CA 127.614 2.365 . . . . 0.0 114.598 175.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -140.06 -2.77 1.56 Allowed Glycine 0 C--N 1.335 0.505 0 N-CA-C 116.08 1.192 . . . . 0.0 116.08 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.64 -73.5 0.62 Allowed Glycine 0 CA--C 1.523 0.55 0 CA-C-N 118.618 1.209 . . . . 0.0 110.16 -170.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -145.29 85.01 0.18 Allowed Glycine 0 N--CA 1.449 -0.493 0 CA-C-O 117.807 -1.552 . . . . 0.0 113.341 177.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.6 t -132.25 -29.45 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 CA-C-N 119.476 1.638 . . . . 0.0 114.738 -171.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.86 -126.88 7.42 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 120.459 1.482 . . . . 0.0 113.919 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -124.57 171.12 10.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.726 1.21 . . . . 0.0 112.134 -168.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -154.71 5.01 0.24 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.44 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.162 0 CA-C-O 116.964 -2.02 . . . . 0.0 112.821 175.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.521 0 N-CA-C 114.694 0.638 . . . . 0.0 114.694 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.62 -129.94 1.32 Allowed Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 173.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 82.7 t -60.88 144.08 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 125.64 1.576 . . . . 0.0 108.657 160.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 168.37 -170.29 42.04 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 114.772 0.669 . . . . 0.0 114.772 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -101.23 -71.91 0.7 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 128.874 2.87 . . . . 0.0 114.758 -175.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.1 pt -84.55 147.04 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 C-N-CA 125.325 1.45 . . . . 0.0 111.721 177.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 tp -73.57 150.42 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 124.331 1.052 . . . . 0.0 113.542 -160.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -111.08 -2.17 15.97 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.096 1.759 . . . . 0.0 112.233 -176.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.0 t80 -52.61 -53.46 46.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -167.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -76.66 -5.14 46.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -177.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.9 pt -124.68 -15.55 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 126.635 1.974 . . . . 0.0 114.946 -176.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -123.52 19.08 7.61 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 126.503 2.001 . . . . 0.0 117.164 176.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.12 -54.51 3.89 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-N 118.76 1.28 . . . . 0.0 115.151 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.23 74.51 0.04 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.514 2.959 . . . . 0.0 113.074 -177.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 77.5 t -122.21 -51.29 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 118.777 1.289 . . . . 0.0 111.656 -171.23 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 156.15 -98.85 0.18 Allowed Glycine 0 C--N 1.336 0.551 0 CA-C-N 118.821 0.737 . . . . 0.0 112.387 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.5 mpt_? -127.56 171.81 11.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 127.054 2.141 . . . . 0.0 112.144 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -143.87 -12.82 0.65 Allowed 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 120.096 -1.628 . . . . 0.0 115.089 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 126.298 1.904 . . . . 0.0 115.352 173.824 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.547 0 N-CA-C 112.923 -0.071 . . . . 0.0 112.923 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.37 -48.46 0.04 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.66 149.36 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.694 1.197 . . . . 0.0 112.158 -170.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.07 -157.31 27.34 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 120.01 -1.682 . . . . 0.0 115.559 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -85.96 -38.85 17.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.362 3.065 . . . . 0.0 114.956 -169.362 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.4 pt -134.59 155.33 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 125.955 1.702 . . . . 0.0 111.173 -174.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.403 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.7 tp -78.51 133.93 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.755 2.022 . . . . 0.0 114.48 -165.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -86.27 -8.96 57.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 118.41 -2.681 . . . . 0.0 114.836 171.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.403 ' H ' HG13 ' A' ' 7' ' ' ILE . 59.6 t80 -38.87 -64.41 0.45 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.58 2.352 . . . . 0.0 113.81 -169.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -69.21 -9.39 52.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 115.924 1.824 . . . . 0.0 115.924 -176.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 25.2 pt -114.77 -18.45 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 125.965 1.706 . . . . 0.0 113.321 178.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -145.28 41.32 1.06 Allowed Glycine 0 C--N 1.335 0.509 0 C-N-CA 127.873 2.654 . . . . 0.0 115.117 -173.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.77 -45.87 2.78 Favored Glycine 0 CA--C 1.522 0.519 0 C-N-CA 128.036 2.731 . . . . 0.0 115.642 161.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.52 21.89 0.09 OUTLIER Glycine 0 CA--C 1.523 0.532 0 N-CA-C 117.111 1.604 . . . . 0.0 117.111 173.007 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -59.31 -33.2 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 124.997 1.319 . . . . 0.0 113.937 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.52 -148.38 20.11 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 119.704 -1.873 . . . . 0.0 113.49 -176.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -80.92 179.54 7.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 178.267 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -160.47 -13.44 0.05 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 176.217 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.983 -1.454 . . . . 0.0 114.369 -178.759 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 N-CA-C 118.687 2.235 . . . . 0.0 118.687 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -160.88 -160.05 10.41 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 120.75 2.275 . . . . 0.0 117.946 -174.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 89.5 t -91.63 150.73 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 124.811 1.244 . . . . 0.0 108.617 173.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.91 -169.28 35.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 116.154 1.222 . . . . 0.0 116.154 -173.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -71.75 -71.07 0.29 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.08 2.952 . . . . 0.0 112.812 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.3 pt -99.76 139.09 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 124.786 1.234 . . . . 0.0 112.628 -164.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.3 tp -67.34 145.85 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 126.17 1.788 . . . . 0.0 112.563 -169.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -109.47 -29.8 8.24 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 127.558 2.343 . . . . 0.0 112.336 -171.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -63.07 -21.03 65.9 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.488 -2.007 . . . . 0.0 115.703 -163.709 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -52.49 -25.77 11.14 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 126.529 1.932 . . . . 0.0 113.662 170.139 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 17.7 pt -121.52 -18.74 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.67 2.388 . . . . 0.0 111.839 169.466 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.8 -124.18 3.2 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 127.521 2.486 . . . . 0.0 111.841 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -177.66 -9.41 0.02 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 120.402 2.921 . . . . 0.0 120.402 -177.466 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 152.88 57.19 0.01 OUTLIER Glycine 0 CA--C 1.523 0.544 0 CA-C-N 120.478 2.139 . . . . 0.0 116.087 172.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.8 t -128.74 -44.42 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 126.198 1.799 . . . . 0.0 110.461 178.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.22 -94.04 0.15 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.154 1.835 . . . . 0.0 115.316 175.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -132.56 169.03 17.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.205 1.802 . . . . 0.0 113.545 -159.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -148.14 12.85 0.97 Allowed 'General case' 0 N--CA 1.449 -0.513 0 CA-C-O 117.864 -1.065 . . . . 0.0 113.699 -174.025 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-N 120.953 1.706 . . . . 0.0 112.305 -177.586 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 CA-C-O 117.974 -1.459 . . . . 0.0 114.381 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.16 -109.92 0.31 Allowed Glycine 0 C--N 1.336 0.549 0 C-N-CA 125.03 1.3 . . . . 0.0 110.668 -172.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.2 p -72.16 159.29 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 122.137 0.97 . . . . 0.0 112.748 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.75 -152.65 24.72 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 127.112 2.291 . . . . 0.0 115.599 170.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -129.0 -46.91 1.23 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 127.511 2.324 . . . . 0.0 110.754 172.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.0 pt -73.35 133.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 125.108 1.363 . . . . 0.0 112.618 171.258 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.7 tp -63.76 157.52 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.263 1.825 . . . . 0.0 113.113 -170.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -136.15 -24.48 1.26 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 127.17 2.188 . . . . 0.0 113.083 171.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -48.19 -29.33 3.63 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 115.99 1.848 . . . . 0.0 115.99 -164.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -60.51 -28.96 68.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 116.942 2.201 . . . . 0.0 116.942 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 27.3 pt -96.27 -33.86 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 127.577 2.351 . . . . 0.0 111.384 160.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -95.61 53.04 1.75 Allowed Glycine 0 C--N 1.335 0.522 0 CA-C-O 118.309 -1.273 . . . . 0.0 114.643 -170.185 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 51.49 -94.43 0.01 OUTLIER Glycine 0 C--N 1.335 0.502 0 C-N-CA 126.578 2.037 . . . . 0.0 116.253 173.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -131.11 9.05 5.69 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.751 2.12 . . . . 0.0 115.562 171.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -72.0 -56.67 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 128.043 2.537 . . . . 0.0 113.725 -157.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 154.88 -125.37 1.68 Allowed Glycine 0 CA--C 1.523 0.547 0 CA-C-N 120.974 1.715 . . . . 0.0 115.649 -172.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -112.29 -178.58 3.45 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 128.179 2.591 . . . . 0.0 111.41 -161.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -143.1 -1.51 1.07 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 119.075 2.991 . . . . 0.0 119.075 163.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 O-C-N 119.623 -1.923 . . . . 0.0 113.931 -178.496 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.539 0 CA-C-O 116.81 -2.106 . . . . 0.0 118.161 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.88 -100.07 0.14 Allowed Glycine 0 C--N 1.336 0.533 0 CA-C-N 119.649 1.724 . . . . 0.0 115.334 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.3 p -156.01 176.56 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-N 121.064 2.432 . . . . 0.0 110.052 -172.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 111.29 -97.9 0.99 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-O 119.72 -0.489 . . . . 0.0 114.126 153.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.6 mttp -107.71 -103.31 0.35 Allowed 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 125.459 1.504 . . . . 0.0 111.007 -163.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.8 pt -63.09 154.35 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 115.716 1.747 . . . . 0.0 115.716 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.8 tp -73.74 156.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.946 1.699 . . . . 0.0 111.838 -174.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -142.56 -22.36 0.66 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.99 2.219 . . . . 0.0 116.99 -178.307 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 25.0 p90 -56.16 -34.85 66.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 119.832 1.197 . . . . 0.0 113.319 -161.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.72 -20.02 45.18 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 119.522 1.055 . . . . 0.0 113.698 177.118 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.3 pt -122.91 20.96 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.601 1.96 . . . . 0.0 111.704 169.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.03 60.29 0.33 Allowed Glycine 0 C--N 1.335 0.513 0 C-N-CA 127.793 2.616 . . . . 0.0 112.341 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.25 -96.59 0.01 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.331 2.872 . . . . 0.0 114.983 174.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.2 14.43 4.57 Favored Glycine 0 CA--C 1.522 0.513 0 C-N-CA 129.347 3.356 . . . . 0.0 115.462 176.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -60.16 -50.99 78.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.619 1.71 . . . . 0.0 110.69 -176.432 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 133.53 -88.15 0.26 Allowed Glycine 0 CA--C 1.523 0.542 0 O-C-N 124.77 1.294 . . . . 0.0 115.915 174.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -114.41 -172.87 2.19 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 128.527 2.731 . . . . 0.0 111.35 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -159.4 -12.97 0.06 Allowed 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 116.57 2.063 . . . . 0.0 116.57 169.105 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 117.23 -1.872 . . . . 0.0 116.185 -168.145 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.56 -85.64 0.06 OUTLIER Glycine 0 CA--C 1.522 0.528 0 C-N-CA 126.821 2.153 . . . . 0.0 108.974 170.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.44 158.48 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 126.211 1.805 . . . . 0.0 112.087 176.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.05 -173.99 33.3 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 119.414 -2.054 . . . . 0.0 113.969 -178.102 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -68.51 -27.8 66.44 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 128.48 2.712 . . . . 0.0 116.757 -174.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.9 pt -140.56 163.72 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 124.808 1.243 . . . . 0.0 112.341 -171.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.69 141.36 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.247 2.219 . . . . 0.0 114.218 -166.175 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -126.17 -22.41 4.08 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 127.618 2.367 . . . . 0.0 113.482 174.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -53.16 -32.41 47.55 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 118.227 2.677 . . . . 0.0 118.227 -169.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -66.37 -15.61 63.42 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 116.29 1.959 . . . . 0.0 116.29 177.028 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 20.6 pt -117.76 11.74 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 128.968 2.907 . . . . 0.0 110.723 169.304 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -155.51 55.61 0.41 Allowed Glycine 0 CA--C 1.522 0.506 0 C-N-CA 126.203 1.858 . . . . 0.0 111.317 -161.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 28.62 -88.66 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 1 C-N-CA 131.973 4.606 . . . . 0.0 115.102 179.297 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.38 33.62 2.55 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 126.354 1.93 . . . . 0.0 114.351 172.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 81.9 t -73.16 -79.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 127.162 2.185 . . . . 0.0 110.306 -178.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -93.12 0.14 Allowed Glycine 0 CA--C 1.522 0.513 0 O-C-N 121.79 -0.569 . . . . 0.0 113.841 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.4 mtt85 -126.33 177.43 6.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 127.661 2.384 . . . . 0.0 113.367 -169.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -154.89 -25.05 0.12 Allowed 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 118.183 2.66 . . . . 0.0 118.183 178.564 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.155 0 C-N-CA 129.336 3.351 . . . . 0.0 115.843 -179.323 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.496 ' H ' ' CG1' ' A' ' 15' ' ' VAL . . . 104.86 -107.53 2.91 Favored Glycine 0 C--N 1.335 0.475 0 O-C-N 120.871 -1.37 . . . . 0.0 112.722 -175.263 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.46 163.68 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 C-N-CA 125.538 1.535 . . . . 0.0 108.935 165.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 149.45 -171.9 29.53 Favored Glycine 0 C--N 1.335 0.515 0 O-C-N 120.704 -1.247 . . . . 0.0 113.568 177.271 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 mptp? -66.45 -83.69 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 125.341 1.456 . . . . 0.0 112.277 -177.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 pt -64.49 149.93 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-O 121.397 0.618 . . . . 0.0 112.154 -175.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.6 tp -61.93 154.04 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.234 1.814 . . . . 0.0 114.97 -179.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -133.8 -26.48 1.56 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.228 2.611 . . . . 0.0 114.941 174.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -55.05 -24.2 23.72 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 118.219 2.674 . . . . 0.0 118.219 -173.323 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -65.81 -16.23 63.62 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.983 1.313 . . . . 0.0 114.474 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.5 pt -123.16 -19.97 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 127.593 2.357 . . . . 0.0 112.591 172.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.36 41.13 2.26 Favored Glycine 0 CA--C 1.522 0.523 0 C-N-CA 128.284 2.85 . . . . 0.0 112.071 179.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.94 -95.61 0.04 OUTLIER Glycine 0 C--N 1.335 0.503 0 C-N-CA 126.485 1.993 . . . . 0.0 116.106 171.006 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -123.77 2.99 9.33 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 126.584 2.04 . . . . 0.0 112.637 -176.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.496 ' CG1' ' H ' ' A' ' 2' ' ' GLY . 50.7 t -53.73 -66.59 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.712 1.605 . . . . 0.0 113.867 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.83 -110.44 0.58 Allowed Glycine 0 C--N 1.335 0.525 0 CA-C-O 118.39 -1.228 . . . . 0.0 114.565 -175.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 60.8 mtm-85 -129.03 167.44 17.49 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 128.595 2.758 . . . . 0.0 110.225 -165.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -151.61 -12.49 0.2 Allowed 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 -178.347 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.127 0 O-C-N 125.522 1.764 . . . . 0.0 116.74 -175.962 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.483 0 CA-C-O 121.981 0.767 . . . . 0.0 112.826 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.58 -95.36 1.34 Allowed Glycine 0 C--N 1.335 0.517 0 C-N-CA 126.447 1.975 . . . . 0.0 112.433 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.86 157.83 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 124.703 1.201 . . . . 0.0 110.206 173.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 160.49 -167.05 35.58 Favored Glycine 0 CA--C 1.523 0.539 0 O-C-N 120.836 -1.165 . . . . 0.0 115.381 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -92.81 -64.84 1.05 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.897 1.679 . . . . 0.0 112.585 176.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 10.7 pt -78.0 145.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 O-C-N 121.489 -0.757 . . . . 0.0 112.083 -179.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.7 tp -65.04 149.25 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 C-N-CA 124.488 1.115 . . . . 0.0 112.271 -169.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -122.4 -20.43 6.1 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 128.535 2.734 . . . . 0.0 112.763 172.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -40.39 -44.95 2.08 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.434 1.894 . . . . 0.0 114.582 175.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -50.38 -21.74 1.56 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.195 1.924 . . . . 0.0 116.195 174.243 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 pt -131.07 -1.98 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 126.326 1.85 . . . . 0.0 114.734 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -137.0 67.93 0.53 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.945 2.212 . . . . 0.0 112.481 -167.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 30.95 -100.34 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 C-N-CA 129.037 3.208 . . . . 0.0 115.491 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -127.0 13.46 6.72 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 116.063 1.185 . . . . 0.0 116.063 172.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.1 t -61.26 -37.82 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -171.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.77 -93.03 0.37 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 124.997 1.284 . . . . 0.0 112.616 166.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -120.75 175.45 6.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.563 1.945 . . . . 0.0 113.75 -172.793 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.54 -29.8 0.51 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 172.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.122 0 CA-C-N 120.55 1.523 . . . . 0.0 115.782 -172.029 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.488 0 N-CA-C 118.994 2.358 . . . . 0.0 118.994 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.35 -101.84 0.22 Allowed Glycine 0 CA--C 1.522 0.525 0 C-N-CA 128.777 3.084 . . . . 0.0 114.362 165.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 p -73.47 156.25 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 124.272 1.029 . . . . 0.0 112.234 168.096 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 133.81 -175.44 20.29 Favored Glycine 0 CA--C 1.522 0.515 0 O-C-N 118.803 -2.436 . . . . 0.0 112.534 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.2 mttp -84.89 -79.43 0.22 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.449 2.3 . . . . 0.0 111.51 -173.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt -72.75 154.38 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-O 121.981 0.896 . . . . 0.0 111.91 -169.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -63.33 141.57 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 126.8 2.04 . . . . 0.0 112.649 -175.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -125.37 -25.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 127.359 2.263 . . . . 0.0 113.561 174.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -42.33 -40.29 2.43 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 127.791 2.436 . . . . 0.0 116.463 -172.207 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -53.93 -31.11 49.26 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 117.016 2.228 . . . . 0.0 117.016 174.373 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 18.1 pt -112.04 -19.59 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.419 1.488 . . . . 0.0 113.729 172.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -73.14 -34.06 58.67 Favored Glycine 0 C--N 1.335 0.497 0 CA-C-O 118.537 -1.146 . . . . 0.0 112.723 177.119 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.06 -100.21 2.53 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 118.755 1.278 . . . . 0.0 110.666 -169.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -109.54 29.63 9.3 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 128.123 2.773 . . . . 0.0 113.785 -176.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.3 t -107.48 -26.94 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 -157.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.25 -102.52 2.66 Favored Glycine 0 C--N 1.335 0.498 0 O-C-N 121.164 -0.96 . . . . 0.0 113.502 174.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -128.45 -174.51 3.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 124.945 1.298 . . . . 0.0 110.015 -160.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -164.44 -8.72 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 120.349 3.463 . . . . 0.0 120.349 173.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.093 0 C-N-CA 125.406 1.479 . . . . 0.0 115.114 -175.718 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.539 0 CA-C-O 121.728 0.626 . . . . 0.0 111.541 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 116.28 -151.37 18.35 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.947 1.261 . . . . 0.0 114.163 -174.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 90.5 t -70.31 147.34 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.375 1.87 . . . . 0.0 109.934 171.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.23 -173.65 34.11 Favored Glycine 0 CA--C 1.522 0.52 0 O-C-N 120.535 -1.353 . . . . 0.0 111.123 177.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 mttp -88.84 -77.57 0.37 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.506 2.322 . . . . 0.0 112.18 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.0 pt -76.32 141.04 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.524 1.929 . . . . 0.0 110.89 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.422 HG13 ' H ' ' A' ' 9' ' ' TYR . 4.8 tp -61.56 147.34 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.704 1.601 . . . . 0.0 113.197 -173.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -117.66 -3.04 11.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.933 2.493 . . . . 0.0 110.821 176.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.422 ' H ' HG13 ' A' ' 7' ' ' ILE . 60.8 t80 -38.1 -53.78 1.38 Allowed 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 128.197 2.599 . . . . 0.0 114.053 -176.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 25.5 p90 -73.35 -12.04 60.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 127.639 2.376 . . . . 0.0 114.485 -175.319 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.2 pt -133.74 -21.02 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 122.314 2.324 . . . . 0.0 116.346 -171.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -115.05 47.69 1.01 Allowed Glycine 0 C--N 1.335 0.498 0 CA-C-N 119.356 0.98 . . . . 0.0 114.359 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.65 -78.4 1.02 Allowed Glycine 0 CA--C 1.523 0.576 0 C-N-CA 124.017 0.818 . . . . 0.0 112.894 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 163.98 71.09 0.02 OUTLIER Glycine 0 CA--C 1.523 0.564 0 C-N-CA 126.071 1.796 . . . . 0.0 113.271 -175.012 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -120.78 -53.77 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 120.913 -1.345 . . . . 0.0 111.412 173.464 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.54 -95.75 0.11 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 121.517 1.962 . . . . 0.0 113.608 177.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -121.17 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.37 3.068 . . . . 0.0 114.281 -171.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -153.73 -30.83 0.12 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 116.984 2.216 . . . . 0.0 116.984 172.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.064 -1.965 . . . . 0.0 115.713 -171.008 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 119.529 2.572 . . . . 0.0 119.529 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.69 -140.6 2.93 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.891 2.186 . . . . 0.0 114.898 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.4 p -100.09 157.95 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.089 1.355 . . . . 0.0 113.038 176.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 141.78 -156.9 26.12 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 120.055 -1.653 . . . . 0.0 115.075 164.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -77.11 -76.53 0.17 Allowed 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.99 2.516 . . . . 0.0 113.347 -174.407 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.8 pt -80.02 147.47 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-O 122.609 1.195 . . . . 0.0 112.906 -174.255 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -61.96 138.8 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 C-N-CA 124.924 1.29 . . . . 0.0 113.026 -173.416 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -143.76 7.15 1.44 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.542 2.337 . . . . 0.0 113.423 -172.337 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -68.65 -26.74 65.48 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 118.75 -2.469 . . . . 0.0 113.959 -171.134 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -82.31 -8.15 59.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 117.546 2.424 . . . . 0.0 117.546 173.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.2 pt -133.0 82.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 127.192 2.197 . . . . 0.0 111.085 175.444 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 125.45 37.47 0.52 Allowed Glycine 0 CA--C 1.523 0.543 0 C-N-CA 124.773 1.178 . . . . 0.0 113.153 -170.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.2 -56.81 5.08 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 127.659 2.552 . . . . 0.0 113.656 163.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.9 -11.16 0.05 OUTLIER Glycine 0 C--N 1.335 0.522 0 C-N-CA 125.23 1.395 . . . . 0.0 115.53 -177.521 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.2 t -49.58 -27.15 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 C-N-CA 126.999 2.12 . . . . 0.0 115.779 -170.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.16 -89.34 0.17 Allowed Glycine 0 C--N 1.335 0.486 0 CA-C-N 122.028 2.194 . . . . 0.0 115.773 160.61 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -129.83 -176.89 4.06 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 127.645 2.378 . . . . 0.0 113.029 -166.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -155.52 -10.33 0.11 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 116.657 2.095 . . . . 0.0 116.657 169.404 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.122 -1.932 . . . . 0.0 116.679 -176.989 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.506 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.11 -111.14 0.32 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-N 121.376 2.588 . . . . 0.0 115.925 176.046 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.4 p -138.21 145.06 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 128.64 2.776 . . . . 0.0 111.218 -159.232 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.56 -173.95 33.65 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 127.483 2.468 . . . . 0.0 114.709 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.32 -53.84 5.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 172.128 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.2 pt -85.64 149.37 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-O 122.254 1.026 . . . . 0.0 113.412 178.484 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.6 tp -68.79 149.02 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 125.598 1.559 . . . . 0.0 114.26 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -118.91 -14.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 126.702 2.001 . . . . 0.0 111.683 175.276 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -35.45 -57.98 0.6 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.926 2.09 . . . . 0.0 115.299 177.196 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -47.18 -37.87 10.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 116.902 2.186 . . . . 0.0 116.902 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 34.3 pt -109.74 -10.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 127.613 2.365 . . . . 0.0 115.73 -178.047 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -144.59 39.09 1.24 Allowed Glycine 0 C--N 1.336 0.535 0 O-C-N 119.579 -1.951 . . . . 0.0 114.296 -165.081 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.23 -80.29 1.64 Allowed Glycine 0 CA--C 1.522 0.512 0 C-N-CA 126.007 1.765 . . . . 0.0 112.692 163.501 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.7 2.64 0.04 OUTLIER Glycine 0 CA--C 1.522 0.509 0 N-CA-C 116.596 1.398 . . . . 0.0 116.596 -165.066 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.3 t -72.31 -42.29 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 CA-C-N 118.154 0.977 . . . . 0.0 109.949 -169.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -100.2 0.2 Allowed Glycine 0 N--CA 1.448 -0.518 0 CA-C-O 121.757 0.643 . . . . 0.0 113.2 175.105 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -119.34 178.08 4.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 128.451 2.7 . . . . 0.0 112.675 -167.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -149.39 -32.9 0.21 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 117.599 2.444 . . . . 0.0 117.599 170.305 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.144 0 CA-C-O 116.917 -2.046 . . . . 0.0 113.078 -175.994 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.524 0 N-CA-C 116.8 1.48 . . . . 0.0 116.8 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.44 -107.1 0.2 Allowed Glycine 0 C--N 1.335 0.513 0 CA-C-N 119.847 1.824 . . . . 0.0 114.726 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.8 p -128.66 153.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 126.86 2.064 . . . . 0.0 114.259 -152.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 109.21 -142.16 16.15 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 115.367 0.907 . . . . 0.0 115.367 162.21 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -77.0 -32.67 57.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 116.777 2.14 . . . . 0.0 116.777 -153.003 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.8 pt -139.75 150.39 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-O 121.903 0.858 . . . . 0.0 109.959 -175.49 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.1 tp -58.95 150.18 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.794 2.038 . . . . 0.0 113.369 -171.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -133.77 -27.23 1.5 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 126.586 1.955 . . . . 0.0 110.709 175.577 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -51.46 -40.44 59.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 121.389 1.904 . . . . 0.0 115.516 -166.18 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 12.6 p90 -55.54 -14.08 1.88 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.715 2.006 . . . . 0.0 115.372 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.1 pt -118.77 -38.6 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 C-N-CA 125.968 1.707 . . . . 0.0 112.224 162.288 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.88 67.02 0.78 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 127.992 2.71 . . . . 0.0 112.276 -171.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 47.9 -93.15 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 129.21 3.29 . . . . 0.0 114.239 178.504 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -143.8 3.09 1.51 Allowed Glycine 0 C--N 1.335 0.52 0 C-N-CA 125.41 1.481 . . . . 0.0 116.544 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -63.34 -37.66 80.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 119.402 1.601 . . . . 0.0 113.408 -160.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.89 -99.86 0.22 Allowed Glycine 0 C--N 1.335 0.516 0 C-N-CA 125.912 1.72 . . . . 0.0 112.455 171.039 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -116.17 -174.08 2.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.135 2.174 . . . . 0.0 114.288 -171.219 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -153.89 -20.91 0.14 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 115.427 1.64 . . . . 0.0 115.427 168.031 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 127.019 2.247 . . . . 0.0 116.852 -179.051 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.482 0 N-CA-C 120.819 3.087 . . . . 0.0 120.819 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.05 -117.29 0.42 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-N 120.9 2.35 . . . . 0.0 115.251 -174.635 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -133.0 159.09 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 127.304 2.241 . . . . 0.0 109.894 -170.253 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.31 -162.88 29.69 Favored Glycine 0 CA--C 1.523 0.546 0 O-C-N 119.682 -1.886 . . . . 0.0 110.293 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 mttp -86.32 -70.79 0.58 Allowed 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 125.023 1.329 . . . . 0.0 113.469 -176.009 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.44 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.9 pt -73.46 157.23 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 122.545 1.164 . . . . 0.0 112.311 171.532 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.47 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.9 tp -71.62 142.64 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 127.836 2.454 . . . . 0.0 115.027 -175.201 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -105.29 -23.42 12.87 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 129.323 3.049 . . . . 0.0 110.459 173.031 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.47 ' H ' HG13 ' A' ' 7' ' ' ILE . 4.6 t80 -43.11 -49.08 6.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.642 2.777 . . . . 0.0 115.424 -168.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -63.71 -11.9 30.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.083 1.753 . . . . 0.0 114.442 -175.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.5 pt -127.38 16.28 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 127.702 2.401 . . . . 0.0 113.078 172.6 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.09 73.1 0.23 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.439 1.018 . . . . 0.0 113.151 -168.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 25.79 -84.92 0.0 OUTLIER Glycine 0 N--CA 1.448 -0.502 1 C-N-CA 132.13 4.681 . . . . 0.0 114.728 -176.645 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -160.95 76.06 0.18 Allowed Glycine 0 C--N 1.336 0.546 0 C-N-CA 126.2 1.857 . . . . 0.0 113.032 161.591 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.21 -55.7 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 CA-C-O 122.173 0.987 . . . . 0.0 111.404 177.409 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.11 -110.65 0.45 Allowed Glycine 0 C--N 1.336 0.539 0 O-C-N 119.433 -2.042 . . . . 0.0 114.393 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -123.03 172.42 8.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.875 2.07 . . . . 0.0 115.407 -162.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -152.5 -7.24 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.233 1.568 . . . . 0.0 115.233 173.732 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.44 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 115.819 -2.656 . . . . 0.0 115.929 -171.29 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.473 0 N-CA-C 117.597 1.799 . . . . 0.0 117.597 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.33 -144.32 4.03 Favored Glycine 0 CA--C 1.522 0.493 0 CA-C-N 120.118 1.959 . . . . 0.0 115.412 -174.645 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 53.5 t -99.34 142.31 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 127.92 2.488 . . . . 0.0 108.022 175.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 167.11 -173.16 42.33 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 125.976 1.751 . . . . 0.0 114.45 -171.568 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -85.46 -44.96 12.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 115.939 1.829 . . . . 0.0 115.939 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 36.9 pt -103.84 133.13 48.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 126.468 1.907 . . . . 0.0 111.007 -166.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.9 tp -63.62 117.63 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 C-N-CA 127.307 2.243 . . . . 0.0 115.256 -164.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -95.19 -21.62 18.36 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 127.042 2.137 . . . . 0.0 112.494 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -49.46 -47.47 48.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.098 1.759 . . . . 0.0 110.355 -173.044 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -58.75 -17.88 26.92 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.018 2.127 . . . . 0.0 115.79 -175.64 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.7 pt -132.16 -9.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 125.714 1.605 . . . . 0.0 113.948 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -124.34 40.93 1.82 Allowed Glycine 0 CA--C 1.522 0.497 0 C-N-CA 129.286 3.327 . . . . 0.0 112.141 -170.75 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.98 -81.22 0.05 OUTLIER Glycine 0 C--N 1.335 0.516 0 C-N-CA 128.646 3.022 . . . . 0.0 111.658 -177.736 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -158.75 23.41 0.33 Allowed Glycine 0 C--N 1.335 0.49 0 C-N-CA 127.11 2.291 . . . . 0.0 115.79 174.497 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.23 -63.07 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 119.348 1.574 . . . . 0.0 112.901 -169.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.34 -105.58 0.21 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 120.236 1.38 . . . . 0.0 113.907 -176.133 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.7 mpt_? -146.89 154.58 41.46 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.967 1.707 . . . . 0.0 114.99 -171.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -127.4 7.6 6.43 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 120.735 3.606 . . . . 0.0 120.735 -162.623 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 118.733 -1.037 . . . . 0.0 115.182 -178.552 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.472 0 N-CA-C 116.45 1.34 . . . . 0.0 116.45 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.47 -100.11 0.14 Allowed Glycine 0 CA--C 1.522 0.527 0 C-N-CA 126.629 2.062 . . . . 0.0 108.61 176.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.2 t -114.35 160.94 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 126.685 1.994 . . . . 0.0 109.164 177.161 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.97 -177.63 33.76 Favored Glycine 0 C--N 1.335 0.503 0 O-C-N 120.956 -1.09 . . . . 0.0 114.315 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.2 mttp -67.43 -53.91 24.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.201 2.2 . . . . 0.0 112.52 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.431 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.3 pt -114.38 155.13 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 CA-C-O 122.685 1.231 . . . . 0.0 111.761 -168.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -69.38 139.56 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 113.227 -1.806 . . . . 0.0 114.746 -160.428 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -117.55 -20.29 9.07 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 127.024 2.13 . . . . 0.0 111.736 171.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -45.62 -33.08 2.66 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 116.2 1.926 . . . . 0.0 116.2 173.391 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -67.23 -14.01 62.51 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 127.826 2.45 . . . . 0.0 115.532 175.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 36.2 pt -129.16 -6.9 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 127.459 2.304 . . . . 0.0 114.36 176.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -152.48 92.5 0.14 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.738 1.637 . . . . 0.0 113.55 -175.278 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 29.03 -93.56 0.01 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 130.012 3.672 . . . . 0.0 115.02 159.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -124.49 17.73 7.35 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 126.691 2.091 . . . . 0.0 113.922 175.033 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.1 t -90.32 40.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.527 2.331 . . . . 0.0 111.92 -170.128 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 43.48 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 129.617 3.484 . . . . 0.0 118.286 167.078 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -138.54 170.42 16.03 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.281 1.833 . . . . 0.0 113.81 -166.082 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -146.18 -2.86 0.68 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 174.349 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.431 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.25 1.105 0 N-CA-C 117.543 1.777 . . . . 0.0 117.543 -175.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.455 0 CA-C-O 121.221 0.345 . . . . 0.0 112.69 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 165.39 -48.04 0.28 Allowed Glycine 0 CA--C 1.522 0.515 0 C-N-CA 128.359 2.885 . . . . 0.0 114.486 168.003 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -119.25 137.61 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 126.779 2.032 . . . . 0.0 111.588 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.19 -171.21 37.17 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 116.489 1.356 . . . . 0.0 116.489 -179.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 40.6 mttp -76.61 -50.46 13.76 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 129.458 3.103 . . . . 0.0 114.095 177.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.1 pt -121.29 151.96 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 O-C-N 124.251 0.97 . . . . 0.0 111.782 -172.034 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.532 HG13 ' H ' ' A' ' 9' ' ' TYR . 7.7 tp -68.91 139.02 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 127.762 2.425 . . . . 0.0 115.003 -165.795 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -111.11 -3.04 15.61 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.57 2.348 . . . . 0.0 112.318 177.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.532 ' H ' HG13 ' A' ' 7' ' ' ILE . 71.1 t80 -47.21 -48.45 24.02 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 128.625 2.77 . . . . 0.0 115.437 -170.573 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.57 -9.11 16.93 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.8 pt -125.57 0.96 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 122.413 2.369 . . . . 0.0 113.655 172.356 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.66 5.52 10.69 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 126.98 2.229 . . . . 0.0 116.381 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.77 -70.55 0.93 Allowed Glycine 0 C--N 1.335 0.49 0 O-C-N 120.3 -1.706 . . . . 0.0 115.296 -171.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -163.46 13.95 0.1 Allowed Glycine 0 C--N 1.335 0.496 0 CA-C-O 117.878 -1.512 . . . . 0.0 115.582 -163.125 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.1 t -81.85 -75.09 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 121.254 2.527 . . . . 0.0 110.729 -177.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.44 -122.63 0.78 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 118.351 2.1 . . . . 0.0 118.351 178.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 68.7 mtt180 -107.85 176.84 5.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 126.852 2.061 . . . . 0.0 111.731 -168.504 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 p90 -151.66 -19.51 0.19 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 117.92 2.563 . . . . 0.0 117.92 174.329 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 117.682 -1.621 . . . . 0.0 113.994 -175.039 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 CA-C-O 116.534 -2.259 . . . . 0.0 116.439 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.3 -161.09 11.63 Favored Glycine 0 C--N 1.336 0.543 0 CA-C-N 120.694 2.247 . . . . 0.0 111.001 -177.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -133.08 153.96 38.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.208 1.803 . . . . 0.0 109.431 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.13 -141.44 8.25 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.966 -2.053 . . . . 0.0 107.966 -161.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mtmp? -126.27 -54.45 1.47 Allowed 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 116.225 -1.845 . . . . 0.0 112.394 -166.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 32.8 pt -79.27 136.11 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 CA-C-N 120.3 1.409 . . . . 0.0 109.53 174.515 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.519 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.8 tp -70.9 139.23 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 114.279 1.214 . . . . 0.0 114.279 -170.129 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -90.88 -4.7 56.35 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.405 1.882 . . . . 0.0 113.231 174.642 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.519 ' H ' HG13 ' A' ' 7' ' ' ILE . 72.8 t80 -46.64 -58.15 4.11 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 126.166 1.786 . . . . 0.0 113.689 -174.587 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.2 -13.7 5.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 119.345 -2.097 . . . . 0.0 115.59 176.769 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 29.7 pt -128.53 6.36 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 128.539 2.735 . . . . 0.0 115.254 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.77 -9.06 0.03 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 64.92 -18.66 0.12 Allowed Glycine 0 C--N 1.335 0.503 0 C-N-CA 128.246 2.831 . . . . 0.0 119.881 161.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.65 34.03 0.45 Allowed Glycine 0 C--N 1.335 0.482 0 CA-C-N 121.227 2.513 . . . . 0.0 116.514 -166.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 79.8 t -135.22 -76.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.871 1.836 . . . . 0.0 111.799 177.521 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -176.93 -115.69 0.44 Allowed Glycine 0 N--CA 1.448 -0.527 0 O-C-N 120.573 -1.329 . . . . 0.0 115.598 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 8.9 mpt_? -112.79 178.63 4.22 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.801 2.04 . . . . 0.0 112.5 -172.466 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -149.06 -3.82 0.43 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 116.889 2.181 . . . . 0.0 116.889 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 O-C-N 119.132 -2.23 . . . . 0.0 113.354 -176.95 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.466 0 N-CA-C 119.302 2.481 . . . . 0.0 119.302 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.15 -105.37 0.18 Allowed Glycine 0 C--N 1.335 0.519 0 O-C-N 119.852 -1.969 . . . . 0.0 112.196 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -150.8 170.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-O 121.132 0.491 . . . . 0.0 110.238 -175.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.02 -119.68 1.27 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 124.202 0.906 . . . . 0.0 112.64 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.9 mttp -130.35 -55.94 1.09 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 128.899 2.88 . . . . 0.0 110.566 -169.056 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.6 pt -90.35 149.91 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.054 1.342 . . . . 0.0 111.238 -175.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.2 tp -86.29 149.21 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.698 1.999 . . . . 0.0 112.889 -160.149 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -128.33 -31.62 2.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 126.784 2.034 . . . . 0.0 116.11 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -54.32 -24.88 20.99 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 -165.368 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -69.73 -22.7 63.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.502 2.321 . . . . 0.0 113.475 176.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 24.1 pt -110.06 20.78 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.418 2.287 . . . . 0.0 111.635 169.125 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -138.52 -69.52 0.05 OUTLIER Glycine 0 CA--C 1.523 0.535 0 O-C-N 120.651 -1.281 . . . . 0.0 114.313 -170.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 150.74 -82.02 0.18 Allowed Glycine 0 C--N 1.335 0.507 0 C-N-CA 129.511 3.434 . . . . 0.0 110.143 -167.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.63 2.69 0.09 OUTLIER Glycine 0 C--N 1.335 0.507 0 N-CA-C 118.693 2.237 . . . . 0.0 118.693 -166.536 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 76.2 t -67.95 -29.62 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-N 120.644 2.222 . . . . 0.0 112.966 -179.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.47 -96.89 0.71 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 126.471 1.986 . . . . 0.0 113.327 161.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -95.87 178.92 5.28 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.302 2.641 . . . . 0.0 113.675 -178.23 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.4 p90 -159.46 -8.57 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 121.002 1.728 . . . . 0.0 114.981 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 117.08 -1.955 . . . . 0.0 111.707 -171.14 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.468 0 CA-C-O 122.554 1.085 . . . . 0.0 112.171 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.19 -70.16 0.03 OUTLIER Glycine 0 CA--C 1.522 0.525 0 C-N-CA 126.001 1.762 . . . . 0.0 113.041 172.651 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.9 t -137.49 154.44 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.293 1.837 . . . . 0.0 108.035 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.87 -168.53 33.42 Favored Glycine 0 C--N 1.335 0.514 0 O-C-N 121.102 -0.999 . . . . 0.0 111.697 -166.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.2 mttp -98.1 -53.84 3.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 115.553 -2.165 . . . . 0.0 112.95 -172.307 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.449 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 31.2 pt -84.5 151.38 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.939 1.245 . . . . 0.0 111.695 169.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.89 147.77 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 126.849 2.059 . . . . 0.0 114.119 -178.375 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -113.9 -20.38 11.09 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.534 2.734 . . . . 0.0 112.272 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 49.3 t80 -10.71 -73.33 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 129.916 3.286 . . . . 0.0 115.248 169.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -54.72 -18.51 4.75 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 131.204 3.802 . . . . 0.0 115.649 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.6 pt -121.01 15.21 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 C-N-CA 127.614 2.365 . . . . 0.0 114.598 175.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -140.06 -2.77 1.56 Allowed Glycine 0 C--N 1.335 0.505 0 N-CA-C 116.08 1.192 . . . . 0.0 116.08 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.64 -73.5 0.62 Allowed Glycine 0 CA--C 1.523 0.55 0 CA-C-N 118.618 1.209 . . . . 0.0 110.16 -170.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -145.29 85.01 0.18 Allowed Glycine 0 N--CA 1.449 -0.493 0 CA-C-O 117.807 -1.552 . . . . 0.0 113.341 177.455 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.6 t -132.25 -29.45 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 CA-C-N 119.476 1.638 . . . . 0.0 114.738 -171.025 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.86 -126.88 7.42 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 120.459 1.482 . . . . 0.0 113.919 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -124.57 171.12 10.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.726 1.21 . . . . 0.0 112.134 -168.433 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -154.71 5.01 0.24 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.449 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.162 0 CA-C-O 116.964 -2.02 . . . . 0.0 112.821 175.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.521 0 N-CA-C 114.694 0.638 . . . . 0.0 114.694 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.62 -129.94 1.32 Allowed Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 173.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 82.7 t -60.88 144.08 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 125.64 1.576 . . . . 0.0 108.657 160.662 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 168.37 -170.29 42.04 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 114.772 0.669 . . . . 0.0 114.772 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -101.23 -71.91 0.7 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 128.874 2.87 . . . . 0.0 114.758 -175.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.1 pt -84.55 147.04 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 C-N-CA 125.325 1.45 . . . . 0.0 111.721 177.064 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 tp -73.57 150.42 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 124.331 1.052 . . . . 0.0 113.542 -160.488 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -111.08 -2.17 15.97 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.096 1.759 . . . . 0.0 112.233 -176.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.0 t80 -52.61 -53.46 46.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -167.147 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -76.66 -5.14 46.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -177.735 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.9 pt -124.68 -15.55 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 126.635 1.974 . . . . 0.0 114.946 -176.783 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -123.52 19.08 7.61 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 126.503 2.001 . . . . 0.0 117.164 176.006 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.12 -54.51 3.89 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-N 118.76 1.28 . . . . 0.0 115.151 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.23 74.51 0.04 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.514 2.959 . . . . 0.0 113.074 -177.701 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 77.5 t -122.21 -51.29 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 118.777 1.289 . . . . 0.0 111.656 -171.23 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 156.15 -98.85 0.18 Allowed Glycine 0 C--N 1.336 0.551 0 CA-C-N 118.821 0.737 . . . . 0.0 112.387 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.5 mpt_? -127.56 171.81 11.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 127.054 2.141 . . . . 0.0 112.144 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -143.87 -12.82 0.65 Allowed 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 120.096 -1.628 . . . . 0.0 115.089 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 126.298 1.904 . . . . 0.0 115.352 173.824 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.547 0 N-CA-C 112.923 -0.071 . . . . 0.0 112.923 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.37 -48.46 0.04 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.66 149.36 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.694 1.197 . . . . 0.0 112.158 -170.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.07 -157.31 27.34 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 120.01 -1.682 . . . . 0.0 115.559 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -85.96 -38.85 17.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.362 3.065 . . . . 0.0 114.956 -169.362 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.4 pt -134.59 155.33 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 125.955 1.702 . . . . 0.0 111.173 -174.61 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.448 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.7 tp -78.51 133.93 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.755 2.022 . . . . 0.0 114.48 -165.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -86.27 -8.96 57.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 118.41 -2.681 . . . . 0.0 114.836 171.229 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.448 ' H ' HG13 ' A' ' 7' ' ' ILE . 59.6 t80 -38.87 -64.41 0.45 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.58 2.352 . . . . 0.0 113.81 -169.499 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -69.21 -9.39 52.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 115.924 1.824 . . . . 0.0 115.924 -176.177 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 25.2 pt -114.77 -18.45 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 125.965 1.706 . . . . 0.0 113.321 178.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -145.28 41.32 1.06 Allowed Glycine 0 C--N 1.335 0.509 0 C-N-CA 127.873 2.654 . . . . 0.0 115.117 -173.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.77 -45.87 2.78 Favored Glycine 0 CA--C 1.522 0.519 0 C-N-CA 128.036 2.731 . . . . 0.0 115.642 161.523 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.52 21.89 0.09 OUTLIER Glycine 0 CA--C 1.523 0.532 0 N-CA-C 117.111 1.604 . . . . 0.0 117.111 173.007 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -59.31 -33.2 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 124.997 1.319 . . . . 0.0 113.937 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.52 -148.38 20.11 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 119.704 -1.873 . . . . 0.0 113.49 -176.637 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -80.92 179.54 7.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 178.267 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -160.47 -13.44 0.05 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 176.217 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.983 -1.454 . . . . 0.0 114.369 -178.759 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 N-CA-C 118.687 2.235 . . . . 0.0 118.687 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -160.88 -160.05 10.41 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 120.75 2.275 . . . . 0.0 117.946 -174.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 89.5 t -91.63 150.73 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 124.811 1.244 . . . . 0.0 108.617 173.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.91 -169.28 35.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 116.154 1.222 . . . . 0.0 116.154 -173.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -71.75 -71.07 0.29 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.08 2.952 . . . . 0.0 112.812 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.3 pt -99.76 139.09 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 124.786 1.234 . . . . 0.0 112.628 -164.682 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.3 tp -67.34 145.85 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 126.17 1.788 . . . . 0.0 112.563 -169.669 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -109.47 -29.8 8.24 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 127.558 2.343 . . . . 0.0 112.336 -171.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -63.07 -21.03 65.9 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.488 -2.007 . . . . 0.0 115.703 -163.709 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -52.49 -25.77 11.14 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 126.529 1.932 . . . . 0.0 113.662 170.139 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 17.7 pt -121.52 -18.74 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.67 2.388 . . . . 0.0 111.839 169.466 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.8 -124.18 3.2 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 127.521 2.486 . . . . 0.0 111.841 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -177.66 -9.41 0.02 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 120.402 2.921 . . . . 0.0 120.402 -177.466 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 152.88 57.19 0.01 OUTLIER Glycine 0 CA--C 1.523 0.544 0 CA-C-N 120.478 2.139 . . . . 0.0 116.087 172.293 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.8 t -128.74 -44.42 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 126.198 1.799 . . . . 0.0 110.461 178.439 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.22 -94.04 0.15 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.154 1.835 . . . . 0.0 115.316 175.468 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -132.56 169.03 17.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.205 1.802 . . . . 0.0 113.545 -159.023 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -148.14 12.85 0.97 Allowed 'General case' 0 N--CA 1.449 -0.513 0 CA-C-O 117.864 -1.065 . . . . 0.0 113.699 -174.025 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-N 120.953 1.706 . . . . 0.0 112.305 -177.586 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 CA-C-O 117.974 -1.459 . . . . 0.0 114.381 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.16 -109.92 0.31 Allowed Glycine 0 C--N 1.336 0.549 0 C-N-CA 125.03 1.3 . . . . 0.0 110.668 -172.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.2 p -72.16 159.29 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 122.137 0.97 . . . . 0.0 112.748 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.75 -152.65 24.72 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 127.112 2.291 . . . . 0.0 115.599 170.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -129.0 -46.91 1.23 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 127.511 2.324 . . . . 0.0 110.754 172.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.0 pt -73.35 133.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 125.108 1.363 . . . . 0.0 112.618 171.258 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.7 tp -63.76 157.52 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.263 1.825 . . . . 0.0 113.113 -170.205 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -136.15 -24.48 1.26 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 127.17 2.188 . . . . 0.0 113.083 171.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -48.19 -29.33 3.63 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 115.99 1.848 . . . . 0.0 115.99 -164.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -60.51 -28.96 68.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 116.942 2.201 . . . . 0.0 116.942 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 27.3 pt -96.27 -33.86 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 127.577 2.351 . . . . 0.0 111.384 160.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -95.61 53.04 1.75 Allowed Glycine 0 C--N 1.335 0.522 0 CA-C-O 118.309 -1.273 . . . . 0.0 114.643 -170.185 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 51.49 -94.43 0.01 OUTLIER Glycine 0 C--N 1.335 0.502 0 C-N-CA 126.578 2.037 . . . . 0.0 116.253 173.405 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -131.11 9.05 5.69 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.751 2.12 . . . . 0.0 115.562 171.596 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -72.0 -56.67 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 128.043 2.537 . . . . 0.0 113.725 -157.686 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 154.88 -125.37 1.68 Allowed Glycine 0 CA--C 1.523 0.547 0 CA-C-N 120.974 1.715 . . . . 0.0 115.649 -172.422 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -112.29 -178.58 3.45 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 128.179 2.591 . . . . 0.0 111.41 -161.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -143.1 -1.51 1.07 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 119.075 2.991 . . . . 0.0 119.075 163.193 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 O-C-N 119.623 -1.923 . . . . 0.0 113.931 -178.496 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.539 0 CA-C-O 116.81 -2.106 . . . . 0.0 118.161 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.88 -100.07 0.14 Allowed Glycine 0 C--N 1.336 0.533 0 CA-C-N 119.649 1.724 . . . . 0.0 115.334 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.3 p -156.01 176.56 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-N 121.064 2.432 . . . . 0.0 110.052 -172.206 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 111.29 -97.9 0.99 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-O 119.72 -0.489 . . . . 0.0 114.126 153.337 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.6 mttp -107.71 -103.31 0.35 Allowed 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 125.459 1.504 . . . . 0.0 111.007 -163.003 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.8 pt -63.09 154.35 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 115.716 1.747 . . . . 0.0 115.716 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.8 tp -73.74 156.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.946 1.699 . . . . 0.0 111.838 -174.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -142.56 -22.36 0.66 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.99 2.219 . . . . 0.0 116.99 -178.307 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 25.0 p90 -56.16 -34.85 66.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 119.832 1.197 . . . . 0.0 113.319 -161.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.72 -20.02 45.18 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 119.522 1.055 . . . . 0.0 113.698 177.118 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.3 pt -122.91 20.96 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.601 1.96 . . . . 0.0 111.704 169.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.03 60.29 0.33 Allowed Glycine 0 C--N 1.335 0.513 0 C-N-CA 127.793 2.616 . . . . 0.0 112.341 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.25 -96.59 0.01 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.331 2.872 . . . . 0.0 114.983 174.458 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.2 14.43 4.57 Favored Glycine 0 CA--C 1.522 0.513 0 C-N-CA 129.347 3.356 . . . . 0.0 115.462 176.197 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -60.16 -50.99 78.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.619 1.71 . . . . 0.0 110.69 -176.432 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 133.53 -88.15 0.26 Allowed Glycine 0 CA--C 1.523 0.542 0 O-C-N 124.77 1.294 . . . . 0.0 115.915 174.356 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -114.41 -172.87 2.19 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 128.527 2.731 . . . . 0.0 111.35 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -159.4 -12.97 0.06 Allowed 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 116.57 2.063 . . . . 0.0 116.57 169.105 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 117.23 -1.872 . . . . 0.0 116.185 -168.145 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.56 -85.64 0.06 OUTLIER Glycine 0 CA--C 1.522 0.528 0 C-N-CA 126.821 2.153 . . . . 0.0 108.974 170.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.44 158.48 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 126.211 1.805 . . . . 0.0 112.087 176.528 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.05 -173.99 33.3 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 119.414 -2.054 . . . . 0.0 113.969 -178.102 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -68.51 -27.8 66.44 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 128.48 2.712 . . . . 0.0 116.757 -174.011 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.9 pt -140.56 163.72 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 124.808 1.243 . . . . 0.0 112.341 -171.471 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.69 141.36 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.247 2.219 . . . . 0.0 114.218 -166.175 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -126.17 -22.41 4.08 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 127.618 2.367 . . . . 0.0 113.482 174.618 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -53.16 -32.41 47.55 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 118.227 2.677 . . . . 0.0 118.227 -169.866 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -66.37 -15.61 63.42 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 116.29 1.959 . . . . 0.0 116.29 177.028 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 20.6 pt -117.76 11.74 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 128.968 2.907 . . . . 0.0 110.723 169.304 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -155.51 55.61 0.41 Allowed Glycine 0 CA--C 1.522 0.506 0 C-N-CA 126.203 1.858 . . . . 0.0 111.317 -161.744 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 28.62 -88.66 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 1 C-N-CA 131.973 4.606 . . . . 0.0 115.102 179.297 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.38 33.62 2.55 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 126.354 1.93 . . . . 0.0 114.351 172.257 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 81.9 t -73.16 -79.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 127.162 2.185 . . . . 0.0 110.306 -178.532 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -93.12 0.14 Allowed Glycine 0 CA--C 1.522 0.513 0 O-C-N 121.79 -0.569 . . . . 0.0 113.841 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.4 mtt85 -126.33 177.43 6.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 127.661 2.384 . . . . 0.0 113.367 -169.031 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -154.89 -25.05 0.12 Allowed 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 118.183 2.66 . . . . 0.0 118.183 178.564 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.155 0 C-N-CA 129.336 3.351 . . . . 0.0 115.843 -179.323 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.511 ' H ' ' CG1' ' A' ' 15' ' ' VAL . . . 104.86 -107.53 2.91 Favored Glycine 0 C--N 1.335 0.475 0 O-C-N 120.871 -1.37 . . . . 0.0 112.722 -175.263 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.46 163.68 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 C-N-CA 125.538 1.535 . . . . 0.0 108.935 165.827 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 149.45 -171.9 29.53 Favored Glycine 0 C--N 1.335 0.515 0 O-C-N 120.704 -1.247 . . . . 0.0 113.568 177.271 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 mptp? -66.45 -83.69 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 125.341 1.456 . . . . 0.0 112.277 -177.662 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 pt -64.49 149.93 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-O 121.397 0.618 . . . . 0.0 112.154 -175.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.6 tp -61.93 154.04 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.234 1.814 . . . . 0.0 114.97 -179.485 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -133.8 -26.48 1.56 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.228 2.611 . . . . 0.0 114.941 174.766 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -55.05 -24.2 23.72 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 118.219 2.674 . . . . 0.0 118.219 -173.323 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -65.81 -16.23 63.62 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.983 1.313 . . . . 0.0 114.474 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.5 pt -123.16 -19.97 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 127.593 2.357 . . . . 0.0 112.591 172.426 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.36 41.13 2.26 Favored Glycine 0 CA--C 1.522 0.523 0 C-N-CA 128.284 2.85 . . . . 0.0 112.071 179.002 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.94 -95.61 0.04 OUTLIER Glycine 0 C--N 1.335 0.503 0 C-N-CA 126.485 1.993 . . . . 0.0 116.106 171.006 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -123.77 2.99 9.33 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 126.584 2.04 . . . . 0.0 112.637 -176.264 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.511 ' CG1' ' H ' ' A' ' 2' ' ' GLY . 50.7 t -53.73 -66.59 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.712 1.605 . . . . 0.0 113.867 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.83 -110.44 0.58 Allowed Glycine 0 C--N 1.335 0.525 0 CA-C-O 118.39 -1.228 . . . . 0.0 114.565 -175.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 60.8 mtm-85 -129.03 167.44 17.49 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 128.595 2.758 . . . . 0.0 110.225 -165.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -151.61 -12.49 0.2 Allowed 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 -178.347 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.127 0 O-C-N 125.522 1.764 . . . . 0.0 116.74 -175.962 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.483 0 CA-C-O 121.981 0.767 . . . . 0.0 112.826 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.58 -95.36 1.34 Allowed Glycine 0 C--N 1.335 0.517 0 C-N-CA 126.447 1.975 . . . . 0.0 112.433 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.86 157.83 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 124.703 1.201 . . . . 0.0 110.206 173.583 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 160.49 -167.05 35.58 Favored Glycine 0 CA--C 1.523 0.539 0 O-C-N 120.836 -1.165 . . . . 0.0 115.381 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -92.81 -64.84 1.05 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.897 1.679 . . . . 0.0 112.585 176.815 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 10.7 pt -78.0 145.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 O-C-N 121.489 -0.757 . . . . 0.0 112.083 -179.443 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.7 tp -65.04 149.25 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 C-N-CA 124.488 1.115 . . . . 0.0 112.271 -169.21 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -122.4 -20.43 6.1 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 128.535 2.734 . . . . 0.0 112.763 172.649 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -40.39 -44.95 2.08 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.434 1.894 . . . . 0.0 114.582 175.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -50.38 -21.74 1.56 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.195 1.924 . . . . 0.0 116.195 174.243 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 pt -131.07 -1.98 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 126.326 1.85 . . . . 0.0 114.734 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -137.0 67.93 0.53 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.945 2.212 . . . . 0.0 112.481 -167.54 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 30.95 -100.34 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 C-N-CA 129.037 3.208 . . . . 0.0 115.491 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -127.0 13.46 6.72 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 116.063 1.185 . . . . 0.0 116.063 172.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.1 t -61.26 -37.82 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -171.519 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.77 -93.03 0.37 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 124.997 1.284 . . . . 0.0 112.616 166.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -120.75 175.45 6.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.563 1.945 . . . . 0.0 113.75 -172.793 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.54 -29.8 0.51 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 172.37 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.122 0 CA-C-N 120.55 1.523 . . . . 0.0 115.782 -172.029 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.488 0 N-CA-C 118.994 2.358 . . . . 0.0 118.994 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.35 -101.84 0.22 Allowed Glycine 0 CA--C 1.522 0.525 0 C-N-CA 128.777 3.084 . . . . 0.0 114.362 165.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 p -73.47 156.25 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 124.272 1.029 . . . . 0.0 112.234 168.096 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 133.81 -175.44 20.29 Favored Glycine 0 CA--C 1.522 0.515 0 O-C-N 118.803 -2.436 . . . . 0.0 112.534 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.2 mttp -84.89 -79.43 0.22 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.449 2.3 . . . . 0.0 111.51 -173.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt -72.75 154.38 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-O 121.981 0.896 . . . . 0.0 111.91 -169.756 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -63.33 141.57 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 126.8 2.04 . . . . 0.0 112.649 -175.532 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -125.37 -25.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 127.359 2.263 . . . . 0.0 113.561 174.717 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -42.33 -40.29 2.43 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 127.791 2.436 . . . . 0.0 116.463 -172.207 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -53.93 -31.11 49.26 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 117.016 2.228 . . . . 0.0 117.016 174.373 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 18.1 pt -112.04 -19.59 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.419 1.488 . . . . 0.0 113.729 172.358 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -73.14 -34.06 58.67 Favored Glycine 0 C--N 1.335 0.497 0 CA-C-O 118.537 -1.146 . . . . 0.0 112.723 177.119 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.06 -100.21 2.53 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 118.755 1.278 . . . . 0.0 110.666 -169.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -109.54 29.63 9.3 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 128.123 2.773 . . . . 0.0 113.785 -176.845 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.3 t -107.48 -26.94 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 -157.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.25 -102.52 2.66 Favored Glycine 0 C--N 1.335 0.498 0 O-C-N 121.164 -0.96 . . . . 0.0 113.502 174.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -128.45 -174.51 3.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 124.945 1.298 . . . . 0.0 110.015 -160.369 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -164.44 -8.72 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 120.349 3.463 . . . . 0.0 120.349 173.171 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.093 0 C-N-CA 125.406 1.479 . . . . 0.0 115.114 -175.718 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.539 0 CA-C-O 121.728 0.626 . . . . 0.0 111.541 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 116.28 -151.37 18.35 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.947 1.261 . . . . 0.0 114.163 -174.617 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 90.5 t -70.31 147.34 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.375 1.87 . . . . 0.0 109.934 171.772 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.23 -173.65 34.11 Favored Glycine 0 CA--C 1.522 0.52 0 O-C-N 120.535 -1.353 . . . . 0.0 111.123 177.131 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 mttp -88.84 -77.57 0.37 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.506 2.322 . . . . 0.0 112.18 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.0 pt -76.32 141.04 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.524 1.929 . . . . 0.0 110.89 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.474 HG13 ' H ' ' A' ' 9' ' ' TYR . 4.8 tp -61.56 147.34 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.704 1.601 . . . . 0.0 113.197 -173.606 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -117.66 -3.04 11.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.933 2.493 . . . . 0.0 110.821 176.737 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.474 ' H ' HG13 ' A' ' 7' ' ' ILE . 60.8 t80 -38.1 -53.78 1.38 Allowed 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 128.197 2.599 . . . . 0.0 114.053 -176.799 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.429 ' CD2' HG23 ' A' ' 11' ' ' ILE . 25.5 p90 -73.35 -12.04 60.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 127.639 2.376 . . . . 0.0 114.485 -175.319 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.429 HG23 ' CD2' ' A' ' 10' ' ' PHE . 7.2 pt -133.74 -21.02 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 122.314 2.324 . . . . 0.0 116.346 -171.112 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -115.05 47.69 1.01 Allowed Glycine 0 C--N 1.335 0.498 0 CA-C-N 119.356 0.98 . . . . 0.0 114.359 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.65 -78.4 1.02 Allowed Glycine 0 CA--C 1.523 0.576 0 C-N-CA 124.017 0.818 . . . . 0.0 112.894 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 163.98 71.09 0.02 OUTLIER Glycine 0 CA--C 1.523 0.564 0 C-N-CA 126.071 1.796 . . . . 0.0 113.271 -175.012 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -120.78 -53.77 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 120.913 -1.345 . . . . 0.0 111.412 173.464 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.54 -95.75 0.11 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 121.517 1.962 . . . . 0.0 113.608 177.175 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -121.17 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.37 3.068 . . . . 0.0 114.281 -171.23 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -153.73 -30.83 0.12 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 116.984 2.216 . . . . 0.0 116.984 172.496 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.064 -1.965 . . . . 0.0 115.713 -171.008 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 119.529 2.572 . . . . 0.0 119.529 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.69 -140.6 2.93 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.891 2.186 . . . . 0.0 114.898 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.4 p -100.09 157.95 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.089 1.355 . . . . 0.0 113.038 176.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 141.78 -156.9 26.12 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 120.055 -1.653 . . . . 0.0 115.075 164.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -77.11 -76.53 0.17 Allowed 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.99 2.516 . . . . 0.0 113.347 -174.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.8 pt -80.02 147.47 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-O 122.609 1.195 . . . . 0.0 112.906 -174.255 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -61.96 138.8 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 C-N-CA 124.924 1.29 . . . . 0.0 113.026 -173.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -143.76 7.15 1.44 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.542 2.337 . . . . 0.0 113.423 -172.337 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -68.65 -26.74 65.48 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 118.75 -2.469 . . . . 0.0 113.959 -171.134 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -82.31 -8.15 59.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 117.546 2.424 . . . . 0.0 117.546 173.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.2 pt -133.0 82.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 127.192 2.197 . . . . 0.0 111.085 175.444 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 125.45 37.47 0.52 Allowed Glycine 0 CA--C 1.523 0.543 0 C-N-CA 124.773 1.178 . . . . 0.0 113.153 -170.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.2 -56.81 5.08 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 127.659 2.552 . . . . 0.0 113.656 163.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.9 -11.16 0.05 OUTLIER Glycine 0 C--N 1.335 0.522 0 C-N-CA 125.23 1.395 . . . . 0.0 115.53 -177.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.2 t -49.58 -27.15 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 C-N-CA 126.999 2.12 . . . . 0.0 115.779 -170.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.16 -89.34 0.17 Allowed Glycine 0 C--N 1.335 0.486 0 CA-C-N 122.028 2.194 . . . . 0.0 115.773 160.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -129.83 -176.89 4.06 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 127.645 2.378 . . . . 0.0 113.029 -166.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -155.52 -10.33 0.11 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 116.657 2.095 . . . . 0.0 116.657 169.404 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.122 -1.932 . . . . 0.0 116.679 -176.989 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.506 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.11 -111.14 0.32 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-N 121.376 2.588 . . . . 0.0 115.925 176.046 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.4 p -138.21 145.06 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 128.64 2.776 . . . . 0.0 111.218 -159.232 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.56 -173.95 33.65 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 127.483 2.468 . . . . 0.0 114.709 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.32 -53.84 5.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 172.128 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.2 pt -85.64 149.37 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-O 122.254 1.026 . . . . 0.0 113.412 178.484 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.6 tp -68.79 149.02 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 125.598 1.559 . . . . 0.0 114.26 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -118.91 -14.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 126.702 2.001 . . . . 0.0 111.683 175.276 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -35.45 -57.98 0.6 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.926 2.09 . . . . 0.0 115.299 177.196 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -47.18 -37.87 10.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 116.902 2.186 . . . . 0.0 116.902 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 34.3 pt -109.74 -10.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 127.613 2.365 . . . . 0.0 115.73 -178.047 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -144.59 39.09 1.24 Allowed Glycine 0 C--N 1.336 0.535 0 O-C-N 119.579 -1.951 . . . . 0.0 114.296 -165.081 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.23 -80.29 1.64 Allowed Glycine 0 CA--C 1.522 0.512 0 C-N-CA 126.007 1.765 . . . . 0.0 112.692 163.501 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.7 2.64 0.04 OUTLIER Glycine 0 CA--C 1.522 0.509 0 N-CA-C 116.596 1.398 . . . . 0.0 116.596 -165.066 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.3 t -72.31 -42.29 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 CA-C-N 118.154 0.977 . . . . 0.0 109.949 -169.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -100.2 0.2 Allowed Glycine 0 N--CA 1.448 -0.518 0 CA-C-O 121.757 0.643 . . . . 0.0 113.2 175.105 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -119.34 178.08 4.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 128.451 2.7 . . . . 0.0 112.675 -167.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -149.39 -32.9 0.21 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 117.599 2.444 . . . . 0.0 117.599 170.305 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.144 0 CA-C-O 116.917 -2.046 . . . . 0.0 113.078 -175.994 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.524 0 N-CA-C 116.8 1.48 . . . . 0.0 116.8 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.44 -107.1 0.2 Allowed Glycine 0 C--N 1.335 0.513 0 CA-C-N 119.847 1.824 . . . . 0.0 114.726 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.8 p -128.66 153.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 126.86 2.064 . . . . 0.0 114.259 -152.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 109.21 -142.16 16.15 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 115.367 0.907 . . . . 0.0 115.367 162.21 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -77.0 -32.67 57.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 116.777 2.14 . . . . 0.0 116.777 -153.003 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.8 pt -139.75 150.39 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-O 121.903 0.858 . . . . 0.0 109.959 -175.49 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.1 tp -58.95 150.18 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.794 2.038 . . . . 0.0 113.369 -171.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -133.77 -27.23 1.5 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 126.586 1.955 . . . . 0.0 110.709 175.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -51.46 -40.44 59.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 121.389 1.904 . . . . 0.0 115.516 -166.18 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 12.6 p90 -55.54 -14.08 1.88 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.715 2.006 . . . . 0.0 115.372 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.1 pt -118.77 -38.6 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 C-N-CA 125.968 1.707 . . . . 0.0 112.224 162.288 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.88 67.02 0.78 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 127.992 2.71 . . . . 0.0 112.276 -171.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 47.9 -93.15 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 129.21 3.29 . . . . 0.0 114.239 178.504 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -143.8 3.09 1.51 Allowed Glycine 0 C--N 1.335 0.52 0 C-N-CA 125.41 1.481 . . . . 0.0 116.544 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -63.34 -37.66 80.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 119.402 1.601 . . . . 0.0 113.408 -160.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.89 -99.86 0.22 Allowed Glycine 0 C--N 1.335 0.516 0 C-N-CA 125.912 1.72 . . . . 0.0 112.455 171.039 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -116.17 -174.08 2.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.135 2.174 . . . . 0.0 114.288 -171.219 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -153.89 -20.91 0.14 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 115.427 1.64 . . . . 0.0 115.427 168.031 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 127.019 2.247 . . . . 0.0 116.852 -179.051 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.482 0 N-CA-C 120.819 3.087 . . . . 0.0 120.819 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.05 -117.29 0.42 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-N 120.9 2.35 . . . . 0.0 115.251 -174.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -133.0 159.09 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 127.304 2.241 . . . . 0.0 109.894 -170.253 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.31 -162.88 29.69 Favored Glycine 0 CA--C 1.523 0.546 0 O-C-N 119.682 -1.886 . . . . 0.0 110.293 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 mttp -86.32 -70.79 0.58 Allowed 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 125.023 1.329 . . . . 0.0 113.469 -176.009 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.44 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.9 pt -73.46 157.23 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 122.545 1.164 . . . . 0.0 112.311 171.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.47 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.9 tp -71.62 142.64 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 127.836 2.454 . . . . 0.0 115.027 -175.201 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -105.29 -23.42 12.87 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 129.323 3.049 . . . . 0.0 110.459 173.031 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.47 ' H ' HG13 ' A' ' 7' ' ' ILE . 4.6 t80 -43.11 -49.08 6.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.642 2.777 . . . . 0.0 115.424 -168.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -63.71 -11.9 30.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.083 1.753 . . . . 0.0 114.442 -175.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.5 pt -127.38 16.28 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 127.702 2.401 . . . . 0.0 113.078 172.6 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.09 73.1 0.23 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.439 1.018 . . . . 0.0 113.151 -168.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 25.79 -84.92 0.0 OUTLIER Glycine 0 N--CA 1.448 -0.502 1 C-N-CA 132.13 4.681 . . . . 0.0 114.728 -176.645 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -160.95 76.06 0.18 Allowed Glycine 0 C--N 1.336 0.546 0 C-N-CA 126.2 1.857 . . . . 0.0 113.032 161.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.21 -55.7 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 CA-C-O 122.173 0.987 . . . . 0.0 111.404 177.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.11 -110.65 0.45 Allowed Glycine 0 C--N 1.336 0.539 0 O-C-N 119.433 -2.042 . . . . 0.0 114.393 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -123.03 172.42 8.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.875 2.07 . . . . 0.0 115.407 -162.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -152.5 -7.24 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.233 1.568 . . . . 0.0 115.233 173.732 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.44 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 115.819 -2.656 . . . . 0.0 115.929 -171.29 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.473 0 N-CA-C 117.597 1.799 . . . . 0.0 117.597 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.33 -144.32 4.03 Favored Glycine 0 CA--C 1.522 0.493 0 CA-C-N 120.118 1.959 . . . . 0.0 115.412 -174.645 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 53.5 t -99.34 142.31 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 127.92 2.488 . . . . 0.0 108.022 175.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 167.11 -173.16 42.33 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 125.976 1.751 . . . . 0.0 114.45 -171.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -85.46 -44.96 12.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 115.939 1.829 . . . . 0.0 115.939 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 36.9 pt -103.84 133.13 48.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 126.468 1.907 . . . . 0.0 111.007 -166.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.9 tp -63.62 117.63 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 C-N-CA 127.307 2.243 . . . . 0.0 115.256 -164.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -95.19 -21.62 18.36 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 127.042 2.137 . . . . 0.0 112.494 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -49.46 -47.47 48.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.098 1.759 . . . . 0.0 110.355 -173.044 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -58.75 -17.88 26.92 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.018 2.127 . . . . 0.0 115.79 -175.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.7 pt -132.16 -9.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 125.714 1.605 . . . . 0.0 113.948 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -124.34 40.93 1.82 Allowed Glycine 0 CA--C 1.522 0.497 0 C-N-CA 129.286 3.327 . . . . 0.0 112.141 -170.75 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.98 -81.22 0.05 OUTLIER Glycine 0 C--N 1.335 0.516 0 C-N-CA 128.646 3.022 . . . . 0.0 111.658 -177.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -158.75 23.41 0.33 Allowed Glycine 0 C--N 1.335 0.49 0 C-N-CA 127.11 2.291 . . . . 0.0 115.79 174.497 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.23 -63.07 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 119.348 1.574 . . . . 0.0 112.901 -169.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.34 -105.58 0.21 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 120.236 1.38 . . . . 0.0 113.907 -176.133 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.7 mpt_? -146.89 154.58 41.46 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.967 1.707 . . . . 0.0 114.99 -171.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -127.4 7.6 6.43 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 120.735 3.606 . . . . 0.0 120.735 -162.623 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 118.733 -1.037 . . . . 0.0 115.182 -178.552 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.472 0 N-CA-C 116.45 1.34 . . . . 0.0 116.45 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.47 -100.11 0.14 Allowed Glycine 0 CA--C 1.522 0.527 0 C-N-CA 126.629 2.062 . . . . 0.0 108.61 176.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.2 t -114.35 160.94 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 126.685 1.994 . . . . 0.0 109.164 177.161 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.97 -177.63 33.76 Favored Glycine 0 C--N 1.335 0.503 0 O-C-N 120.956 -1.09 . . . . 0.0 114.315 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.2 mttp -67.43 -53.91 24.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.201 2.2 . . . . 0.0 112.52 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.431 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.3 pt -114.38 155.13 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 CA-C-O 122.685 1.231 . . . . 0.0 111.761 -168.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -69.38 139.56 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 113.227 -1.806 . . . . 0.0 114.746 -160.428 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -117.55 -20.29 9.07 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 127.024 2.13 . . . . 0.0 111.736 171.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -45.62 -33.08 2.66 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 116.2 1.926 . . . . 0.0 116.2 173.391 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -67.23 -14.01 62.51 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 127.826 2.45 . . . . 0.0 115.532 175.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 36.2 pt -129.16 -6.9 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 127.459 2.304 . . . . 0.0 114.36 176.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -152.48 92.5 0.14 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.738 1.637 . . . . 0.0 113.55 -175.278 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 29.03 -93.56 0.01 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 130.012 3.672 . . . . 0.0 115.02 159.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -124.49 17.73 7.35 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 126.691 2.091 . . . . 0.0 113.922 175.033 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.1 t -90.32 40.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.527 2.331 . . . . 0.0 111.92 -170.128 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 43.48 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 129.617 3.484 . . . . 0.0 118.286 167.078 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -138.54 170.42 16.03 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.281 1.833 . . . . 0.0 113.81 -166.082 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -146.18 -2.86 0.68 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 174.349 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.431 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.25 1.105 0 N-CA-C 117.543 1.777 . . . . 0.0 117.543 -175.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.455 0 CA-C-O 121.221 0.345 . . . . 0.0 112.69 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 165.39 -48.04 0.28 Allowed Glycine 0 CA--C 1.522 0.515 0 C-N-CA 128.359 2.885 . . . . 0.0 114.486 168.003 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -119.25 137.61 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 126.779 2.032 . . . . 0.0 111.588 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.19 -171.21 37.17 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 116.489 1.356 . . . . 0.0 116.489 -179.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 40.6 mttp -76.61 -50.46 13.76 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 129.458 3.103 . . . . 0.0 114.095 177.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.1 pt -121.29 151.96 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 O-C-N 124.251 0.97 . . . . 0.0 111.782 -172.034 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.532 HG13 ' H ' ' A' ' 9' ' ' TYR . 7.7 tp -68.91 139.02 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 127.762 2.425 . . . . 0.0 115.003 -165.795 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -111.11 -3.04 15.61 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.57 2.348 . . . . 0.0 112.318 177.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.532 ' H ' HG13 ' A' ' 7' ' ' ILE . 71.1 t80 -47.21 -48.45 24.02 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 128.625 2.77 . . . . 0.0 115.437 -170.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.57 -9.11 16.93 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.8 pt -125.57 0.96 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 122.413 2.369 . . . . 0.0 113.655 172.356 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.66 5.52 10.69 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 126.98 2.229 . . . . 0.0 116.381 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.77 -70.55 0.93 Allowed Glycine 0 C--N 1.335 0.49 0 O-C-N 120.3 -1.706 . . . . 0.0 115.296 -171.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -163.46 13.95 0.1 Allowed Glycine 0 C--N 1.335 0.496 0 CA-C-O 117.878 -1.512 . . . . 0.0 115.582 -163.125 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.1 t -81.85 -75.09 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 121.254 2.527 . . . . 0.0 110.729 -177.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.44 -122.63 0.78 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 118.351 2.1 . . . . 0.0 118.351 178.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 68.7 mtt180 -107.85 176.84 5.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 126.852 2.061 . . . . 0.0 111.731 -168.504 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 p90 -151.66 -19.51 0.19 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 117.92 2.563 . . . . 0.0 117.92 174.329 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 117.682 -1.621 . . . . 0.0 113.994 -175.039 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 CA-C-O 116.534 -2.259 . . . . 0.0 116.439 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.3 -161.09 11.63 Favored Glycine 0 C--N 1.336 0.543 0 CA-C-N 120.694 2.247 . . . . 0.0 111.001 -177.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -133.08 153.96 38.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.208 1.803 . . . . 0.0 109.431 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.13 -141.44 8.25 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.966 -2.053 . . . . 0.0 107.966 -161.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mtmp? -126.27 -54.45 1.47 Allowed 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 116.225 -1.845 . . . . 0.0 112.394 -166.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 32.8 pt -79.27 136.11 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 CA-C-N 120.3 1.409 . . . . 0.0 109.53 174.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.519 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.8 tp -70.9 139.23 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 114.279 1.214 . . . . 0.0 114.279 -170.129 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -90.88 -4.7 56.35 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.405 1.882 . . . . 0.0 113.231 174.642 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.519 ' H ' HG13 ' A' ' 7' ' ' ILE . 72.8 t80 -46.64 -58.15 4.11 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 126.166 1.786 . . . . 0.0 113.689 -174.587 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.2 -13.7 5.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 119.345 -2.097 . . . . 0.0 115.59 176.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 29.7 pt -128.53 6.36 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 128.539 2.735 . . . . 0.0 115.254 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.77 -9.06 0.03 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 64.92 -18.66 0.12 Allowed Glycine 0 C--N 1.335 0.503 0 C-N-CA 128.246 2.831 . . . . 0.0 119.881 161.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.65 34.03 0.45 Allowed Glycine 0 C--N 1.335 0.482 0 CA-C-N 121.227 2.513 . . . . 0.0 116.514 -166.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 79.8 t -135.22 -76.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.871 1.836 . . . . 0.0 111.799 177.521 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -176.93 -115.69 0.44 Allowed Glycine 0 N--CA 1.448 -0.527 0 O-C-N 120.573 -1.329 . . . . 0.0 115.598 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 8.9 mpt_? -112.79 178.63 4.22 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.801 2.04 . . . . 0.0 112.5 -172.466 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -149.06 -3.82 0.43 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 116.889 2.181 . . . . 0.0 116.889 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 O-C-N 119.132 -2.23 . . . . 0.0 113.354 -176.95 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.466 0 N-CA-C 119.302 2.481 . . . . 0.0 119.302 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.15 -105.37 0.18 Allowed Glycine 0 C--N 1.335 0.519 0 O-C-N 119.852 -1.969 . . . . 0.0 112.196 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -150.8 170.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-O 121.132 0.491 . . . . 0.0 110.238 -175.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.02 -119.68 1.27 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 124.202 0.906 . . . . 0.0 112.64 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.9 mttp -130.35 -55.94 1.09 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 128.899 2.88 . . . . 0.0 110.566 -169.056 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.6 pt -90.35 149.91 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.054 1.342 . . . . 0.0 111.238 -175.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.2 tp -86.29 149.21 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.698 1.999 . . . . 0.0 112.889 -160.149 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -128.33 -31.62 2.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 126.784 2.034 . . . . 0.0 116.11 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -54.32 -24.88 20.99 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 -165.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -69.73 -22.7 63.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.502 2.321 . . . . 0.0 113.475 176.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 24.1 pt -110.06 20.78 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.418 2.287 . . . . 0.0 111.635 169.125 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -138.52 -69.52 0.05 OUTLIER Glycine 0 CA--C 1.523 0.535 0 O-C-N 120.651 -1.281 . . . . 0.0 114.313 -170.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 150.74 -82.02 0.18 Allowed Glycine 0 C--N 1.335 0.507 0 C-N-CA 129.511 3.434 . . . . 0.0 110.143 -167.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.63 2.69 0.09 OUTLIER Glycine 0 C--N 1.335 0.507 0 N-CA-C 118.693 2.237 . . . . 0.0 118.693 -166.536 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 76.2 t -67.95 -29.62 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-N 120.644 2.222 . . . . 0.0 112.966 -179.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.47 -96.89 0.71 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 126.471 1.986 . . . . 0.0 113.327 161.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -95.87 178.92 5.28 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.302 2.641 . . . . 0.0 113.675 -178.23 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.4 p90 -159.46 -8.57 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 121.002 1.728 . . . . 0.0 114.981 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 117.08 -1.955 . . . . 0.0 111.707 -171.14 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.468 0 CA-C-O 122.554 1.085 . . . . 0.0 112.171 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.19 -70.16 0.03 OUTLIER Glycine 0 CA--C 1.522 0.525 0 C-N-CA 126.001 1.762 . . . . 0.0 113.041 172.651 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.9 t -137.49 154.44 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.293 1.837 . . . . 0.0 108.035 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.87 -168.53 33.42 Favored Glycine 0 C--N 1.335 0.514 0 O-C-N 121.102 -0.999 . . . . 0.0 111.697 -166.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.2 mttp -98.1 -53.84 3.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 115.553 -2.165 . . . . 0.0 112.95 -172.307 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.449 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 31.2 pt -84.5 151.38 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.939 1.245 . . . . 0.0 111.695 169.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.89 147.77 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 126.849 2.059 . . . . 0.0 114.119 -178.375 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -113.9 -20.38 11.09 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.534 2.734 . . . . 0.0 112.272 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 49.3 t80 -10.71 -73.33 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 129.916 3.286 . . . . 0.0 115.248 169.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -54.72 -18.51 4.75 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 131.204 3.802 . . . . 0.0 115.649 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.6 pt -121.01 15.21 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 C-N-CA 127.614 2.365 . . . . 0.0 114.598 175.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -140.06 -2.77 1.56 Allowed Glycine 0 C--N 1.335 0.505 0 N-CA-C 116.08 1.192 . . . . 0.0 116.08 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.64 -73.5 0.62 Allowed Glycine 0 CA--C 1.523 0.55 0 CA-C-N 118.618 1.209 . . . . 0.0 110.16 -170.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -145.29 85.01 0.18 Allowed Glycine 0 N--CA 1.449 -0.493 0 CA-C-O 117.807 -1.552 . . . . 0.0 113.341 177.455 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.6 t -132.25 -29.45 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 CA-C-N 119.476 1.638 . . . . 0.0 114.738 -171.025 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.86 -126.88 7.42 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 120.459 1.482 . . . . 0.0 113.919 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -124.57 171.12 10.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.726 1.21 . . . . 0.0 112.134 -168.433 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -154.71 5.01 0.24 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.449 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.162 0 CA-C-O 116.964 -2.02 . . . . 0.0 112.821 175.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.521 0 N-CA-C 114.694 0.638 . . . . 0.0 114.694 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.62 -129.94 1.32 Allowed Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 173.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 82.7 t -60.88 144.08 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 125.64 1.576 . . . . 0.0 108.657 160.662 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 168.37 -170.29 42.04 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 114.772 0.669 . . . . 0.0 114.772 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -101.23 -71.91 0.7 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 128.874 2.87 . . . . 0.0 114.758 -175.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.1 pt -84.55 147.04 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 C-N-CA 125.325 1.45 . . . . 0.0 111.721 177.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 tp -73.57 150.42 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 124.331 1.052 . . . . 0.0 113.542 -160.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -111.08 -2.17 15.97 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.096 1.759 . . . . 0.0 112.233 -176.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.0 t80 -52.61 -53.46 46.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -167.147 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -76.66 -5.14 46.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -177.735 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.9 pt -124.68 -15.55 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 126.635 1.974 . . . . 0.0 114.946 -176.783 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -123.52 19.08 7.61 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 126.503 2.001 . . . . 0.0 117.164 176.006 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.12 -54.51 3.89 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-N 118.76 1.28 . . . . 0.0 115.151 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.23 74.51 0.04 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.514 2.959 . . . . 0.0 113.074 -177.701 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 77.5 t -122.21 -51.29 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 118.777 1.289 . . . . 0.0 111.656 -171.23 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 156.15 -98.85 0.18 Allowed Glycine 0 C--N 1.336 0.551 0 CA-C-N 118.821 0.737 . . . . 0.0 112.387 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.5 mpt_? -127.56 171.81 11.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 127.054 2.141 . . . . 0.0 112.144 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -143.87 -12.82 0.65 Allowed 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 120.096 -1.628 . . . . 0.0 115.089 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 126.298 1.904 . . . . 0.0 115.352 173.824 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.547 0 N-CA-C 112.923 -0.071 . . . . 0.0 112.923 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.37 -48.46 0.04 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.66 149.36 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.694 1.197 . . . . 0.0 112.158 -170.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.07 -157.31 27.34 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 120.01 -1.682 . . . . 0.0 115.559 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -85.96 -38.85 17.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.362 3.065 . . . . 0.0 114.956 -169.362 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.4 pt -134.59 155.33 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 125.955 1.702 . . . . 0.0 111.173 -174.61 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.448 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.7 tp -78.51 133.93 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.755 2.022 . . . . 0.0 114.48 -165.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -86.27 -8.96 57.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 118.41 -2.681 . . . . 0.0 114.836 171.229 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.448 ' H ' HG13 ' A' ' 7' ' ' ILE . 59.6 t80 -38.87 -64.41 0.45 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.58 2.352 . . . . 0.0 113.81 -169.499 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -69.21 -9.39 52.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 115.924 1.824 . . . . 0.0 115.924 -176.177 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 25.2 pt -114.77 -18.45 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 125.965 1.706 . . . . 0.0 113.321 178.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -145.28 41.32 1.06 Allowed Glycine 0 C--N 1.335 0.509 0 C-N-CA 127.873 2.654 . . . . 0.0 115.117 -173.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.77 -45.87 2.78 Favored Glycine 0 CA--C 1.522 0.519 0 C-N-CA 128.036 2.731 . . . . 0.0 115.642 161.523 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.52 21.89 0.09 OUTLIER Glycine 0 CA--C 1.523 0.532 0 N-CA-C 117.111 1.604 . . . . 0.0 117.111 173.007 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -59.31 -33.2 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 124.997 1.319 . . . . 0.0 113.937 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.52 -148.38 20.11 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 119.704 -1.873 . . . . 0.0 113.49 -176.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -80.92 179.54 7.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 178.267 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -160.47 -13.44 0.05 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 176.217 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.983 -1.454 . . . . 0.0 114.369 -178.759 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 N-CA-C 118.687 2.235 . . . . 0.0 118.687 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -160.88 -160.05 10.41 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 120.75 2.275 . . . . 0.0 117.946 -174.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 89.5 t -91.63 150.73 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 124.811 1.244 . . . . 0.0 108.617 173.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.91 -169.28 35.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 116.154 1.222 . . . . 0.0 116.154 -173.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -71.75 -71.07 0.29 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.08 2.952 . . . . 0.0 112.812 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.3 pt -99.76 139.09 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 124.786 1.234 . . . . 0.0 112.628 -164.682 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.3 tp -67.34 145.85 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 126.17 1.788 . . . . 0.0 112.563 -169.669 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -109.47 -29.8 8.24 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 127.558 2.343 . . . . 0.0 112.336 -171.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -63.07 -21.03 65.9 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.488 -2.007 . . . . 0.0 115.703 -163.709 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -52.49 -25.77 11.14 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 126.529 1.932 . . . . 0.0 113.662 170.139 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 17.7 pt -121.52 -18.74 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.67 2.388 . . . . 0.0 111.839 169.466 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.8 -124.18 3.2 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 127.521 2.486 . . . . 0.0 111.841 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -177.66 -9.41 0.02 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 120.402 2.921 . . . . 0.0 120.402 -177.466 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 152.88 57.19 0.01 OUTLIER Glycine 0 CA--C 1.523 0.544 0 CA-C-N 120.478 2.139 . . . . 0.0 116.087 172.293 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.8 t -128.74 -44.42 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 126.198 1.799 . . . . 0.0 110.461 178.439 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.22 -94.04 0.15 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.154 1.835 . . . . 0.0 115.316 175.468 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -132.56 169.03 17.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.205 1.802 . . . . 0.0 113.545 -159.023 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -148.14 12.85 0.97 Allowed 'General case' 0 N--CA 1.449 -0.513 0 CA-C-O 117.864 -1.065 . . . . 0.0 113.699 -174.025 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-N 120.953 1.706 . . . . 0.0 112.305 -177.586 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 CA-C-O 117.974 -1.459 . . . . 0.0 114.381 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.16 -109.92 0.31 Allowed Glycine 0 C--N 1.336 0.549 0 C-N-CA 125.03 1.3 . . . . 0.0 110.668 -172.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.2 p -72.16 159.29 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 122.137 0.97 . . . . 0.0 112.748 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.75 -152.65 24.72 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 127.112 2.291 . . . . 0.0 115.599 170.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -129.0 -46.91 1.23 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 127.511 2.324 . . . . 0.0 110.754 172.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.0 pt -73.35 133.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 125.108 1.363 . . . . 0.0 112.618 171.258 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.7 tp -63.76 157.52 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.263 1.825 . . . . 0.0 113.113 -170.205 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -136.15 -24.48 1.26 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 127.17 2.188 . . . . 0.0 113.083 171.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -48.19 -29.33 3.63 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 115.99 1.848 . . . . 0.0 115.99 -164.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -60.51 -28.96 68.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 116.942 2.201 . . . . 0.0 116.942 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 27.3 pt -96.27 -33.86 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 127.577 2.351 . . . . 0.0 111.384 160.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -95.61 53.04 1.75 Allowed Glycine 0 C--N 1.335 0.522 0 CA-C-O 118.309 -1.273 . . . . 0.0 114.643 -170.185 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 51.49 -94.43 0.01 OUTLIER Glycine 0 C--N 1.335 0.502 0 C-N-CA 126.578 2.037 . . . . 0.0 116.253 173.405 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -131.11 9.05 5.69 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.751 2.12 . . . . 0.0 115.562 171.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -72.0 -56.67 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 128.043 2.537 . . . . 0.0 113.725 -157.686 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 154.88 -125.37 1.68 Allowed Glycine 0 CA--C 1.523 0.547 0 CA-C-N 120.974 1.715 . . . . 0.0 115.649 -172.422 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -112.29 -178.58 3.45 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 128.179 2.591 . . . . 0.0 111.41 -161.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -143.1 -1.51 1.07 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 119.075 2.991 . . . . 0.0 119.075 163.193 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 O-C-N 119.623 -1.923 . . . . 0.0 113.931 -178.496 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.539 0 CA-C-O 116.81 -2.106 . . . . 0.0 118.161 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.88 -100.07 0.14 Allowed Glycine 0 C--N 1.336 0.533 0 CA-C-N 119.649 1.724 . . . . 0.0 115.334 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.3 p -156.01 176.56 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-N 121.064 2.432 . . . . 0.0 110.052 -172.206 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 111.29 -97.9 0.99 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-O 119.72 -0.489 . . . . 0.0 114.126 153.337 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.6 mttp -107.71 -103.31 0.35 Allowed 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 125.459 1.504 . . . . 0.0 111.007 -163.003 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.8 pt -63.09 154.35 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 115.716 1.747 . . . . 0.0 115.716 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.8 tp -73.74 156.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.946 1.699 . . . . 0.0 111.838 -174.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -142.56 -22.36 0.66 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.99 2.219 . . . . 0.0 116.99 -178.307 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 25.0 p90 -56.16 -34.85 66.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 119.832 1.197 . . . . 0.0 113.319 -161.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.72 -20.02 45.18 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 119.522 1.055 . . . . 0.0 113.698 177.118 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.3 pt -122.91 20.96 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.601 1.96 . . . . 0.0 111.704 169.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.03 60.29 0.33 Allowed Glycine 0 C--N 1.335 0.513 0 C-N-CA 127.793 2.616 . . . . 0.0 112.341 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.25 -96.59 0.01 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.331 2.872 . . . . 0.0 114.983 174.458 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.2 14.43 4.57 Favored Glycine 0 CA--C 1.522 0.513 0 C-N-CA 129.347 3.356 . . . . 0.0 115.462 176.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -60.16 -50.99 78.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.619 1.71 . . . . 0.0 110.69 -176.432 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 133.53 -88.15 0.26 Allowed Glycine 0 CA--C 1.523 0.542 0 O-C-N 124.77 1.294 . . . . 0.0 115.915 174.356 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -114.41 -172.87 2.19 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 128.527 2.731 . . . . 0.0 111.35 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -159.4 -12.97 0.06 Allowed 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 116.57 2.063 . . . . 0.0 116.57 169.105 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 117.23 -1.872 . . . . 0.0 116.185 -168.145 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.56 -85.64 0.06 OUTLIER Glycine 0 CA--C 1.522 0.528 0 C-N-CA 126.821 2.153 . . . . 0.0 108.974 170.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.44 158.48 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 126.211 1.805 . . . . 0.0 112.087 176.528 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.05 -173.99 33.3 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 119.414 -2.054 . . . . 0.0 113.969 -178.102 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -68.51 -27.8 66.44 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 128.48 2.712 . . . . 0.0 116.757 -174.011 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.9 pt -140.56 163.72 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 124.808 1.243 . . . . 0.0 112.341 -171.471 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.69 141.36 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.247 2.219 . . . . 0.0 114.218 -166.175 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -126.17 -22.41 4.08 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 127.618 2.367 . . . . 0.0 113.482 174.618 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -53.16 -32.41 47.55 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 118.227 2.677 . . . . 0.0 118.227 -169.866 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -66.37 -15.61 63.42 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 116.29 1.959 . . . . 0.0 116.29 177.028 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 20.6 pt -117.76 11.74 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 128.968 2.907 . . . . 0.0 110.723 169.304 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -155.51 55.61 0.41 Allowed Glycine 0 CA--C 1.522 0.506 0 C-N-CA 126.203 1.858 . . . . 0.0 111.317 -161.744 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 28.62 -88.66 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 1 C-N-CA 131.973 4.606 . . . . 0.0 115.102 179.297 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.38 33.62 2.55 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 126.354 1.93 . . . . 0.0 114.351 172.257 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 81.9 t -73.16 -79.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 127.162 2.185 . . . . 0.0 110.306 -178.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -93.12 0.14 Allowed Glycine 0 CA--C 1.522 0.513 0 O-C-N 121.79 -0.569 . . . . 0.0 113.841 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.4 mtt85 -126.33 177.43 6.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 127.661 2.384 . . . . 0.0 113.367 -169.031 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -154.89 -25.05 0.12 Allowed 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 118.183 2.66 . . . . 0.0 118.183 178.564 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.155 0 C-N-CA 129.336 3.351 . . . . 0.0 115.843 -179.323 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.511 ' H ' ' CG1' ' A' ' 15' ' ' VAL . . . 104.86 -107.53 2.91 Favored Glycine 0 C--N 1.335 0.475 0 O-C-N 120.871 -1.37 . . . . 0.0 112.722 -175.263 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.46 163.68 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 C-N-CA 125.538 1.535 . . . . 0.0 108.935 165.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 149.45 -171.9 29.53 Favored Glycine 0 C--N 1.335 0.515 0 O-C-N 120.704 -1.247 . . . . 0.0 113.568 177.271 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 mptp? -66.45 -83.69 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 125.341 1.456 . . . . 0.0 112.277 -177.662 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 pt -64.49 149.93 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-O 121.397 0.618 . . . . 0.0 112.154 -175.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.6 tp -61.93 154.04 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.234 1.814 . . . . 0.0 114.97 -179.485 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -133.8 -26.48 1.56 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.228 2.611 . . . . 0.0 114.941 174.766 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -55.05 -24.2 23.72 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 118.219 2.674 . . . . 0.0 118.219 -173.323 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -65.81 -16.23 63.62 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.983 1.313 . . . . 0.0 114.474 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.5 pt -123.16 -19.97 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 127.593 2.357 . . . . 0.0 112.591 172.426 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.36 41.13 2.26 Favored Glycine 0 CA--C 1.522 0.523 0 C-N-CA 128.284 2.85 . . . . 0.0 112.071 179.002 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.94 -95.61 0.04 OUTLIER Glycine 0 C--N 1.335 0.503 0 C-N-CA 126.485 1.993 . . . . 0.0 116.106 171.006 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -123.77 2.99 9.33 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 126.584 2.04 . . . . 0.0 112.637 -176.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.511 ' CG1' ' H ' ' A' ' 2' ' ' GLY . 50.7 t -53.73 -66.59 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.712 1.605 . . . . 0.0 113.867 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.83 -110.44 0.58 Allowed Glycine 0 C--N 1.335 0.525 0 CA-C-O 118.39 -1.228 . . . . 0.0 114.565 -175.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 60.8 mtm-85 -129.03 167.44 17.49 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 128.595 2.758 . . . . 0.0 110.225 -165.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -151.61 -12.49 0.2 Allowed 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 -178.347 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.127 0 O-C-N 125.522 1.764 . . . . 0.0 116.74 -175.962 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.483 0 CA-C-O 121.981 0.767 . . . . 0.0 112.826 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.58 -95.36 1.34 Allowed Glycine 0 C--N 1.335 0.517 0 C-N-CA 126.447 1.975 . . . . 0.0 112.433 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.86 157.83 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 124.703 1.201 . . . . 0.0 110.206 173.583 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 160.49 -167.05 35.58 Favored Glycine 0 CA--C 1.523 0.539 0 O-C-N 120.836 -1.165 . . . . 0.0 115.381 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -92.81 -64.84 1.05 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.897 1.679 . . . . 0.0 112.585 176.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 10.7 pt -78.0 145.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 O-C-N 121.489 -0.757 . . . . 0.0 112.083 -179.443 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.7 tp -65.04 149.25 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 C-N-CA 124.488 1.115 . . . . 0.0 112.271 -169.21 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -122.4 -20.43 6.1 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 128.535 2.734 . . . . 0.0 112.763 172.649 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -40.39 -44.95 2.08 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.434 1.894 . . . . 0.0 114.582 175.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -50.38 -21.74 1.56 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.195 1.924 . . . . 0.0 116.195 174.243 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 pt -131.07 -1.98 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 126.326 1.85 . . . . 0.0 114.734 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -137.0 67.93 0.53 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.945 2.212 . . . . 0.0 112.481 -167.54 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 30.95 -100.34 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 C-N-CA 129.037 3.208 . . . . 0.0 115.491 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -127.0 13.46 6.72 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 116.063 1.185 . . . . 0.0 116.063 172.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.1 t -61.26 -37.82 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -171.519 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.77 -93.03 0.37 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 124.997 1.284 . . . . 0.0 112.616 166.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -120.75 175.45 6.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.563 1.945 . . . . 0.0 113.75 -172.793 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.54 -29.8 0.51 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 172.37 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.122 0 CA-C-N 120.55 1.523 . . . . 0.0 115.782 -172.029 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.488 0 N-CA-C 118.994 2.358 . . . . 0.0 118.994 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.35 -101.84 0.22 Allowed Glycine 0 CA--C 1.522 0.525 0 C-N-CA 128.777 3.084 . . . . 0.0 114.362 165.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 p -73.47 156.25 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 124.272 1.029 . . . . 0.0 112.234 168.096 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 133.81 -175.44 20.29 Favored Glycine 0 CA--C 1.522 0.515 0 O-C-N 118.803 -2.436 . . . . 0.0 112.534 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.2 mttp -84.89 -79.43 0.22 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.449 2.3 . . . . 0.0 111.51 -173.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt -72.75 154.38 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-O 121.981 0.896 . . . . 0.0 111.91 -169.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -63.33 141.57 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 126.8 2.04 . . . . 0.0 112.649 -175.532 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -125.37 -25.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 127.359 2.263 . . . . 0.0 113.561 174.717 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -42.33 -40.29 2.43 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 127.791 2.436 . . . . 0.0 116.463 -172.207 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -53.93 -31.11 49.26 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 117.016 2.228 . . . . 0.0 117.016 174.373 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 18.1 pt -112.04 -19.59 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.419 1.488 . . . . 0.0 113.729 172.358 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -73.14 -34.06 58.67 Favored Glycine 0 C--N 1.335 0.497 0 CA-C-O 118.537 -1.146 . . . . 0.0 112.723 177.119 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.06 -100.21 2.53 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 118.755 1.278 . . . . 0.0 110.666 -169.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -109.54 29.63 9.3 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 128.123 2.773 . . . . 0.0 113.785 -176.845 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.3 t -107.48 -26.94 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 -157.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.25 -102.52 2.66 Favored Glycine 0 C--N 1.335 0.498 0 O-C-N 121.164 -0.96 . . . . 0.0 113.502 174.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -128.45 -174.51 3.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 124.945 1.298 . . . . 0.0 110.015 -160.369 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -164.44 -8.72 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 120.349 3.463 . . . . 0.0 120.349 173.171 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.093 0 C-N-CA 125.406 1.479 . . . . 0.0 115.114 -175.718 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.539 0 CA-C-O 121.728 0.626 . . . . 0.0 111.541 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 116.28 -151.37 18.35 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.947 1.261 . . . . 0.0 114.163 -174.617 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 90.5 t -70.31 147.34 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.375 1.87 . . . . 0.0 109.934 171.772 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.23 -173.65 34.11 Favored Glycine 0 CA--C 1.522 0.52 0 O-C-N 120.535 -1.353 . . . . 0.0 111.123 177.131 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 mttp -88.84 -77.57 0.37 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.506 2.322 . . . . 0.0 112.18 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.0 pt -76.32 141.04 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.524 1.929 . . . . 0.0 110.89 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.474 HG13 ' H ' ' A' ' 9' ' ' TYR . 4.8 tp -61.56 147.34 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.704 1.601 . . . . 0.0 113.197 -173.606 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -117.66 -3.04 11.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.933 2.493 . . . . 0.0 110.821 176.737 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.474 ' H ' HG13 ' A' ' 7' ' ' ILE . 60.8 t80 -38.1 -53.78 1.38 Allowed 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 128.197 2.599 . . . . 0.0 114.053 -176.799 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.429 ' CD2' HG23 ' A' ' 11' ' ' ILE . 25.5 p90 -73.35 -12.04 60.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 127.639 2.376 . . . . 0.0 114.485 -175.319 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.429 HG23 ' CD2' ' A' ' 10' ' ' PHE . 7.2 pt -133.74 -21.02 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 122.314 2.324 . . . . 0.0 116.346 -171.112 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -115.05 47.69 1.01 Allowed Glycine 0 C--N 1.335 0.498 0 CA-C-N 119.356 0.98 . . . . 0.0 114.359 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.65 -78.4 1.02 Allowed Glycine 0 CA--C 1.523 0.576 0 C-N-CA 124.017 0.818 . . . . 0.0 112.894 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 163.98 71.09 0.02 OUTLIER Glycine 0 CA--C 1.523 0.564 0 C-N-CA 126.071 1.796 . . . . 0.0 113.271 -175.012 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -120.78 -53.77 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 120.913 -1.345 . . . . 0.0 111.412 173.464 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.54 -95.75 0.11 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 121.517 1.962 . . . . 0.0 113.608 177.175 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -121.17 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.37 3.068 . . . . 0.0 114.281 -171.23 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -153.73 -30.83 0.12 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 116.984 2.216 . . . . 0.0 116.984 172.496 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.064 -1.965 . . . . 0.0 115.713 -171.008 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 119.529 2.572 . . . . 0.0 119.529 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.69 -140.6 2.93 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.891 2.186 . . . . 0.0 114.898 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.4 p -100.09 157.95 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.089 1.355 . . . . 0.0 113.038 176.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 141.78 -156.9 26.12 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 120.055 -1.653 . . . . 0.0 115.075 164.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -77.11 -76.53 0.17 Allowed 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.99 2.516 . . . . 0.0 113.347 -174.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.8 pt -80.02 147.47 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-O 122.609 1.195 . . . . 0.0 112.906 -174.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -61.96 138.8 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 C-N-CA 124.924 1.29 . . . . 0.0 113.026 -173.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -143.76 7.15 1.44 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.542 2.337 . . . . 0.0 113.423 -172.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -68.65 -26.74 65.48 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 118.75 -2.469 . . . . 0.0 113.959 -171.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -82.31 -8.15 59.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 117.546 2.424 . . . . 0.0 117.546 173.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.2 pt -133.0 82.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 127.192 2.197 . . . . 0.0 111.085 175.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 125.45 37.47 0.52 Allowed Glycine 0 CA--C 1.523 0.543 0 C-N-CA 124.773 1.178 . . . . 0.0 113.153 -170.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.2 -56.81 5.08 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 127.659 2.552 . . . . 0.0 113.656 163.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.9 -11.16 0.05 OUTLIER Glycine 0 C--N 1.335 0.522 0 C-N-CA 125.23 1.395 . . . . 0.0 115.53 -177.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.2 t -49.58 -27.15 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 C-N-CA 126.999 2.12 . . . . 0.0 115.779 -170.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.16 -89.34 0.17 Allowed Glycine 0 C--N 1.335 0.486 0 CA-C-N 122.028 2.194 . . . . 0.0 115.773 160.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -129.83 -176.89 4.06 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 127.645 2.378 . . . . 0.0 113.029 -166.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -155.52 -10.33 0.11 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 116.657 2.095 . . . . 0.0 116.657 169.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.122 -1.932 . . . . 0.0 116.679 -176.989 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.506 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.11 -111.14 0.32 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-N 121.376 2.588 . . . . 0.0 115.925 176.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.4 p -138.21 145.06 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 128.64 2.776 . . . . 0.0 111.218 -159.232 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.56 -173.95 33.65 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 127.483 2.468 . . . . 0.0 114.709 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.32 -53.84 5.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 172.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.2 pt -85.64 149.37 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-O 122.254 1.026 . . . . 0.0 113.412 178.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.6 tp -68.79 149.02 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 125.598 1.559 . . . . 0.0 114.26 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -118.91 -14.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 126.702 2.001 . . . . 0.0 111.683 175.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -35.45 -57.98 0.6 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.926 2.09 . . . . 0.0 115.299 177.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -47.18 -37.87 10.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 116.902 2.186 . . . . 0.0 116.902 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 34.3 pt -109.74 -10.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 127.613 2.365 . . . . 0.0 115.73 -178.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -144.59 39.09 1.24 Allowed Glycine 0 C--N 1.336 0.535 0 O-C-N 119.579 -1.951 . . . . 0.0 114.296 -165.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.23 -80.29 1.64 Allowed Glycine 0 CA--C 1.522 0.512 0 C-N-CA 126.007 1.765 . . . . 0.0 112.692 163.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.7 2.64 0.04 OUTLIER Glycine 0 CA--C 1.522 0.509 0 N-CA-C 116.596 1.398 . . . . 0.0 116.596 -165.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.3 t -72.31 -42.29 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 CA-C-N 118.154 0.977 . . . . 0.0 109.949 -169.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -100.2 0.2 Allowed Glycine 0 N--CA 1.448 -0.518 0 CA-C-O 121.757 0.643 . . . . 0.0 113.2 175.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -119.34 178.08 4.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 128.451 2.7 . . . . 0.0 112.675 -167.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -149.39 -32.9 0.21 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 117.599 2.444 . . . . 0.0 117.599 170.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.144 0 CA-C-O 116.917 -2.046 . . . . 0.0 113.078 -175.994 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.524 0 N-CA-C 116.8 1.48 . . . . 0.0 116.8 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.44 -107.1 0.2 Allowed Glycine 0 C--N 1.335 0.513 0 CA-C-N 119.847 1.824 . . . . 0.0 114.726 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.8 p -128.66 153.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 126.86 2.064 . . . . 0.0 114.259 -152.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 109.21 -142.16 16.15 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 115.367 0.907 . . . . 0.0 115.367 162.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -77.0 -32.67 57.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 116.777 2.14 . . . . 0.0 116.777 -153.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.8 pt -139.75 150.39 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-O 121.903 0.858 . . . . 0.0 109.959 -175.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.1 tp -58.95 150.18 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.794 2.038 . . . . 0.0 113.369 -171.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -133.77 -27.23 1.5 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 126.586 1.955 . . . . 0.0 110.709 175.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -51.46 -40.44 59.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 121.389 1.904 . . . . 0.0 115.516 -166.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 12.6 p90 -55.54 -14.08 1.88 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.715 2.006 . . . . 0.0 115.372 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.1 pt -118.77 -38.6 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 C-N-CA 125.968 1.707 . . . . 0.0 112.224 162.288 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.88 67.02 0.78 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 127.992 2.71 . . . . 0.0 112.276 -171.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 47.9 -93.15 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 129.21 3.29 . . . . 0.0 114.239 178.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -143.8 3.09 1.51 Allowed Glycine 0 C--N 1.335 0.52 0 C-N-CA 125.41 1.481 . . . . 0.0 116.544 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -63.34 -37.66 80.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 119.402 1.601 . . . . 0.0 113.408 -160.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.89 -99.86 0.22 Allowed Glycine 0 C--N 1.335 0.516 0 C-N-CA 125.912 1.72 . . . . 0.0 112.455 171.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -116.17 -174.08 2.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.135 2.174 . . . . 0.0 114.288 -171.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -153.89 -20.91 0.14 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 115.427 1.64 . . . . 0.0 115.427 168.031 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 127.019 2.247 . . . . 0.0 116.852 -179.051 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.482 0 N-CA-C 120.819 3.087 . . . . 0.0 120.819 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.05 -117.29 0.42 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-N 120.9 2.35 . . . . 0.0 115.251 -174.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -133.0 159.09 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 127.304 2.241 . . . . 0.0 109.894 -170.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.31 -162.88 29.69 Favored Glycine 0 CA--C 1.523 0.546 0 O-C-N 119.682 -1.886 . . . . 0.0 110.293 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 mttp -86.32 -70.79 0.58 Allowed 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 125.023 1.329 . . . . 0.0 113.469 -176.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.44 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.9 pt -73.46 157.23 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 122.545 1.164 . . . . 0.0 112.311 171.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.47 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.9 tp -71.62 142.64 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 127.836 2.454 . . . . 0.0 115.027 -175.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -105.29 -23.42 12.87 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 129.323 3.049 . . . . 0.0 110.459 173.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.47 ' H ' HG13 ' A' ' 7' ' ' ILE . 4.6 t80 -43.11 -49.08 6.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.642 2.777 . . . . 0.0 115.424 -168.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -63.71 -11.9 30.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.083 1.753 . . . . 0.0 114.442 -175.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.5 pt -127.38 16.28 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 127.702 2.401 . . . . 0.0 113.078 172.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.09 73.1 0.23 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.439 1.018 . . . . 0.0 113.151 -168.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 25.79 -84.92 0.0 OUTLIER Glycine 0 N--CA 1.448 -0.502 1 C-N-CA 132.13 4.681 . . . . 0.0 114.728 -176.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -160.95 76.06 0.18 Allowed Glycine 0 C--N 1.336 0.546 0 C-N-CA 126.2 1.857 . . . . 0.0 113.032 161.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.21 -55.7 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 CA-C-O 122.173 0.987 . . . . 0.0 111.404 177.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.11 -110.65 0.45 Allowed Glycine 0 C--N 1.336 0.539 0 O-C-N 119.433 -2.042 . . . . 0.0 114.393 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -123.03 172.42 8.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.875 2.07 . . . . 0.0 115.407 -162.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -152.5 -7.24 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.233 1.568 . . . . 0.0 115.233 173.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.44 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 115.819 -2.656 . . . . 0.0 115.929 -171.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.473 0 N-CA-C 117.597 1.799 . . . . 0.0 117.597 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.33 -144.32 4.03 Favored Glycine 0 CA--C 1.522 0.493 0 CA-C-N 120.118 1.959 . . . . 0.0 115.412 -174.645 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 53.5 t -99.34 142.31 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 127.92 2.488 . . . . 0.0 108.022 175.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 167.11 -173.16 42.33 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 125.976 1.751 . . . . 0.0 114.45 -171.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -85.46 -44.96 12.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 115.939 1.829 . . . . 0.0 115.939 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 36.9 pt -103.84 133.13 48.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 126.468 1.907 . . . . 0.0 111.007 -166.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.9 tp -63.62 117.63 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 C-N-CA 127.307 2.243 . . . . 0.0 115.256 -164.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -95.19 -21.62 18.36 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 127.042 2.137 . . . . 0.0 112.494 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -49.46 -47.47 48.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.098 1.759 . . . . 0.0 110.355 -173.044 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -58.75 -17.88 26.92 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.018 2.127 . . . . 0.0 115.79 -175.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.7 pt -132.16 -9.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 125.714 1.605 . . . . 0.0 113.948 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -124.34 40.93 1.82 Allowed Glycine 0 CA--C 1.522 0.497 0 C-N-CA 129.286 3.327 . . . . 0.0 112.141 -170.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.98 -81.22 0.05 OUTLIER Glycine 0 C--N 1.335 0.516 0 C-N-CA 128.646 3.022 . . . . 0.0 111.658 -177.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -158.75 23.41 0.33 Allowed Glycine 0 C--N 1.335 0.49 0 C-N-CA 127.11 2.291 . . . . 0.0 115.79 174.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.23 -63.07 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 119.348 1.574 . . . . 0.0 112.901 -169.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.34 -105.58 0.21 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 120.236 1.38 . . . . 0.0 113.907 -176.133 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.7 mpt_? -146.89 154.58 41.46 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.967 1.707 . . . . 0.0 114.99 -171.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -127.4 7.6 6.43 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 120.735 3.606 . . . . 0.0 120.735 -162.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 118.733 -1.037 . . . . 0.0 115.182 -178.552 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.472 0 N-CA-C 116.45 1.34 . . . . 0.0 116.45 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.47 -100.11 0.14 Allowed Glycine 0 CA--C 1.522 0.527 0 C-N-CA 126.629 2.062 . . . . 0.0 108.61 176.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.2 t -114.35 160.94 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 126.685 1.994 . . . . 0.0 109.164 177.161 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.97 -177.63 33.76 Favored Glycine 0 C--N 1.335 0.503 0 O-C-N 120.956 -1.09 . . . . 0.0 114.315 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.2 mttp -67.43 -53.91 24.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.201 2.2 . . . . 0.0 112.52 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.431 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.3 pt -114.38 155.13 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 CA-C-O 122.685 1.231 . . . . 0.0 111.761 -168.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -69.38 139.56 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 113.227 -1.806 . . . . 0.0 114.746 -160.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -117.55 -20.29 9.07 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 127.024 2.13 . . . . 0.0 111.736 171.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -45.62 -33.08 2.66 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 116.2 1.926 . . . . 0.0 116.2 173.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -67.23 -14.01 62.51 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 127.826 2.45 . . . . 0.0 115.532 175.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 36.2 pt -129.16 -6.9 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 127.459 2.304 . . . . 0.0 114.36 176.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -152.48 92.5 0.14 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.738 1.637 . . . . 0.0 113.55 -175.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 29.03 -93.56 0.01 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 130.012 3.672 . . . . 0.0 115.02 159.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -124.49 17.73 7.35 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 126.691 2.091 . . . . 0.0 113.922 175.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.1 t -90.32 40.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.527 2.331 . . . . 0.0 111.92 -170.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 43.48 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 129.617 3.484 . . . . 0.0 118.286 167.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -138.54 170.42 16.03 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.281 1.833 . . . . 0.0 113.81 -166.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -146.18 -2.86 0.68 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 174.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.431 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.25 1.105 0 N-CA-C 117.543 1.777 . . . . 0.0 117.543 -175.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.455 0 CA-C-O 121.221 0.345 . . . . 0.0 112.69 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 165.39 -48.04 0.28 Allowed Glycine 0 CA--C 1.522 0.515 0 C-N-CA 128.359 2.885 . . . . 0.0 114.486 168.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -119.25 137.61 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 126.779 2.032 . . . . 0.0 111.588 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.19 -171.21 37.17 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 116.489 1.356 . . . . 0.0 116.489 -179.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 40.6 mttp -76.61 -50.46 13.76 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 129.458 3.103 . . . . 0.0 114.095 177.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.1 pt -121.29 151.96 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 O-C-N 124.251 0.97 . . . . 0.0 111.782 -172.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.532 HG13 ' H ' ' A' ' 9' ' ' TYR . 7.7 tp -68.91 139.02 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 127.762 2.425 . . . . 0.0 115.003 -165.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -111.11 -3.04 15.61 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.57 2.348 . . . . 0.0 112.318 177.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.532 ' H ' HG13 ' A' ' 7' ' ' ILE . 71.1 t80 -47.21 -48.45 24.02 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 128.625 2.77 . . . . 0.0 115.437 -170.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.57 -9.11 16.93 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.8 pt -125.57 0.96 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 122.413 2.369 . . . . 0.0 113.655 172.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.66 5.52 10.69 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 126.98 2.229 . . . . 0.0 116.381 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.77 -70.55 0.93 Allowed Glycine 0 C--N 1.335 0.49 0 O-C-N 120.3 -1.706 . . . . 0.0 115.296 -171.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -163.46 13.95 0.1 Allowed Glycine 0 C--N 1.335 0.496 0 CA-C-O 117.878 -1.512 . . . . 0.0 115.582 -163.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.1 t -81.85 -75.09 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 121.254 2.527 . . . . 0.0 110.729 -177.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.44 -122.63 0.78 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 118.351 2.1 . . . . 0.0 118.351 178.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 68.7 mtt180 -107.85 176.84 5.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 126.852 2.061 . . . . 0.0 111.731 -168.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 p90 -151.66 -19.51 0.19 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 117.92 2.563 . . . . 0.0 117.92 174.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 117.682 -1.621 . . . . 0.0 113.994 -175.039 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 CA-C-O 116.534 -2.259 . . . . 0.0 116.439 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.3 -161.09 11.63 Favored Glycine 0 C--N 1.336 0.543 0 CA-C-N 120.694 2.247 . . . . 0.0 111.001 -177.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -133.08 153.96 38.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.208 1.803 . . . . 0.0 109.431 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.13 -141.44 8.25 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.966 -2.053 . . . . 0.0 107.966 -161.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mtmp? -126.27 -54.45 1.47 Allowed 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 116.225 -1.845 . . . . 0.0 112.394 -166.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 32.8 pt -79.27 136.11 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 CA-C-N 120.3 1.409 . . . . 0.0 109.53 174.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.519 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.8 tp -70.9 139.23 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 114.279 1.214 . . . . 0.0 114.279 -170.129 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -90.88 -4.7 56.35 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.405 1.882 . . . . 0.0 113.231 174.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.519 ' H ' HG13 ' A' ' 7' ' ' ILE . 72.8 t80 -46.64 -58.15 4.11 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 126.166 1.786 . . . . 0.0 113.689 -174.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.2 -13.7 5.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 119.345 -2.097 . . . . 0.0 115.59 176.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 29.7 pt -128.53 6.36 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 128.539 2.735 . . . . 0.0 115.254 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.77 -9.06 0.03 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 64.92 -18.66 0.12 Allowed Glycine 0 C--N 1.335 0.503 0 C-N-CA 128.246 2.831 . . . . 0.0 119.881 161.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.65 34.03 0.45 Allowed Glycine 0 C--N 1.335 0.482 0 CA-C-N 121.227 2.513 . . . . 0.0 116.514 -166.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 79.8 t -135.22 -76.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.871 1.836 . . . . 0.0 111.799 177.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -176.93 -115.69 0.44 Allowed Glycine 0 N--CA 1.448 -0.527 0 O-C-N 120.573 -1.329 . . . . 0.0 115.598 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 8.9 mpt_? -112.79 178.63 4.22 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.801 2.04 . . . . 0.0 112.5 -172.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -149.06 -3.82 0.43 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 116.889 2.181 . . . . 0.0 116.889 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 O-C-N 119.132 -2.23 . . . . 0.0 113.354 -176.95 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.466 0 N-CA-C 119.302 2.481 . . . . 0.0 119.302 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.15 -105.37 0.18 Allowed Glycine 0 C--N 1.335 0.519 0 O-C-N 119.852 -1.969 . . . . 0.0 112.196 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -150.8 170.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-O 121.132 0.491 . . . . 0.0 110.238 -175.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.02 -119.68 1.27 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 124.202 0.906 . . . . 0.0 112.64 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.9 mttp -130.35 -55.94 1.09 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 128.899 2.88 . . . . 0.0 110.566 -169.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.6 pt -90.35 149.91 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.054 1.342 . . . . 0.0 111.238 -175.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.2 tp -86.29 149.21 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.698 1.999 . . . . 0.0 112.889 -160.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -128.33 -31.62 2.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 126.784 2.034 . . . . 0.0 116.11 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -54.32 -24.88 20.99 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 -165.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -69.73 -22.7 63.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.502 2.321 . . . . 0.0 113.475 176.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 24.1 pt -110.06 20.78 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.418 2.287 . . . . 0.0 111.635 169.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -138.52 -69.52 0.05 OUTLIER Glycine 0 CA--C 1.523 0.535 0 O-C-N 120.651 -1.281 . . . . 0.0 114.313 -170.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 150.74 -82.02 0.18 Allowed Glycine 0 C--N 1.335 0.507 0 C-N-CA 129.511 3.434 . . . . 0.0 110.143 -167.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.63 2.69 0.09 OUTLIER Glycine 0 C--N 1.335 0.507 0 N-CA-C 118.693 2.237 . . . . 0.0 118.693 -166.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 76.2 t -67.95 -29.62 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-N 120.644 2.222 . . . . 0.0 112.966 -179.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.47 -96.89 0.71 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 126.471 1.986 . . . . 0.0 113.327 161.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -95.87 178.92 5.28 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.302 2.641 . . . . 0.0 113.675 -178.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.4 p90 -159.46 -8.57 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 121.002 1.728 . . . . 0.0 114.981 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 117.08 -1.955 . . . . 0.0 111.707 -171.14 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.468 0 CA-C-O 122.554 1.085 . . . . 0.0 112.171 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.19 -70.16 0.03 OUTLIER Glycine 0 CA--C 1.522 0.525 0 C-N-CA 126.001 1.762 . . . . 0.0 113.041 172.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.9 t -137.49 154.44 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.293 1.837 . . . . 0.0 108.035 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.87 -168.53 33.42 Favored Glycine 0 C--N 1.335 0.514 0 O-C-N 121.102 -0.999 . . . . 0.0 111.697 -166.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.2 mttp -98.1 -53.84 3.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 115.553 -2.165 . . . . 0.0 112.95 -172.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.449 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 31.2 pt -84.5 151.38 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.939 1.245 . . . . 0.0 111.695 169.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.89 147.77 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 126.849 2.059 . . . . 0.0 114.119 -178.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -113.9 -20.38 11.09 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.534 2.734 . . . . 0.0 112.272 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 49.3 t80 -10.71 -73.33 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 129.916 3.286 . . . . 0.0 115.248 169.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -54.72 -18.51 4.75 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 131.204 3.802 . . . . 0.0 115.649 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.6 pt -121.01 15.21 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 C-N-CA 127.614 2.365 . . . . 0.0 114.598 175.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -140.06 -2.77 1.56 Allowed Glycine 0 C--N 1.335 0.505 0 N-CA-C 116.08 1.192 . . . . 0.0 116.08 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.64 -73.5 0.62 Allowed Glycine 0 CA--C 1.523 0.55 0 CA-C-N 118.618 1.209 . . . . 0.0 110.16 -170.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -145.29 85.01 0.18 Allowed Glycine 0 N--CA 1.449 -0.493 0 CA-C-O 117.807 -1.552 . . . . 0.0 113.341 177.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.6 t -132.25 -29.45 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 CA-C-N 119.476 1.638 . . . . 0.0 114.738 -171.025 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.86 -126.88 7.42 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 120.459 1.482 . . . . 0.0 113.919 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -124.57 171.12 10.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.726 1.21 . . . . 0.0 112.134 -168.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -154.71 5.01 0.24 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.449 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.162 0 CA-C-O 116.964 -2.02 . . . . 0.0 112.821 175.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.521 0 N-CA-C 114.694 0.638 . . . . 0.0 114.694 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.62 -129.94 1.32 Allowed Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 173.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 82.7 t -60.88 144.08 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 125.64 1.576 . . . . 0.0 108.657 160.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 168.37 -170.29 42.04 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 114.772 0.669 . . . . 0.0 114.772 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -101.23 -71.91 0.7 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 128.874 2.87 . . . . 0.0 114.758 -175.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.1 pt -84.55 147.04 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 C-N-CA 125.325 1.45 . . . . 0.0 111.721 177.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 tp -73.57 150.42 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 124.331 1.052 . . . . 0.0 113.542 -160.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -111.08 -2.17 15.97 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.096 1.759 . . . . 0.0 112.233 -176.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.0 t80 -52.61 -53.46 46.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -167.147 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -76.66 -5.14 46.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -177.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.9 pt -124.68 -15.55 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 126.635 1.974 . . . . 0.0 114.946 -176.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -123.52 19.08 7.61 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 126.503 2.001 . . . . 0.0 117.164 176.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.12 -54.51 3.89 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-N 118.76 1.28 . . . . 0.0 115.151 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.23 74.51 0.04 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.514 2.959 . . . . 0.0 113.074 -177.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 77.5 t -122.21 -51.29 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 118.777 1.289 . . . . 0.0 111.656 -171.23 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 156.15 -98.85 0.18 Allowed Glycine 0 C--N 1.336 0.551 0 CA-C-N 118.821 0.737 . . . . 0.0 112.387 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.5 mpt_? -127.56 171.81 11.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 127.054 2.141 . . . . 0.0 112.144 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -143.87 -12.82 0.65 Allowed 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 120.096 -1.628 . . . . 0.0 115.089 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 126.298 1.904 . . . . 0.0 115.352 173.824 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.547 0 N-CA-C 112.923 -0.071 . . . . 0.0 112.923 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.37 -48.46 0.04 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.66 149.36 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.694 1.197 . . . . 0.0 112.158 -170.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.07 -157.31 27.34 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 120.01 -1.682 . . . . 0.0 115.559 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -85.96 -38.85 17.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.362 3.065 . . . . 0.0 114.956 -169.362 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.4 pt -134.59 155.33 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 125.955 1.702 . . . . 0.0 111.173 -174.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.448 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.7 tp -78.51 133.93 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.755 2.022 . . . . 0.0 114.48 -165.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -86.27 -8.96 57.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 118.41 -2.681 . . . . 0.0 114.836 171.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.448 ' H ' HG13 ' A' ' 7' ' ' ILE . 59.6 t80 -38.87 -64.41 0.45 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.58 2.352 . . . . 0.0 113.81 -169.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -69.21 -9.39 52.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 115.924 1.824 . . . . 0.0 115.924 -176.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 25.2 pt -114.77 -18.45 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 125.965 1.706 . . . . 0.0 113.321 178.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -145.28 41.32 1.06 Allowed Glycine 0 C--N 1.335 0.509 0 C-N-CA 127.873 2.654 . . . . 0.0 115.117 -173.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.77 -45.87 2.78 Favored Glycine 0 CA--C 1.522 0.519 0 C-N-CA 128.036 2.731 . . . . 0.0 115.642 161.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.52 21.89 0.09 OUTLIER Glycine 0 CA--C 1.523 0.532 0 N-CA-C 117.111 1.604 . . . . 0.0 117.111 173.007 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -59.31 -33.2 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 124.997 1.319 . . . . 0.0 113.937 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.52 -148.38 20.11 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 119.704 -1.873 . . . . 0.0 113.49 -176.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -80.92 179.54 7.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 178.267 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -160.47 -13.44 0.05 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 176.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.983 -1.454 . . . . 0.0 114.369 -178.759 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 N-CA-C 118.687 2.235 . . . . 0.0 118.687 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -160.88 -160.05 10.41 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 120.75 2.275 . . . . 0.0 117.946 -174.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 89.5 t -91.63 150.73 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 124.811 1.244 . . . . 0.0 108.617 173.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.91 -169.28 35.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 116.154 1.222 . . . . 0.0 116.154 -173.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -71.75 -71.07 0.29 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.08 2.952 . . . . 0.0 112.812 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.3 pt -99.76 139.09 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 124.786 1.234 . . . . 0.0 112.628 -164.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.3 tp -67.34 145.85 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 126.17 1.788 . . . . 0.0 112.563 -169.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -109.47 -29.8 8.24 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 127.558 2.343 . . . . 0.0 112.336 -171.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -63.07 -21.03 65.9 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.488 -2.007 . . . . 0.0 115.703 -163.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -52.49 -25.77 11.14 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 126.529 1.932 . . . . 0.0 113.662 170.139 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 17.7 pt -121.52 -18.74 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.67 2.388 . . . . 0.0 111.839 169.466 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.8 -124.18 3.2 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 127.521 2.486 . . . . 0.0 111.841 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -177.66 -9.41 0.02 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 120.402 2.921 . . . . 0.0 120.402 -177.466 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 152.88 57.19 0.01 OUTLIER Glycine 0 CA--C 1.523 0.544 0 CA-C-N 120.478 2.139 . . . . 0.0 116.087 172.293 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.8 t -128.74 -44.42 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 126.198 1.799 . . . . 0.0 110.461 178.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.22 -94.04 0.15 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.154 1.835 . . . . 0.0 115.316 175.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -132.56 169.03 17.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.205 1.802 . . . . 0.0 113.545 -159.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -148.14 12.85 0.97 Allowed 'General case' 0 N--CA 1.449 -0.513 0 CA-C-O 117.864 -1.065 . . . . 0.0 113.699 -174.025 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-N 120.953 1.706 . . . . 0.0 112.305 -177.586 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 CA-C-O 117.974 -1.459 . . . . 0.0 114.381 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.16 -109.92 0.31 Allowed Glycine 0 C--N 1.336 0.549 0 C-N-CA 125.03 1.3 . . . . 0.0 110.668 -172.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.2 p -72.16 159.29 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 122.137 0.97 . . . . 0.0 112.748 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.75 -152.65 24.72 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 127.112 2.291 . . . . 0.0 115.599 170.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -129.0 -46.91 1.23 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 127.511 2.324 . . . . 0.0 110.754 172.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.0 pt -73.35 133.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 125.108 1.363 . . . . 0.0 112.618 171.258 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.7 tp -63.76 157.52 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.263 1.825 . . . . 0.0 113.113 -170.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -136.15 -24.48 1.26 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 127.17 2.188 . . . . 0.0 113.083 171.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -48.19 -29.33 3.63 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 115.99 1.848 . . . . 0.0 115.99 -164.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -60.51 -28.96 68.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 116.942 2.201 . . . . 0.0 116.942 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 27.3 pt -96.27 -33.86 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 127.577 2.351 . . . . 0.0 111.384 160.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -95.61 53.04 1.75 Allowed Glycine 0 C--N 1.335 0.522 0 CA-C-O 118.309 -1.273 . . . . 0.0 114.643 -170.185 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 51.49 -94.43 0.01 OUTLIER Glycine 0 C--N 1.335 0.502 0 C-N-CA 126.578 2.037 . . . . 0.0 116.253 173.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -131.11 9.05 5.69 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.751 2.12 . . . . 0.0 115.562 171.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -72.0 -56.67 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 128.043 2.537 . . . . 0.0 113.725 -157.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 154.88 -125.37 1.68 Allowed Glycine 0 CA--C 1.523 0.547 0 CA-C-N 120.974 1.715 . . . . 0.0 115.649 -172.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -112.29 -178.58 3.45 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 128.179 2.591 . . . . 0.0 111.41 -161.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -143.1 -1.51 1.07 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 119.075 2.991 . . . . 0.0 119.075 163.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 O-C-N 119.623 -1.923 . . . . 0.0 113.931 -178.496 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.539 0 CA-C-O 116.81 -2.106 . . . . 0.0 118.161 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.88 -100.07 0.14 Allowed Glycine 0 C--N 1.336 0.533 0 CA-C-N 119.649 1.724 . . . . 0.0 115.334 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.3 p -156.01 176.56 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-N 121.064 2.432 . . . . 0.0 110.052 -172.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 111.29 -97.9 0.99 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-O 119.72 -0.489 . . . . 0.0 114.126 153.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.6 mttp -107.71 -103.31 0.35 Allowed 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 125.459 1.504 . . . . 0.0 111.007 -163.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.8 pt -63.09 154.35 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 115.716 1.747 . . . . 0.0 115.716 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.8 tp -73.74 156.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.946 1.699 . . . . 0.0 111.838 -174.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -142.56 -22.36 0.66 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.99 2.219 . . . . 0.0 116.99 -178.307 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 25.0 p90 -56.16 -34.85 66.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 119.832 1.197 . . . . 0.0 113.319 -161.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.72 -20.02 45.18 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 119.522 1.055 . . . . 0.0 113.698 177.118 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.3 pt -122.91 20.96 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.601 1.96 . . . . 0.0 111.704 169.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.03 60.29 0.33 Allowed Glycine 0 C--N 1.335 0.513 0 C-N-CA 127.793 2.616 . . . . 0.0 112.341 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.25 -96.59 0.01 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.331 2.872 . . . . 0.0 114.983 174.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.2 14.43 4.57 Favored Glycine 0 CA--C 1.522 0.513 0 C-N-CA 129.347 3.356 . . . . 0.0 115.462 176.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -60.16 -50.99 78.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.619 1.71 . . . . 0.0 110.69 -176.432 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 133.53 -88.15 0.26 Allowed Glycine 0 CA--C 1.523 0.542 0 O-C-N 124.77 1.294 . . . . 0.0 115.915 174.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -114.41 -172.87 2.19 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 128.527 2.731 . . . . 0.0 111.35 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -159.4 -12.97 0.06 Allowed 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 116.57 2.063 . . . . 0.0 116.57 169.105 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 117.23 -1.872 . . . . 0.0 116.185 -168.145 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.56 -85.64 0.06 OUTLIER Glycine 0 CA--C 1.522 0.528 0 C-N-CA 126.821 2.153 . . . . 0.0 108.974 170.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.44 158.48 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 126.211 1.805 . . . . 0.0 112.087 176.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.05 -173.99 33.3 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 119.414 -2.054 . . . . 0.0 113.969 -178.102 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -68.51 -27.8 66.44 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 128.48 2.712 . . . . 0.0 116.757 -174.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.9 pt -140.56 163.72 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 124.808 1.243 . . . . 0.0 112.341 -171.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.69 141.36 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.247 2.219 . . . . 0.0 114.218 -166.175 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -126.17 -22.41 4.08 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 127.618 2.367 . . . . 0.0 113.482 174.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -53.16 -32.41 47.55 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 118.227 2.677 . . . . 0.0 118.227 -169.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -66.37 -15.61 63.42 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 116.29 1.959 . . . . 0.0 116.29 177.028 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 20.6 pt -117.76 11.74 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 128.968 2.907 . . . . 0.0 110.723 169.304 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -155.51 55.61 0.41 Allowed Glycine 0 CA--C 1.522 0.506 0 C-N-CA 126.203 1.858 . . . . 0.0 111.317 -161.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 28.62 -88.66 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 1 C-N-CA 131.973 4.606 . . . . 0.0 115.102 179.297 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.38 33.62 2.55 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 126.354 1.93 . . . . 0.0 114.351 172.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 81.9 t -73.16 -79.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 127.162 2.185 . . . . 0.0 110.306 -178.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -93.12 0.14 Allowed Glycine 0 CA--C 1.522 0.513 0 O-C-N 121.79 -0.569 . . . . 0.0 113.841 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.4 mtt85 -126.33 177.43 6.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 127.661 2.384 . . . . 0.0 113.367 -169.031 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -154.89 -25.05 0.12 Allowed 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 118.183 2.66 . . . . 0.0 118.183 178.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.155 0 C-N-CA 129.336 3.351 . . . . 0.0 115.843 -179.323 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.511 ' H ' ' CG1' ' A' ' 15' ' ' VAL . . . 104.86 -107.53 2.91 Favored Glycine 0 C--N 1.335 0.475 0 O-C-N 120.871 -1.37 . . . . 0.0 112.722 -175.263 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.46 163.68 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 C-N-CA 125.538 1.535 . . . . 0.0 108.935 165.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 149.45 -171.9 29.53 Favored Glycine 0 C--N 1.335 0.515 0 O-C-N 120.704 -1.247 . . . . 0.0 113.568 177.271 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 mptp? -66.45 -83.69 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 125.341 1.456 . . . . 0.0 112.277 -177.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 pt -64.49 149.93 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-O 121.397 0.618 . . . . 0.0 112.154 -175.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.6 tp -61.93 154.04 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.234 1.814 . . . . 0.0 114.97 -179.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -133.8 -26.48 1.56 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.228 2.611 . . . . 0.0 114.941 174.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -55.05 -24.2 23.72 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 118.219 2.674 . . . . 0.0 118.219 -173.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -65.81 -16.23 63.62 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.983 1.313 . . . . 0.0 114.474 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.5 pt -123.16 -19.97 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 127.593 2.357 . . . . 0.0 112.591 172.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.36 41.13 2.26 Favored Glycine 0 CA--C 1.522 0.523 0 C-N-CA 128.284 2.85 . . . . 0.0 112.071 179.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.94 -95.61 0.04 OUTLIER Glycine 0 C--N 1.335 0.503 0 C-N-CA 126.485 1.993 . . . . 0.0 116.106 171.006 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -123.77 2.99 9.33 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 126.584 2.04 . . . . 0.0 112.637 -176.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.511 ' CG1' ' H ' ' A' ' 2' ' ' GLY . 50.7 t -53.73 -66.59 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.712 1.605 . . . . 0.0 113.867 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.83 -110.44 0.58 Allowed Glycine 0 C--N 1.335 0.525 0 CA-C-O 118.39 -1.228 . . . . 0.0 114.565 -175.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 60.8 mtm-85 -129.03 167.44 17.49 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 128.595 2.758 . . . . 0.0 110.225 -165.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -151.61 -12.49 0.2 Allowed 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 -178.347 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.127 0 O-C-N 125.522 1.764 . . . . 0.0 116.74 -175.962 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.483 0 CA-C-O 121.981 0.767 . . . . 0.0 112.826 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.58 -95.36 1.34 Allowed Glycine 0 C--N 1.335 0.517 0 C-N-CA 126.447 1.975 . . . . 0.0 112.433 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.86 157.83 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 124.703 1.201 . . . . 0.0 110.206 173.583 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 160.49 -167.05 35.58 Favored Glycine 0 CA--C 1.523 0.539 0 O-C-N 120.836 -1.165 . . . . 0.0 115.381 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -92.81 -64.84 1.05 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.897 1.679 . . . . 0.0 112.585 176.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 10.7 pt -78.0 145.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 O-C-N 121.489 -0.757 . . . . 0.0 112.083 -179.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.7 tp -65.04 149.25 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 C-N-CA 124.488 1.115 . . . . 0.0 112.271 -169.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -122.4 -20.43 6.1 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 128.535 2.734 . . . . 0.0 112.763 172.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -40.39 -44.95 2.08 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.434 1.894 . . . . 0.0 114.582 175.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -50.38 -21.74 1.56 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.195 1.924 . . . . 0.0 116.195 174.243 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 pt -131.07 -1.98 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 126.326 1.85 . . . . 0.0 114.734 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -137.0 67.93 0.53 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.945 2.212 . . . . 0.0 112.481 -167.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 30.95 -100.34 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 C-N-CA 129.037 3.208 . . . . 0.0 115.491 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -127.0 13.46 6.72 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 116.063 1.185 . . . . 0.0 116.063 172.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.1 t -61.26 -37.82 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -171.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.77 -93.03 0.37 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 124.997 1.284 . . . . 0.0 112.616 166.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -120.75 175.45 6.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.563 1.945 . . . . 0.0 113.75 -172.793 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.54 -29.8 0.51 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 172.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.122 0 CA-C-N 120.55 1.523 . . . . 0.0 115.782 -172.029 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.488 0 N-CA-C 118.994 2.358 . . . . 0.0 118.994 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.35 -101.84 0.22 Allowed Glycine 0 CA--C 1.522 0.525 0 C-N-CA 128.777 3.084 . . . . 0.0 114.362 165.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 p -73.47 156.25 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 124.272 1.029 . . . . 0.0 112.234 168.096 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 133.81 -175.44 20.29 Favored Glycine 0 CA--C 1.522 0.515 0 O-C-N 118.803 -2.436 . . . . 0.0 112.534 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.2 mttp -84.89 -79.43 0.22 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.449 2.3 . . . . 0.0 111.51 -173.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt -72.75 154.38 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-O 121.981 0.896 . . . . 0.0 111.91 -169.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -63.33 141.57 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 126.8 2.04 . . . . 0.0 112.649 -175.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -125.37 -25.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 127.359 2.263 . . . . 0.0 113.561 174.717 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -42.33 -40.29 2.43 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 127.791 2.436 . . . . 0.0 116.463 -172.207 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -53.93 -31.11 49.26 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 117.016 2.228 . . . . 0.0 117.016 174.373 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 18.1 pt -112.04 -19.59 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.419 1.488 . . . . 0.0 113.729 172.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -73.14 -34.06 58.67 Favored Glycine 0 C--N 1.335 0.497 0 CA-C-O 118.537 -1.146 . . . . 0.0 112.723 177.119 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.06 -100.21 2.53 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 118.755 1.278 . . . . 0.0 110.666 -169.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -109.54 29.63 9.3 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 128.123 2.773 . . . . 0.0 113.785 -176.845 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.3 t -107.48 -26.94 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 -157.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.25 -102.52 2.66 Favored Glycine 0 C--N 1.335 0.498 0 O-C-N 121.164 -0.96 . . . . 0.0 113.502 174.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -128.45 -174.51 3.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 124.945 1.298 . . . . 0.0 110.015 -160.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -164.44 -8.72 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 120.349 3.463 . . . . 0.0 120.349 173.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.093 0 C-N-CA 125.406 1.479 . . . . 0.0 115.114 -175.718 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.539 0 CA-C-O 121.728 0.626 . . . . 0.0 111.541 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 116.28 -151.37 18.35 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.947 1.261 . . . . 0.0 114.163 -174.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 90.5 t -70.31 147.34 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.375 1.87 . . . . 0.0 109.934 171.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.23 -173.65 34.11 Favored Glycine 0 CA--C 1.522 0.52 0 O-C-N 120.535 -1.353 . . . . 0.0 111.123 177.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 mttp -88.84 -77.57 0.37 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.506 2.322 . . . . 0.0 112.18 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.0 pt -76.32 141.04 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.524 1.929 . . . . 0.0 110.89 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.474 HG13 ' H ' ' A' ' 9' ' ' TYR . 4.8 tp -61.56 147.34 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.704 1.601 . . . . 0.0 113.197 -173.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -117.66 -3.04 11.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.933 2.493 . . . . 0.0 110.821 176.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.474 ' H ' HG13 ' A' ' 7' ' ' ILE . 60.8 t80 -38.1 -53.78 1.38 Allowed 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 128.197 2.599 . . . . 0.0 114.053 -176.799 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.429 ' CD2' HG23 ' A' ' 11' ' ' ILE . 25.5 p90 -73.35 -12.04 60.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 127.639 2.376 . . . . 0.0 114.485 -175.319 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.429 HG23 ' CD2' ' A' ' 10' ' ' PHE . 7.2 pt -133.74 -21.02 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 122.314 2.324 . . . . 0.0 116.346 -171.112 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -115.05 47.69 1.01 Allowed Glycine 0 C--N 1.335 0.498 0 CA-C-N 119.356 0.98 . . . . 0.0 114.359 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.65 -78.4 1.02 Allowed Glycine 0 CA--C 1.523 0.576 0 C-N-CA 124.017 0.818 . . . . 0.0 112.894 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 163.98 71.09 0.02 OUTLIER Glycine 0 CA--C 1.523 0.564 0 C-N-CA 126.071 1.796 . . . . 0.0 113.271 -175.012 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -120.78 -53.77 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 120.913 -1.345 . . . . 0.0 111.412 173.464 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.54 -95.75 0.11 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 121.517 1.962 . . . . 0.0 113.608 177.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -121.17 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.37 3.068 . . . . 0.0 114.281 -171.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -153.73 -30.83 0.12 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 116.984 2.216 . . . . 0.0 116.984 172.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.064 -1.965 . . . . 0.0 115.713 -171.008 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 119.529 2.572 . . . . 0.0 119.529 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.69 -140.6 2.93 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.891 2.186 . . . . 0.0 114.898 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.4 p -100.09 157.95 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.089 1.355 . . . . 0.0 113.038 176.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 141.78 -156.9 26.12 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 120.055 -1.653 . . . . 0.0 115.075 164.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -77.11 -76.53 0.17 Allowed 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.99 2.516 . . . . 0.0 113.347 -174.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.8 pt -80.02 147.47 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-O 122.609 1.195 . . . . 0.0 112.906 -174.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -61.96 138.8 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 C-N-CA 124.924 1.29 . . . . 0.0 113.026 -173.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -143.76 7.15 1.44 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.542 2.337 . . . . 0.0 113.423 -172.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -68.65 -26.74 65.48 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 118.75 -2.469 . . . . 0.0 113.959 -171.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -82.31 -8.15 59.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 117.546 2.424 . . . . 0.0 117.546 173.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.2 pt -133.0 82.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 127.192 2.197 . . . . 0.0 111.085 175.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 125.45 37.47 0.52 Allowed Glycine 0 CA--C 1.523 0.543 0 C-N-CA 124.773 1.178 . . . . 0.0 113.153 -170.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.2 -56.81 5.08 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 127.659 2.552 . . . . 0.0 113.656 163.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.9 -11.16 0.05 OUTLIER Glycine 0 C--N 1.335 0.522 0 C-N-CA 125.23 1.395 . . . . 0.0 115.53 -177.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.2 t -49.58 -27.15 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 C-N-CA 126.999 2.12 . . . . 0.0 115.779 -170.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.16 -89.34 0.17 Allowed Glycine 0 C--N 1.335 0.486 0 CA-C-N 122.028 2.194 . . . . 0.0 115.773 160.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -129.83 -176.89 4.06 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 127.645 2.378 . . . . 0.0 113.029 -166.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -155.52 -10.33 0.11 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 116.657 2.095 . . . . 0.0 116.657 169.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.122 -1.932 . . . . 0.0 116.679 -176.989 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.506 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.11 -111.14 0.32 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-N 121.376 2.588 . . . . 0.0 115.925 176.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.4 p -138.21 145.06 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 128.64 2.776 . . . . 0.0 111.218 -159.232 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.56 -173.95 33.65 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 127.483 2.468 . . . . 0.0 114.709 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.32 -53.84 5.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 172.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.2 pt -85.64 149.37 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-O 122.254 1.026 . . . . 0.0 113.412 178.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.6 tp -68.79 149.02 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 125.598 1.559 . . . . 0.0 114.26 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -118.91 -14.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 126.702 2.001 . . . . 0.0 111.683 175.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -35.45 -57.98 0.6 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.926 2.09 . . . . 0.0 115.299 177.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -47.18 -37.87 10.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 116.902 2.186 . . . . 0.0 116.902 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 34.3 pt -109.74 -10.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 C-N-CA 127.613 2.365 . . . . 0.0 115.73 -178.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -144.59 39.09 1.24 Allowed Glycine 0 C--N 1.336 0.535 0 O-C-N 119.579 -1.951 . . . . 0.0 114.296 -165.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.23 -80.29 1.64 Allowed Glycine 0 CA--C 1.522 0.512 0 C-N-CA 126.007 1.765 . . . . 0.0 112.692 163.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.7 2.64 0.04 OUTLIER Glycine 0 CA--C 1.522 0.509 0 N-CA-C 116.596 1.398 . . . . 0.0 116.596 -165.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.3 t -72.31 -42.29 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 CA-C-N 118.154 0.977 . . . . 0.0 109.949 -169.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -100.2 0.2 Allowed Glycine 0 N--CA 1.448 -0.518 0 CA-C-O 121.757 0.643 . . . . 0.0 113.2 175.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -119.34 178.08 4.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 128.451 2.7 . . . . 0.0 112.675 -167.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -149.39 -32.9 0.21 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 117.599 2.444 . . . . 0.0 117.599 170.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.144 0 CA-C-O 116.917 -2.046 . . . . 0.0 113.078 -175.994 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.524 0 N-CA-C 116.8 1.48 . . . . 0.0 116.8 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.44 -107.1 0.2 Allowed Glycine 0 C--N 1.335 0.513 0 CA-C-N 119.847 1.824 . . . . 0.0 114.726 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.8 p -128.66 153.64 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 126.86 2.064 . . . . 0.0 114.259 -152.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 109.21 -142.16 16.15 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 115.367 0.907 . . . . 0.0 115.367 162.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -77.0 -32.67 57.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 116.777 2.14 . . . . 0.0 116.777 -153.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.8 pt -139.75 150.39 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-O 121.903 0.858 . . . . 0.0 109.959 -175.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.1 tp -58.95 150.18 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.794 2.038 . . . . 0.0 113.369 -171.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -133.77 -27.23 1.5 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 126.586 1.955 . . . . 0.0 110.709 175.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -51.46 -40.44 59.44 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 121.389 1.904 . . . . 0.0 115.516 -166.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 12.6 p90 -55.54 -14.08 1.88 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.715 2.006 . . . . 0.0 115.372 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.1 pt -118.77 -38.6 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 C-N-CA 125.968 1.707 . . . . 0.0 112.224 162.288 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.88 67.02 0.78 Allowed Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 127.992 2.71 . . . . 0.0 112.276 -171.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 47.9 -93.15 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 129.21 3.29 . . . . 0.0 114.239 178.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -143.8 3.09 1.51 Allowed Glycine 0 C--N 1.335 0.52 0 C-N-CA 125.41 1.481 . . . . 0.0 116.544 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -63.34 -37.66 80.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 119.402 1.601 . . . . 0.0 113.408 -160.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.89 -99.86 0.22 Allowed Glycine 0 C--N 1.335 0.516 0 C-N-CA 125.912 1.72 . . . . 0.0 112.455 171.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -116.17 -174.08 2.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.135 2.174 . . . . 0.0 114.288 -171.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -153.89 -20.91 0.14 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 115.427 1.64 . . . . 0.0 115.427 168.031 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 127.019 2.247 . . . . 0.0 116.852 -179.051 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.482 0 N-CA-C 120.819 3.087 . . . . 0.0 120.819 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.05 -117.29 0.42 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-N 120.9 2.35 . . . . 0.0 115.251 -174.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -133.0 159.09 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 C-N-CA 127.304 2.241 . . . . 0.0 109.894 -170.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.31 -162.88 29.69 Favored Glycine 0 CA--C 1.523 0.546 0 O-C-N 119.682 -1.886 . . . . 0.0 110.293 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 mttp -86.32 -70.79 0.58 Allowed 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 125.023 1.329 . . . . 0.0 113.469 -176.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.44 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.9 pt -73.46 157.23 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 122.545 1.164 . . . . 0.0 112.311 171.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.47 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.9 tp -71.62 142.64 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 127.836 2.454 . . . . 0.0 115.027 -175.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -105.29 -23.42 12.87 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 129.323 3.049 . . . . 0.0 110.459 173.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.47 ' H ' HG13 ' A' ' 7' ' ' ILE . 4.6 t80 -43.11 -49.08 6.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.642 2.777 . . . . 0.0 115.424 -168.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -63.71 -11.9 30.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.083 1.753 . . . . 0.0 114.442 -175.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 44.5 pt -127.38 16.28 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 127.702 2.401 . . . . 0.0 113.078 172.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.09 73.1 0.23 Allowed Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.439 1.018 . . . . 0.0 113.151 -168.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 25.79 -84.92 0.0 OUTLIER Glycine 0 N--CA 1.448 -0.502 1 C-N-CA 132.13 4.681 . . . . 0.0 114.728 -176.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -160.95 76.06 0.18 Allowed Glycine 0 C--N 1.336 0.546 0 C-N-CA 126.2 1.857 . . . . 0.0 113.032 161.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 5.3 t -103.21 -55.7 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 CA-C-O 122.173 0.987 . . . . 0.0 111.404 177.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.11 -110.65 0.45 Allowed Glycine 0 C--N 1.336 0.539 0 O-C-N 119.433 -2.042 . . . . 0.0 114.393 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -123.03 172.42 8.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 126.875 2.07 . . . . 0.0 115.407 -162.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -152.5 -7.24 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.233 1.568 . . . . 0.0 115.233 173.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.44 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 115.819 -2.656 . . . . 0.0 115.929 -171.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.473 0 N-CA-C 117.597 1.799 . . . . 0.0 117.597 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.33 -144.32 4.03 Favored Glycine 0 CA--C 1.522 0.493 0 CA-C-N 120.118 1.959 . . . . 0.0 115.412 -174.645 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 53.5 t -99.34 142.31 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 127.92 2.488 . . . . 0.0 108.022 175.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 167.11 -173.16 42.33 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 125.976 1.751 . . . . 0.0 114.45 -171.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -85.46 -44.96 12.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 115.939 1.829 . . . . 0.0 115.939 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 36.9 pt -103.84 133.13 48.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 126.468 1.907 . . . . 0.0 111.007 -166.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.9 tp -63.62 117.63 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 C-N-CA 127.307 2.243 . . . . 0.0 115.256 -164.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -95.19 -21.62 18.36 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 127.042 2.137 . . . . 0.0 112.494 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -49.46 -47.47 48.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.098 1.759 . . . . 0.0 110.355 -173.044 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -58.75 -17.88 26.92 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.018 2.127 . . . . 0.0 115.79 -175.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.7 pt -132.16 -9.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 125.714 1.605 . . . . 0.0 113.948 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -124.34 40.93 1.82 Allowed Glycine 0 CA--C 1.522 0.497 0 C-N-CA 129.286 3.327 . . . . 0.0 112.141 -170.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.98 -81.22 0.05 OUTLIER Glycine 0 C--N 1.335 0.516 0 C-N-CA 128.646 3.022 . . . . 0.0 111.658 -177.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -158.75 23.41 0.33 Allowed Glycine 0 C--N 1.335 0.49 0 C-N-CA 127.11 2.291 . . . . 0.0 115.79 174.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.23 -63.07 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 119.348 1.574 . . . . 0.0 112.901 -169.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.34 -105.58 0.21 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 120.236 1.38 . . . . 0.0 113.907 -176.133 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.7 mpt_? -146.89 154.58 41.46 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.967 1.707 . . . . 0.0 114.99 -171.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -127.4 7.6 6.43 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 120.735 3.606 . . . . 0.0 120.735 -162.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 118.733 -1.037 . . . . 0.0 115.182 -178.552 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.472 0 N-CA-C 116.45 1.34 . . . . 0.0 116.45 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.47 -100.11 0.14 Allowed Glycine 0 CA--C 1.522 0.527 0 C-N-CA 126.629 2.062 . . . . 0.0 108.61 176.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.2 t -114.35 160.94 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 126.685 1.994 . . . . 0.0 109.164 177.161 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.97 -177.63 33.76 Favored Glycine 0 C--N 1.335 0.503 0 O-C-N 120.956 -1.09 . . . . 0.0 114.315 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.2 mttp -67.43 -53.91 24.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 127.201 2.2 . . . . 0.0 112.52 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.431 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 7.3 pt -114.38 155.13 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 CA-C-O 122.685 1.231 . . . . 0.0 111.761 -168.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -69.38 139.56 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 113.227 -1.806 . . . . 0.0 114.746 -160.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -117.55 -20.29 9.07 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 127.024 2.13 . . . . 0.0 111.736 171.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.6 t80 -45.62 -33.08 2.66 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 116.2 1.926 . . . . 0.0 116.2 173.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -67.23 -14.01 62.51 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 127.826 2.45 . . . . 0.0 115.532 175.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 36.2 pt -129.16 -6.9 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 C-N-CA 127.459 2.304 . . . . 0.0 114.36 176.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -152.48 92.5 0.14 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.738 1.637 . . . . 0.0 113.55 -175.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 29.03 -93.56 0.01 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 130.012 3.672 . . . . 0.0 115.02 159.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -124.49 17.73 7.35 Favored Glycine 0 CA--C 1.523 0.544 0 C-N-CA 126.691 2.091 . . . . 0.0 113.922 175.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.1 t -90.32 40.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.527 2.331 . . . . 0.0 111.92 -170.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 43.48 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.523 0.543 0 C-N-CA 129.617 3.484 . . . . 0.0 118.286 167.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -138.54 170.42 16.03 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.281 1.833 . . . . 0.0 113.81 -166.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -146.18 -2.86 0.68 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 174.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.431 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.25 1.105 0 N-CA-C 117.543 1.777 . . . . 0.0 117.543 -175.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.455 0 CA-C-O 121.221 0.345 . . . . 0.0 112.69 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 165.39 -48.04 0.28 Allowed Glycine 0 CA--C 1.522 0.515 0 C-N-CA 128.359 2.885 . . . . 0.0 114.486 168.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.7 p -119.25 137.61 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 126.779 2.032 . . . . 0.0 111.588 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.19 -171.21 37.17 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 116.489 1.356 . . . . 0.0 116.489 -179.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 40.6 mttp -76.61 -50.46 13.76 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 129.458 3.103 . . . . 0.0 114.095 177.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.1 pt -121.29 151.96 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 O-C-N 124.251 0.97 . . . . 0.0 111.782 -172.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.532 HG13 ' H ' ' A' ' 9' ' ' TYR . 7.7 tp -68.91 139.02 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 127.762 2.425 . . . . 0.0 115.003 -165.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -111.11 -3.04 15.61 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.57 2.348 . . . . 0.0 112.318 177.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.532 ' H ' HG13 ' A' ' 7' ' ' ILE . 71.1 t80 -47.21 -48.45 24.02 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 128.625 2.77 . . . . 0.0 115.437 -170.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -64.57 -9.11 16.93 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.8 pt -125.57 0.96 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 122.413 2.369 . . . . 0.0 113.655 172.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.66 5.52 10.69 Favored Glycine 0 CA--C 1.523 0.55 0 C-N-CA 126.98 2.229 . . . . 0.0 116.381 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.77 -70.55 0.93 Allowed Glycine 0 C--N 1.335 0.49 0 O-C-N 120.3 -1.706 . . . . 0.0 115.296 -171.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -163.46 13.95 0.1 Allowed Glycine 0 C--N 1.335 0.496 0 CA-C-O 117.878 -1.512 . . . . 0.0 115.582 -163.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.1 t -81.85 -75.09 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 121.254 2.527 . . . . 0.0 110.729 -177.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.44 -122.63 0.78 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 118.351 2.1 . . . . 0.0 118.351 178.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 68.7 mtt180 -107.85 176.84 5.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 126.852 2.061 . . . . 0.0 111.731 -168.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 p90 -151.66 -19.51 0.19 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 117.92 2.563 . . . . 0.0 117.92 174.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 117.682 -1.621 . . . . 0.0 113.994 -175.039 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 CA-C-O 116.534 -2.259 . . . . 0.0 116.439 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.3 -161.09 11.63 Favored Glycine 0 C--N 1.336 0.543 0 CA-C-N 120.694 2.247 . . . . 0.0 111.001 -177.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -133.08 153.96 38.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.208 1.803 . . . . 0.0 109.431 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.13 -141.44 8.25 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 107.966 -2.053 . . . . 0.0 107.966 -161.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mtmp? -126.27 -54.45 1.47 Allowed 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 116.225 -1.845 . . . . 0.0 112.394 -166.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 32.8 pt -79.27 136.11 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 CA-C-N 120.3 1.409 . . . . 0.0 109.53 174.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.519 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.8 tp -70.9 139.23 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 114.279 1.214 . . . . 0.0 114.279 -170.129 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -90.88 -4.7 56.35 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.405 1.882 . . . . 0.0 113.231 174.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.519 ' H ' HG13 ' A' ' 7' ' ' ILE . 72.8 t80 -46.64 -58.15 4.11 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 126.166 1.786 . . . . 0.0 113.689 -174.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.2 -13.7 5.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 119.345 -2.097 . . . . 0.0 115.59 176.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 29.7 pt -128.53 6.36 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 128.539 2.735 . . . . 0.0 115.254 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.77 -9.06 0.03 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 64.92 -18.66 0.12 Allowed Glycine 0 C--N 1.335 0.503 0 C-N-CA 128.246 2.831 . . . . 0.0 119.881 161.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.65 34.03 0.45 Allowed Glycine 0 C--N 1.335 0.482 0 CA-C-N 121.227 2.513 . . . . 0.0 116.514 -166.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 79.8 t -135.22 -76.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.871 1.836 . . . . 0.0 111.799 177.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -176.93 -115.69 0.44 Allowed Glycine 0 N--CA 1.448 -0.527 0 O-C-N 120.573 -1.329 . . . . 0.0 115.598 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 8.9 mpt_? -112.79 178.63 4.22 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 126.801 2.04 . . . . 0.0 112.5 -172.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -149.06 -3.82 0.43 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 116.889 2.181 . . . . 0.0 116.889 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 O-C-N 119.132 -2.23 . . . . 0.0 113.354 -176.95 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.466 0 N-CA-C 119.302 2.481 . . . . 0.0 119.302 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.15 -105.37 0.18 Allowed Glycine 0 C--N 1.335 0.519 0 O-C-N 119.852 -1.969 . . . . 0.0 112.196 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -150.8 170.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-O 121.132 0.491 . . . . 0.0 110.238 -175.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.02 -119.68 1.27 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 124.202 0.906 . . . . 0.0 112.64 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.9 mttp -130.35 -55.94 1.09 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 128.899 2.88 . . . . 0.0 110.566 -169.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.6 pt -90.35 149.91 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.054 1.342 . . . . 0.0 111.238 -175.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.2 tp -86.29 149.21 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.698 1.999 . . . . 0.0 112.889 -160.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -128.33 -31.62 2.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 126.784 2.034 . . . . 0.0 116.11 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -54.32 -24.88 20.99 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 -165.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -69.73 -22.7 63.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.502 2.321 . . . . 0.0 113.475 176.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 24.1 pt -110.06 20.78 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.418 2.287 . . . . 0.0 111.635 169.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -138.52 -69.52 0.05 OUTLIER Glycine 0 CA--C 1.523 0.535 0 O-C-N 120.651 -1.281 . . . . 0.0 114.313 -170.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 150.74 -82.02 0.18 Allowed Glycine 0 C--N 1.335 0.507 0 C-N-CA 129.511 3.434 . . . . 0.0 110.143 -167.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.63 2.69 0.09 OUTLIER Glycine 0 C--N 1.335 0.507 0 N-CA-C 118.693 2.237 . . . . 0.0 118.693 -166.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 76.2 t -67.95 -29.62 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-N 120.644 2.222 . . . . 0.0 112.966 -179.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.47 -96.89 0.71 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 126.471 1.986 . . . . 0.0 113.327 161.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -95.87 178.92 5.28 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.302 2.641 . . . . 0.0 113.675 -178.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.4 p90 -159.46 -8.57 0.06 Allowed 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 121.002 1.728 . . . . 0.0 114.981 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 117.08 -1.955 . . . . 0.0 111.707 -171.14 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.468 0 CA-C-O 122.554 1.085 . . . . 0.0 112.171 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.19 -70.16 0.03 OUTLIER Glycine 0 CA--C 1.522 0.525 0 C-N-CA 126.001 1.762 . . . . 0.0 113.041 172.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 23.9 t -137.49 154.44 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.293 1.837 . . . . 0.0 108.035 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.87 -168.53 33.42 Favored Glycine 0 C--N 1.335 0.514 0 O-C-N 121.102 -0.999 . . . . 0.0 111.697 -166.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.2 mttp -98.1 -53.84 3.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-O 115.553 -2.165 . . . . 0.0 112.95 -172.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.449 ' H ' ' HA3' ' A' ' 19' ' ' GLY . 31.2 pt -84.5 151.38 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 119.939 1.245 . . . . 0.0 111.695 169.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.3 tp -68.89 147.77 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 126.849 2.059 . . . . 0.0 114.119 -178.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -113.9 -20.38 11.09 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 128.534 2.734 . . . . 0.0 112.272 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 49.3 t80 -10.71 -73.33 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 129.916 3.286 . . . . 0.0 115.248 169.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -54.72 -18.51 4.75 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 131.204 3.802 . . . . 0.0 115.649 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.6 pt -121.01 15.21 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 C-N-CA 127.614 2.365 . . . . 0.0 114.598 175.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -140.06 -2.77 1.56 Allowed Glycine 0 C--N 1.335 0.505 0 N-CA-C 116.08 1.192 . . . . 0.0 116.08 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.64 -73.5 0.62 Allowed Glycine 0 CA--C 1.523 0.55 0 CA-C-N 118.618 1.209 . . . . 0.0 110.16 -170.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -145.29 85.01 0.18 Allowed Glycine 0 N--CA 1.449 -0.493 0 CA-C-O 117.807 -1.552 . . . . 0.0 113.341 177.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.6 t -132.25 -29.45 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 CA-C-N 119.476 1.638 . . . . 0.0 114.738 -171.025 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.86 -126.88 7.42 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 120.459 1.482 . . . . 0.0 113.919 -178.035 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -124.57 171.12 10.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 124.726 1.21 . . . . 0.0 112.134 -168.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -154.71 5.01 0.24 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 177.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.449 ' HA3' ' H ' ' A' ' 6' ' ' ILE . . . . . . . . 0 C--O 1.251 1.162 0 CA-C-O 116.964 -2.02 . . . . 0.0 112.821 175.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.521 0 N-CA-C 114.694 0.638 . . . . 0.0 114.694 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.62 -129.94 1.32 Allowed Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 173.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 82.7 t -60.88 144.08 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 125.64 1.576 . . . . 0.0 108.657 160.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 168.37 -170.29 42.04 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 114.772 0.669 . . . . 0.0 114.772 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.1 mttp -101.23 -71.91 0.7 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 128.874 2.87 . . . . 0.0 114.758 -175.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.1 pt -84.55 147.04 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 C-N-CA 125.325 1.45 . . . . 0.0 111.721 177.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 tp -73.57 150.42 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 124.331 1.052 . . . . 0.0 113.542 -160.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -111.08 -2.17 15.97 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.096 1.759 . . . . 0.0 112.233 -176.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.0 t80 -52.61 -53.46 46.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -167.147 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -76.66 -5.14 46.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -177.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.9 pt -124.68 -15.55 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 126.635 1.974 . . . . 0.0 114.946 -176.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -123.52 19.08 7.61 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 126.503 2.001 . . . . 0.0 117.164 176.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.12 -54.51 3.89 Favored Glycine 0 C--N 1.335 0.508 0 CA-C-N 118.76 1.28 . . . . 0.0 115.151 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.23 74.51 0.04 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.514 2.959 . . . . 0.0 113.074 -177.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 77.5 t -122.21 -51.29 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 118.777 1.289 . . . . 0.0 111.656 -171.23 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 156.15 -98.85 0.18 Allowed Glycine 0 C--N 1.336 0.551 0 CA-C-N 118.821 0.737 . . . . 0.0 112.387 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.5 mpt_? -127.56 171.81 11.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 127.054 2.141 . . . . 0.0 112.144 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -143.87 -12.82 0.65 Allowed 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 120.096 -1.628 . . . . 0.0 115.089 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 C-N-CA 126.298 1.904 . . . . 0.0 115.352 173.824 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.547 0 N-CA-C 112.923 -0.071 . . . . 0.0 112.923 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.37 -48.46 0.04 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.1 p -140.66 149.36 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.694 1.197 . . . . 0.0 112.158 -170.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.07 -157.31 27.34 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 120.01 -1.682 . . . . 0.0 115.559 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -85.96 -38.85 17.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.362 3.065 . . . . 0.0 114.956 -169.362 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.4 pt -134.59 155.33 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 C-N-CA 125.955 1.702 . . . . 0.0 111.173 -174.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.448 HG13 ' H ' ' A' ' 9' ' ' TYR . 5.7 tp -78.51 133.93 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 126.755 2.022 . . . . 0.0 114.48 -165.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -86.27 -8.96 57.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 118.41 -2.681 . . . . 0.0 114.836 171.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.448 ' H ' HG13 ' A' ' 7' ' ' ILE . 59.6 t80 -38.87 -64.41 0.45 Allowed 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.58 2.352 . . . . 0.0 113.81 -169.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -69.21 -9.39 52.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 115.924 1.824 . . . . 0.0 115.924 -176.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 25.2 pt -114.77 -18.45 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 125.965 1.706 . . . . 0.0 113.321 178.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -145.28 41.32 1.06 Allowed Glycine 0 C--N 1.335 0.509 0 C-N-CA 127.873 2.654 . . . . 0.0 115.117 -173.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.77 -45.87 2.78 Favored Glycine 0 CA--C 1.522 0.519 0 C-N-CA 128.036 2.731 . . . . 0.0 115.642 161.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.52 21.89 0.09 OUTLIER Glycine 0 CA--C 1.523 0.532 0 N-CA-C 117.111 1.604 . . . . 0.0 117.111 173.007 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.6 t -59.31 -33.2 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 124.997 1.319 . . . . 0.0 113.937 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.52 -148.38 20.11 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 119.704 -1.873 . . . . 0.0 113.49 -176.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -80.92 179.54 7.8 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 178.267 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -160.47 -13.44 0.05 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 176.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.17 0 CA-C-O 117.983 -1.454 . . . . 0.0 114.369 -178.759 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 N-CA-C 118.687 2.235 . . . . 0.0 118.687 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -160.88 -160.05 10.41 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 120.75 2.275 . . . . 0.0 117.946 -174.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 89.5 t -91.63 150.73 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 124.811 1.244 . . . . 0.0 108.617 173.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.91 -169.28 35.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 116.154 1.222 . . . . 0.0 116.154 -173.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -71.75 -71.07 0.29 Allowed 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.08 2.952 . . . . 0.0 112.812 175.003 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.3 pt -99.76 139.09 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 124.786 1.234 . . . . 0.0 112.628 -164.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.3 tp -67.34 145.85 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 126.17 1.788 . . . . 0.0 112.563 -169.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -109.47 -29.8 8.24 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 127.558 2.343 . . . . 0.0 112.336 -171.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -63.07 -21.03 65.9 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.488 -2.007 . . . . 0.0 115.703 -163.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 8.4 p90 -52.49 -25.77 11.14 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 126.529 1.932 . . . . 0.0 113.662 170.139 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 17.7 pt -121.52 -18.74 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.67 2.388 . . . . 0.0 111.839 169.466 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.8 -124.18 3.2 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 127.521 2.486 . . . . 0.0 111.841 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -177.66 -9.41 0.02 OUTLIER Glycine 0 CA--C 1.522 0.505 0 N-CA-C 120.402 2.921 . . . . 0.0 120.402 -177.466 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 152.88 57.19 0.01 OUTLIER Glycine 0 CA--C 1.523 0.544 0 CA-C-N 120.478 2.139 . . . . 0.0 116.087 172.293 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.8 t -128.74 -44.42 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 126.198 1.799 . . . . 0.0 110.461 178.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.22 -94.04 0.15 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.154 1.835 . . . . 0.0 115.316 175.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -132.56 169.03 17.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.205 1.802 . . . . 0.0 113.545 -159.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -148.14 12.85 0.97 Allowed 'General case' 0 N--CA 1.449 -0.513 0 CA-C-O 117.864 -1.065 . . . . 0.0 113.699 -174.025 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-N 120.953 1.706 . . . . 0.0 112.305 -177.586 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 CA-C-O 117.974 -1.459 . . . . 0.0 114.381 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.16 -109.92 0.31 Allowed Glycine 0 C--N 1.336 0.549 0 C-N-CA 125.03 1.3 . . . . 0.0 110.668 -172.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.2 p -72.16 159.29 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 122.137 0.97 . . . . 0.0 112.748 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.75 -152.65 24.72 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 127.112 2.291 . . . . 0.0 115.599 170.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.3 mtmp? -129.0 -46.91 1.23 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 127.511 2.324 . . . . 0.0 110.754 172.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.0 pt -73.35 133.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 125.108 1.363 . . . . 0.0 112.618 171.258 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.7 tp -63.76 157.52 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.263 1.825 . . . . 0.0 113.113 -170.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -136.15 -24.48 1.26 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 127.17 2.188 . . . . 0.0 113.083 171.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -48.19 -29.33 3.63 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 115.99 1.848 . . . . 0.0 115.99 -164.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -60.51 -28.96 68.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 116.942 2.201 . . . . 0.0 116.942 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 27.3 pt -96.27 -33.86 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 127.577 2.351 . . . . 0.0 111.384 160.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -95.61 53.04 1.75 Allowed Glycine 0 C--N 1.335 0.522 0 CA-C-O 118.309 -1.273 . . . . 0.0 114.643 -170.185 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 51.49 -94.43 0.01 OUTLIER Glycine 0 C--N 1.335 0.502 0 C-N-CA 126.578 2.037 . . . . 0.0 116.253 173.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -131.11 9.05 5.69 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 126.751 2.12 . . . . 0.0 115.562 171.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -72.0 -56.67 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 128.043 2.537 . . . . 0.0 113.725 -157.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 154.88 -125.37 1.68 Allowed Glycine 0 CA--C 1.523 0.547 0 CA-C-N 120.974 1.715 . . . . 0.0 115.649 -172.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -112.29 -178.58 3.45 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 128.179 2.591 . . . . 0.0 111.41 -161.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.7 p90 -143.1 -1.51 1.07 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 119.075 2.991 . . . . 0.0 119.075 163.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 O-C-N 119.623 -1.923 . . . . 0.0 113.931 -178.496 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.539 0 CA-C-O 116.81 -2.106 . . . . 0.0 118.161 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.88 -100.07 0.14 Allowed Glycine 0 C--N 1.336 0.533 0 CA-C-N 119.649 1.724 . . . . 0.0 115.334 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.3 p -156.01 176.56 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-N 121.064 2.432 . . . . 0.0 110.052 -172.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 111.29 -97.9 0.99 Allowed Glycine 0 C--N 1.335 0.507 0 CA-C-O 119.72 -0.489 . . . . 0.0 114.126 153.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.6 mttp -107.71 -103.31 0.35 Allowed 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 125.459 1.504 . . . . 0.0 111.007 -163.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.8 pt -63.09 154.35 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 115.716 1.747 . . . . 0.0 115.716 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.8 tp -73.74 156.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.946 1.699 . . . . 0.0 111.838 -174.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -142.56 -22.36 0.66 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.99 2.219 . . . . 0.0 116.99 -178.307 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 25.0 p90 -56.16 -34.85 66.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 119.832 1.197 . . . . 0.0 113.319 -161.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.72 -20.02 45.18 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 119.522 1.055 . . . . 0.0 113.698 177.118 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.3 pt -122.91 20.96 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 126.601 1.96 . . . . 0.0 111.704 169.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -158.03 60.29 0.33 Allowed Glycine 0 C--N 1.335 0.513 0 C-N-CA 127.793 2.616 . . . . 0.0 112.341 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.25 -96.59 0.01 OUTLIER Glycine 0 C--N 1.336 0.54 0 C-N-CA 128.331 2.872 . . . . 0.0 114.983 174.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.2 14.43 4.57 Favored Glycine 0 CA--C 1.522 0.513 0 C-N-CA 129.347 3.356 . . . . 0.0 115.462 176.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -60.16 -50.99 78.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 119.619 1.71 . . . . 0.0 110.69 -176.432 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 133.53 -88.15 0.26 Allowed Glycine 0 CA--C 1.523 0.542 0 O-C-N 124.77 1.294 . . . . 0.0 115.915 174.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -114.41 -172.87 2.19 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 128.527 2.731 . . . . 0.0 111.35 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -159.4 -12.97 0.06 Allowed 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 116.57 2.063 . . . . 0.0 116.57 169.105 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.129 0 CA-C-O 117.23 -1.872 . . . . 0.0 116.185 -168.145 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.56 -85.64 0.06 OUTLIER Glycine 0 CA--C 1.522 0.528 0 C-N-CA 126.821 2.153 . . . . 0.0 108.974 170.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.44 158.48 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 C-N-CA 126.211 1.805 . . . . 0.0 112.087 176.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.05 -173.99 33.3 Favored Glycine 0 C--N 1.335 0.51 0 O-C-N 119.414 -2.054 . . . . 0.0 113.969 -178.102 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -68.51 -27.8 66.44 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 128.48 2.712 . . . . 0.0 116.757 -174.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.9 pt -140.56 163.72 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 124.808 1.243 . . . . 0.0 112.341 -171.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.69 141.36 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 C-N-CA 127.247 2.219 . . . . 0.0 114.218 -166.175 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -126.17 -22.41 4.08 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 127.618 2.367 . . . . 0.0 113.482 174.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -53.16 -32.41 47.55 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 118.227 2.677 . . . . 0.0 118.227 -169.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -66.37 -15.61 63.42 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 116.29 1.959 . . . . 0.0 116.29 177.028 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 20.6 pt -117.76 11.74 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 128.968 2.907 . . . . 0.0 110.723 169.304 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -155.51 55.61 0.41 Allowed Glycine 0 CA--C 1.522 0.506 0 C-N-CA 126.203 1.858 . . . . 0.0 111.317 -161.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 28.62 -88.66 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 1 C-N-CA 131.973 4.606 . . . . 0.0 115.102 179.297 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.38 33.62 2.55 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 126.354 1.93 . . . . 0.0 114.351 172.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 81.9 t -73.16 -79.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 127.162 2.185 . . . . 0.0 110.306 -178.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.1 -93.12 0.14 Allowed Glycine 0 CA--C 1.522 0.513 0 O-C-N 121.79 -0.569 . . . . 0.0 113.841 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 78.4 mtt85 -126.33 177.43 6.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 127.661 2.384 . . . . 0.0 113.367 -169.031 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -154.89 -25.05 0.12 Allowed 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 118.183 2.66 . . . . 0.0 118.183 178.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.155 0 C-N-CA 129.336 3.351 . . . . 0.0 115.843 -179.323 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.511 ' H ' ' CG1' ' A' ' 15' ' ' VAL . . . 104.86 -107.53 2.91 Favored Glycine 0 C--N 1.335 0.475 0 O-C-N 120.871 -1.37 . . . . 0.0 112.722 -175.263 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.46 163.68 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 C-N-CA 125.538 1.535 . . . . 0.0 108.935 165.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 149.45 -171.9 29.53 Favored Glycine 0 C--N 1.335 0.515 0 O-C-N 120.704 -1.247 . . . . 0.0 113.568 177.271 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.7 mptp? -66.45 -83.69 0.02 OUTLIER 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 125.341 1.456 . . . . 0.0 112.277 -177.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 pt -64.49 149.93 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-O 121.397 0.618 . . . . 0.0 112.154 -175.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.6 tp -61.93 154.04 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 126.234 1.814 . . . . 0.0 114.97 -179.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -133.8 -26.48 1.56 Allowed 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.228 2.611 . . . . 0.0 114.941 174.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -55.05 -24.2 23.72 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 118.219 2.674 . . . . 0.0 118.219 -173.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -65.81 -16.23 63.62 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.983 1.313 . . . . 0.0 114.474 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.5 pt -123.16 -19.97 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 127.593 2.357 . . . . 0.0 112.591 172.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.36 41.13 2.26 Favored Glycine 0 CA--C 1.522 0.523 0 C-N-CA 128.284 2.85 . . . . 0.0 112.071 179.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.94 -95.61 0.04 OUTLIER Glycine 0 C--N 1.335 0.503 0 C-N-CA 126.485 1.993 . . . . 0.0 116.106 171.006 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -123.77 2.99 9.33 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 126.584 2.04 . . . . 0.0 112.637 -176.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.511 ' CG1' ' H ' ' A' ' 2' ' ' GLY . 50.7 t -53.73 -66.59 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.712 1.605 . . . . 0.0 113.867 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 143.83 -110.44 0.58 Allowed Glycine 0 C--N 1.335 0.525 0 CA-C-O 118.39 -1.228 . . . . 0.0 114.565 -175.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 60.8 mtm-85 -129.03 167.44 17.49 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 128.595 2.758 . . . . 0.0 110.225 -165.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -151.61 -12.49 0.2 Allowed 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 -178.347 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.127 0 O-C-N 125.522 1.764 . . . . 0.0 116.74 -175.962 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.483 0 CA-C-O 121.981 0.767 . . . . 0.0 112.826 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.58 -95.36 1.34 Allowed Glycine 0 C--N 1.335 0.517 0 C-N-CA 126.447 1.975 . . . . 0.0 112.433 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.86 157.83 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 124.703 1.201 . . . . 0.0 110.206 173.583 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 160.49 -167.05 35.58 Favored Glycine 0 CA--C 1.523 0.539 0 O-C-N 120.836 -1.165 . . . . 0.0 115.381 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -92.81 -64.84 1.05 Allowed 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 125.897 1.679 . . . . 0.0 112.585 176.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 10.7 pt -78.0 145.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 O-C-N 121.489 -0.757 . . . . 0.0 112.083 -179.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.7 tp -65.04 149.25 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 C-N-CA 124.488 1.115 . . . . 0.0 112.271 -169.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -122.4 -20.43 6.1 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 128.535 2.734 . . . . 0.0 112.763 172.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -40.39 -44.95 2.08 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.434 1.894 . . . . 0.0 114.582 175.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -50.38 -21.74 1.56 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 116.195 1.924 . . . . 0.0 116.195 174.243 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 pt -131.07 -1.98 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 126.326 1.85 . . . . 0.0 114.734 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -137.0 67.93 0.53 Allowed Glycine 0 C--N 1.335 0.527 0 C-N-CA 126.945 2.212 . . . . 0.0 112.481 -167.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 30.95 -100.34 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 C-N-CA 129.037 3.208 . . . . 0.0 115.491 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -127.0 13.46 6.72 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 116.063 1.185 . . . . 0.0 116.063 172.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.1 t -61.26 -37.82 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -171.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.77 -93.03 0.37 Allowed Glycine 0 C--N 1.336 0.539 0 C-N-CA 124.997 1.284 . . . . 0.0 112.616 166.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -120.75 175.45 6.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.563 1.945 . . . . 0.0 113.75 -172.793 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.54 -29.8 0.51 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 172.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.122 0 CA-C-N 120.55 1.523 . . . . 0.0 115.782 -172.029 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.488 0 N-CA-C 118.994 2.358 . . . . 0.0 118.994 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.35 -101.84 0.22 Allowed Glycine 0 CA--C 1.522 0.525 0 C-N-CA 128.777 3.084 . . . . 0.0 114.362 165.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 p -73.47 156.25 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 C-N-CA 124.272 1.029 . . . . 0.0 112.234 168.096 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 133.81 -175.44 20.29 Favored Glycine 0 CA--C 1.522 0.515 0 O-C-N 118.803 -2.436 . . . . 0.0 112.534 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.2 mttp -84.89 -79.43 0.22 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.449 2.3 . . . . 0.0 111.51 -173.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt -72.75 154.38 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-O 121.981 0.896 . . . . 0.0 111.91 -169.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -63.33 141.57 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 126.8 2.04 . . . . 0.0 112.649 -175.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -125.37 -25.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 127.359 2.263 . . . . 0.0 113.561 174.717 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -42.33 -40.29 2.43 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 127.791 2.436 . . . . 0.0 116.463 -172.207 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -53.93 -31.11 49.26 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 117.016 2.228 . . . . 0.0 117.016 174.373 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 18.1 pt -112.04 -19.59 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.419 1.488 . . . . 0.0 113.729 172.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -73.14 -34.06 58.67 Favored Glycine 0 C--N 1.335 0.497 0 CA-C-O 118.537 -1.146 . . . . 0.0 112.723 177.119 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.06 -100.21 2.53 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 118.755 1.278 . . . . 0.0 110.666 -169.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -109.54 29.63 9.3 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 128.123 2.773 . . . . 0.0 113.785 -176.845 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.3 t -107.48 -26.94 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 -157.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.25 -102.52 2.66 Favored Glycine 0 C--N 1.335 0.498 0 O-C-N 121.164 -0.96 . . . . 0.0 113.502 174.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -128.45 -174.51 3.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 124.945 1.298 . . . . 0.0 110.015 -160.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -164.44 -8.72 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 120.349 3.463 . . . . 0.0 120.349 173.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.093 0 C-N-CA 125.406 1.479 . . . . 0.0 115.114 -175.718 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.539 0 CA-C-O 121.728 0.626 . . . . 0.0 111.541 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 116.28 -151.37 18.35 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.947 1.261 . . . . 0.0 114.163 -174.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 90.5 t -70.31 147.34 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 126.375 1.87 . . . . 0.0 109.934 171.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 156.23 -173.65 34.11 Favored Glycine 0 CA--C 1.522 0.52 0 O-C-N 120.535 -1.353 . . . . 0.0 111.123 177.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 mttp -88.84 -77.57 0.37 Allowed 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.506 2.322 . . . . 0.0 112.18 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.0 pt -76.32 141.04 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.524 1.929 . . . . 0.0 110.89 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.474 HG13 ' H ' ' A' ' 9' ' ' TYR . 4.8 tp -61.56 147.34 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 125.704 1.601 . . . . 0.0 113.197 -173.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -117.66 -3.04 11.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 127.933 2.493 . . . . 0.0 110.821 176.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.474 ' H ' HG13 ' A' ' 7' ' ' ILE . 60.8 t80 -38.1 -53.78 1.38 Allowed 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 128.197 2.599 . . . . 0.0 114.053 -176.799 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.429 ' CD2' HG23 ' A' ' 11' ' ' ILE . 25.5 p90 -73.35 -12.04 60.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 127.639 2.376 . . . . 0.0 114.485 -175.319 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.429 HG23 ' CD2' ' A' ' 10' ' ' PHE . 7.2 pt -133.74 -21.02 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 122.314 2.324 . . . . 0.0 116.346 -171.112 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -115.05 47.69 1.01 Allowed Glycine 0 C--N 1.335 0.498 0 CA-C-N 119.356 0.98 . . . . 0.0 114.359 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.65 -78.4 1.02 Allowed Glycine 0 CA--C 1.523 0.576 0 C-N-CA 124.017 0.818 . . . . 0.0 112.894 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 163.98 71.09 0.02 OUTLIER Glycine 0 CA--C 1.523 0.564 0 C-N-CA 126.071 1.796 . . . . 0.0 113.271 -175.012 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -120.78 -53.77 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 120.913 -1.345 . . . . 0.0 111.412 173.464 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.54 -95.75 0.11 Allowed Glycine 0 CA--C 1.522 0.502 0 CA-C-N 121.517 1.962 . . . . 0.0 113.608 177.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -121.17 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.37 3.068 . . . . 0.0 114.281 -171.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -153.73 -30.83 0.12 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 116.984 2.216 . . . . 0.0 116.984 172.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.064 -1.965 . . . . 0.0 115.713 -171.008 . . . . . . . . 0 0 . 1 stop_ save_